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The human peroxisomal FAD-dependent enzyme D-amino acid oxidase 
(hDAAO, EC 1.4.3.3) plays a key role in important physiological processes by 
catalyzing the stereospecific degradation of several D-amino acids (D-AAs). A 
number of studies demonstrated that a dysregulation in processes regulating 
D-AAs concentration is related to the mechanism(s) predisposing to several 
pathologies (i.e. renal damage, schizophrenia, Alzheimer’s disease, 
amyotrophic lateral sclerosis). The important role played by hDAAO in 
modulating D-AAs levels increased the interest for this flavoenzyme: while 
structural and biochemical properties have been extensively investigated, 
the modulation of its functionality by FAD and ligand binding remain elusive. 
Recently, it has been suggested that the flavoenzyme could be mistargeted 
(to cytosol and nuclei) following treatment with propiverine. A putative 
nuclear translocation signal (NTS) in the primary sequence of rDAAO has 
been identified (117-TPS-119, corresponding to the 118-TPR-120 sequence in 
hDAAO). Mistargeting also alters DAAO degradation as the nuclear form of 
the flavoenzyme is pushed to proteasomal degradation. Moreover, it has 
been reported that a processed form of the mouse DAAO is secreted in the 
intestinal lumen after the cleavage of a signal peptide near the N-terminus. 
Thus, the DAAO has been proposed to control the homeostasis of gut 
microbiota by the production of hydrogen peroxide generated by its activity 
on intestinal D-amino acids, originating from food or microbial cell wall.   
Here, we deepened the investigation on some of the key biochemical 
properties of the recombinant enzyme. These studies demonstrate that 
hDAAO activity is finely tuned through ligand/flavin binding. 
Moreover, we focused on mistargeting by studying a DAAO variant lacking 
the N-terminal signal peptide (thus shedding light on the mechanism of 
microbiota selection in the gut) and two variants at position 120 residue 
belonging to a nuclear translocation signal. The targeting seems a way to 
modulate hDAAO functionality. 
Modulation of cellular targeting allows hDAAO to fulfil different physiological 
functions, such as the control of the levels of the neuromodulator D-Ser in 
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the CNS and of other D-AAs in different tissues or the selection of microbiota 
in the gut.  
A full elucidation of the regulation mechanisms of this human flavoenzyme, 
especially related to its role in different tissues, will allow to clarify important 






































D-amino acid oxidase (DAAO, E.C. 1.4.3.3) has been discovered in 1935 in pig 
kidney by H. Krebs, who reported that this tissue contains the system to 
deaminate, by oxidation, not only the “natural” L-amino acids, but also those 
“non-natural” belonging to the D-series (Krebs, 1935). DAAO catalyzes the 
specific oxidative deamination of hydrophobic, neutral, polar and basic D-
amino acids to the corresponding imino acids, which in aqueous solutions 
non-enzymatically hydrolyze to the corresponding α-ketoacids and ammonia, 
in concomitance with the reduction of FAD. The cofactor then reoxidizes on 
molecular oxygen, yielding hydrogen peroxide (Figure 1) (Massey et al., 1961; 








Figure 1. Schematic reaction of D-amino acid oxidase (Sacchi et al., 2018). 
 
During the years, DAAO has been extensively investigated and soon became 
the prototype of FAD-containing oxidases (Curti et al., 1992). All the chemical 
aspects of the flavoenzyme reactivity and its biochemical properties were 
described in detail between 1950 and 1980 using the proteins purified from 
pig kidney (pkDAAO), Rhodotorula gracilis (RgDAAO) and Trigonopsis 
variabilis (TvDAAO) which 3D structures were solved in 1996 and 2000 
(Mattevi et al., 1996; Mizutani et al., 1996; Umhau et al., 2000). Less was 
known at that time about the human enzyme although in humans the DAAO 
activity was detected in the central nervous system (CNS) for the first time in 
1966 (Neims et al., 1966) and the DAAO gene  was cloned in the 1980s 
(Momoi et al., 1988), the recombinant protein was purified and partially 
characterized in 2000 (0.3-0.5 mg protein/L culture medium) (Raibekas et al., 
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2000). Significant improvement in the purification procedure (4 mg/L) 
together with a more detailed characterization was obtained in 2006 (Molla 
et al., 2006) and the 3D structure of hDAAO was published in the same year 
(Kawazoe etal., 2006). The physiological role of human DAAO (hDAAO) 
remained elusive until 1992, when substantial amounts of free D-amino acids 
were detected in the brain and other tissues by novel sensitive analytical 
methods (Hashimoto et al., 1992; Hashimoto et al., 1993; Nagata et al., 
1992a; Nagata et al., 1992b). Subsequently several studies were conducted 
with the aim to identify specific physiological roles for D-amino acids and the 
role of DAAO in their metabolic control ( Wang et al., 2000; Wolosker et al., 
2002; Fuchs et al., 2005). The elucidation of the physiological functions of 
DAAO was also due to the use of the mutant ddY/DAAO-/- mice strain 
expressing the inactive G181R variant (Konno & Yasumura, 1983): large 
amounts of D-amino acids were present in the urines and tissues of these 
animals. In particular, D-serine (D-Ser) levels were increased (10-fold) in brain 
regions where DAAO is expressed (Konno & Yasumura, 1983). Interestingly, 
also the occupancy of the N-methyl-D-aspartate receptors (NMDAr) glycine 
modulatory site and the NMDAr activity appeared to be enhanced, thus 
suggesting a putative regulative role for DAAO on the degradation of this D-
AA and consequently on NMDAr mediated neurotransmission (Konno & 
Yasumura, 1983). Subsequently, the endogenous distribution of this D-amino 
acid in the brain appeared to be strictly related with the NMDAr one 
(Hashimoto et al. 1993; Schell et al., 1995). This observation provided the 
evidence that it might act as a neuromodulator of glutamatergic 
neurotransmission (Figure 2) (Mothet et al., 2000). NMDAr are the most 
important synaptic receptors in the CNS: distributed throughout the brain, 
they play a major role in glutamatergic synaptic transmission (Wenthold et 
al., 2003). 
The NMDArs are  known as “coincidence detectors” because of  their 
requirement for more than one agonist to operate: the receptor channel is 
blocked by Mg2+, depolarization removes this block and enables ion flux when 
the receptor binds both glutamate (on NR2 subunit) and a co-agonist (on NR1 
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subunit) (Kemp & McKernan, 2002; Prybylowski & Wenthold, 2004; Inanobe 
et al., 2005). The regulation of NMDAr transmission by a second agonist may 
be considered a mechanism to protect against the effects of overstimulation 
of the NMDAr (excitotoxicity) (Johnson & Ascher, 1987; McBain et al., 1989; 
Wenthold et al., 2003; Fuchs et al., 2011). Co-agonist binding increases the 
receptor's affinity for glutamate, decreases its desensitization and promotes 
NMDAr turnover by internalization. 
In the brain, D-Ser is synthesized in neurons from the L-enantiomer precursor 
by the PLP-dependent enzyme Serine Racemase (SR, E.C. 5.1.1.18) (Wolosker 
et al., 1999) and is degraded either by SR itself (through an αβ-elimination 











Figure 2. Schematic representation of the NMDAr. Glutamate and D-Ser bind to the 
GluN1 and GluN2 subunit, respectively, of the agonist-binding domain (ABD) on the 
extracellular segment, which also includes the N-terminal domain (NTD), the redox 
and polyamine regulatory sites. The transmembrane domain (TMD) contains the ion 
channel and the site for the magnesium blockade. The C-terminal domain (CTD) is 
located on the intracellular side of the membrane (Billard, 2018). 
 
According to the so call “serine shuttle” model (Figure 3), once D-Ser is 
released by neurons, it is taken up by the surrounding astrocytes for storage 
and subsequent activity-dependent release (Wolosker, 2011; Wolosker & 
Radzishevsky, 2013). Considering the poor expression of SR in astrocytes, in 
these cells DAAO is the main enzyme responsible for the degradation of D-
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Ser. Thus the flavoenzyme can indirectly control the concentrations of D-Ser 
at the synapses and consequently regulate the activation of NMDAr by 
modulating the availability of the neuromodulator at the coagonist binding-










Figure 3. The serine shuttle model. L-serine is synthesized from glucose in the 
astrocytes and released through the ASCT1 transporter. It is then taken-up by 
neurons through the Asc-1 transporter where it is converted to D-Ser by SR. D-Ser is 
released in the extracellular space through Asc-1 and taken-up through ASCT1 by 
astrocytes where it is degraded by DAAO (Wolosker, 2011). Figure from (Billard, 
2018). 
1.1 Physiological and pathological role of DAAO 
Putative DAAO genes have been identified in all kingdoms; the main 
exception is represented by plants. The residues of the active-site and those 
interacting with the cofactor are highly conserved across species. DAAO plays 
several roles in different organisms. In microorganisms, it plays a key role in 
the catabolism of D-AAs: they may represent a carbon, nitrogen and energy 
source. In invertebrates and lower vertebrates it has diverse and specific 
functions, such as the biosynthesis of eye pigment in D. melanogaster, the 
regression of the tail in amphibians, and the intestinal adsorption of D-AAs in 
birds (Pollegioni et al., 2007). In humans, DAAO gene is encoded in a single 
copy in the genome on chromosome 12 (region 12q23-24) (Konno, 2001) and 
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it is constituted by 11 exons and 10 introns and covers 20 kb (Figure 4) (Fukui 











Figure 4. The DAAO gene and transcript. The DAAO gene is located on 12q24 region. 
It includes 11 exons (numbered). The 5′ untranslated region (shaded gray) is on exon 
1 and part of exon 2, exons 2-11 encode the open-reading frame, and the 3′ 
untranslated region (shaded gray) is located on exon 11. The long grey dashed arrow 
indicates the transcriptional start site (exon 1) and the GC box, cAMP-responsive 
element, and sterol-dependent repressor sequences. The short grey dashed arrow 
indicates the additional regulatory sequences, three TATA boxes and a transcription-
enhancing CAAT box. Figure modified from (Verrall et al., 2010). 
 
The overall AA sequence is well conserved among the mammalian DAAOs 
(Pollegioni et al., 2007). The protein is highly expressed in liver, kidney, and 
brain (Figure 5). In liver and kidney DAAO is responsible for the detoxification 
and degradation of D-amino acids originating from the cell wall of intestinal 
bacteria, from diet and endogenous racemization. Interestingly, the urine of 
ddY/DAAO-/- mice was reported to contain abnormally high amounts of D-
AAs, thus confirming this hypothesis (Koibuchi et al., 1995; Sasabe et al., 
2014). In kidney the enzyme is expressed in proximal tubule cells and is 
associated with renal damage due to the nephrotoxicity caused by the 
production of H2O2 during the elimination of D-Ser and D-proparglyglycine 
mediated by DAAO (Konno et al., 2000; Maekawa et al., 2005).  Accordingly, 
renal ROS levels are strongly affected by DAAO activity: the injection of high 
doses of D-Ser in rats causes massive and generalized aminoaciduria, 
glucosuria, and proteinuria, due to the oxidative stress generated in tubule 
cells (Krug et al., 2007).  
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Notably, it has been recently proposed that in kidney and brain DAAO could 
take part in a new pathway (DAAO/3-MST) linked to hydrogen sulfide (H2S) 
production (Shibuya et al., 2013): DAAO degrades D-cysteine (D-Cys) yielding 
3-mercaptopyruvate, which is converted to H2S by the mitochondrial 3-
mercaptopyruvate sulfurtransferase (3MST). It is known that H2S could affect 
the release of renin regulating kidney excretory function and blood pressure 
(Shibuya & Kimura, 2013). Interestingly, in the brain H2S act as an 
endogenous gaseous transmitter which is able to modulate synaptic signaling 
by activating NMDAr in neurons, as well as astrocytes that surround the 
synapse (Abe & Kimura, 1996; Nagai et al., 2004).  
The DAAO expression has been also reported on the surface of  human 
neutrophilic leucocytes, where the enzyme, together with the 
myeloperoxidase, may generate H2O2 upon the oxidation of D-Ala derived 
from bacterial peptidoglycan, thus playing a protective role against infections 
(Robinson et al., 1978). These findings were supported by the observation 
that, compared to the wild-type mice, the ddY/DAAO-/- are more susceptible 









Figure 5. Schematic representation of expression pattern of DAAO gene in different 
human tissues. Values are shown as logarithm of RPKM value (reads per kilobase of 
transcript per million mapped reads). The data presented in this plot were obtained 
from the Genotype-Tissue Expression (GTEx) Project Portal 




Recently, it has been proposed that in mice hDAAO could be secreted into 
the lumen by intestinal epithelial cells, where the enzyme could control the 
composition of gut microbiota (Sasabe et al., 2016): both DAAO protein and 
activity were detected in the villus ephitelium of the proximal and middle 
small intestine of mice and humans. A processed form of the murine protein 
appeared to be secreted by goblet cells, likely due to the presence of a signal 
peptide and a predicted cleavage site near the N-terminus (Sasabe et al., 
2016). Host DAAO has been proposed to be induced and released as a 
response to certain intestinal microbiota to react to microbial metabolites. 
Indeed, several free D-AAs (known as DAAO substrates) are released in the 
colonic lumen by commensal microbiota activity (Matsumoto et al., 2018). 
The H2O2 produced by DAAO reaction could thus exert a dual role: in host 
defense limiting colonization of pathogenic bacteria, and in controlling 
microbiota composition since certain bacteria receive benefits from D-AAs 











Figure 6. A model of intestinal epithelial homeostasis established by the interplay of 
D-AAs and DAAO, proposed by (Sasabe et al., 2016). Commensal microbiota produce 
free D-AAs (a). The microbiota induces production of DAAO by the intestinal 
epithelium (b) which is secreted into the lumen by goblet cells and oxidizes mucosal 
D-AAs (c). Hydrogen peroxide produced by DAAO reaction protects the proximal 




In the CNS DAAO degrades D-Ser, and hDAAO expression is complementary 
to the observed levels of the coagonist: the enzyme is detected in the 
cerebellum and brainstem (where D-Der levels are low) while its expression 
is lower in the forebrain (where D-Ser concentration is higher) (Horiike et al., 
1994; Verrall et al., 2007; Madeira et al., 2008). Recently, hDAAO activity has 
been confirmed in the forebrain. It has also been identified in the 
corticospinal tract of the white matter and in the motor pathway of the gray 
matter at astrocytic level, where the enzyme activity could prevent 
excitotoxicity due to an overactivation of the NMDAr-mediated transmission 
(Sacchi et al., 2011; Sasabe et al., 2014). Furthermore, the flavoenzyme 
activity was detected in dopaminergic neurons of the nigrostriatal system 
(Sasabe et al., 2014). Here, hDAAO efficiently metabolizes D-DOPA, which is 
converted to dihydroxyphenylpyruvic acid and then transaminated to L-
DOPA, thus  affecting the metabolism of dopamine, norepinephrine and 
epinephrine.  
From a pathological point of view, an anomalous activity of the enzyme might 
produce remarkable alterations in D-Ser concentration in the brain, and 
consequently in NMDAr functioning. Notably, such a dysfunction has been 
proposed as one of the mechanisms that concur to the settle of various 
pathologies such as amyotrophic lateral sclerosis, Alzheimer’s disease, 
schizophrenia, etc. (Verrall et al., 2007; Billard, 2008; Madeira et al., 2008; 
Wolosker et al., 2008; Verrall et al., 2010). 
Recently, DNA variants located on DAAO gene have been associated to the 
outcome of familial amyotrophic lateral sclerosis (fALS) (an adult-onset 
neurodegenerative disease caused by the loss of motor neurons): the R199W 
substitution in hDAAO has been correlated to the onset of the pathology 
(Mitchell et al., 2010; Cirulli et al., 2015). This substitution abolishes DAAO 
activity due to protein instability and lower kinetic efficiency on D-Ser 
(Cappelletti et al., 2015a), promotes the formation of protein aggregates, 
activates the autophagy system and increases apoptosis in motor neuron cell 
lines or primary motor neuron cultures (Figure 7) (Paul & De Belleroche, 
2012; Paul et al., 2014). The neurotoxic effect depends from D-Ser: co-
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culturing motor neurons with glial cells expressing R199W hDAAO variant 
was sufficient to induce apoptosis in motor neurons, an effect not observed 
in the presence of an NMDAr antagonist specific for D-Ser binding-site (Paul 
et al., 2014). Studies on the recombinant R199W hDAAO variant suggest that 
the pathological effect of this substitution could be related to D-Ser 
accumulation due to the loss of function of the catabolic enzyme (Cappelletti 
et al., 2015a), yielding in vivo to an increase in synaptic concentration of the 
neuromodulator and, as a result, to the overactivation of NMDAr-mediated 
transmission and the consequent excitotoxicity (Figure 7). Furthermore, the 
transgenic mouse lines expressing R199W DAAO variant exhibit the same 
features of the others ALS mice models (SOD1G93A mice) (Kondori et al., 
2017). Moreover, both in these mice and in the SOD1G93A models, D-Ser 
accumulated in the spinal cord and DAAO activity resulted suppressed in the 











Figure 7. Glutamatergic transmission in ALS. The presynaptic hyperexcitability 
generates excessive glutamate release from the presynaptic neuron. Moreover, the 
reduced expression of the glial transporter GLAST/GLT1 causes an increase in the 
extracellular levels of glutamate, producing an hyperactivation of NMDAr, with a 
consequent cellular excitotoxicity. Moreover, both neurons and astrocytes 
accumulate protein aggregates, increased Ca2+ and ROS/RNS concentrations. An 
abnormally high concentration of D-Ser at the synapse would be crucial for these 
processes to occur. Figure modified from (Spalloni et al., 2013). 
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Neurodegeneration mediated by NMDAr and D-Ser concentration alterations 
were also proposed to contribute to Alzheimer’s disease (AD) and aging 
progression and alterations in D-Ser levels were observed in AD patient 
(Billard, 2008; Madeira et al., 2015). A defective activation of NMDAr, due to 
decreased level of D-Ser, was shown to occur in aged tissues: the 
hypoactivation of these receptors might result in a loss of plasticity and 
cognitive deficits in the aging brain (Ikonomidou et al., 1999). Indeed, 
increased levels of DAAO have been reported in the serum of patients with 
mild cognitive impairment or with severe AD. Nevertheless, the role of 
NMDAr in AD pathogenesis is more complex: excitotoxicity, due to the 
overstimulation of NMDAr, has been also correlated to the onset of AD 
(Tannenberg et al., 2004). Increased D-Ser levels were reported in AD 
patients (Madeira et al., 2008).  
A hypofunction of NMDAr mediated transmission is thought to be possibly 
involved in schizophrenia, due to a decrease in synaptic D-Ser levels. 
Interestingly, increased enzymatic activity and gene or protein expression of 
hDAAO were reported in cerebral cortex, cerebellum, medulla oblungata and 
choroid plexus of schizophrenic patients (Coyle et al., 2003; Coyle, 2006; 
Kapoor et al., 2006; Verrall et al., 2007; Burnet et al., 2008; Madeira et al., 
2008; Ono et al., 2009; Verrall et al., 2010). Alongside, clinical trials 
demonstrated the beneficial effects of D-Ser as add-on pharmacotherapy 
(Heresco-Levy et al., 2005). Moreover, in 2002 the G72 gene encoding a small 
protein (pLG72), which is the main interactor of DAAO, was linked to 
schizophrenia as the DAAO gene itself (Chumakov et al., 2002; Sacchi et al., 
2016).  
1.2 Cellular function and localization of hDAAO 
Concerning the subcellular localization of hDAAO, the flavoenzyme contains 
the PTS1 signal at C-terminus: the peptide Ser-His-Leu which directs its 
targeting to the peroxisomes (Horiike et al., 1994; Moreno et al., 1999). An 
intriguinging issue concerns the way in which the peroxisomal hDAAO can 
access D-Ser cytosolic storage: D-Ser could enter to the peroxisomes through 
a not yet assessed membrane transport mechanism; alternatively, an active 
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form of DAAO might exist in the cytosol, directly affecting D-Ser cellular 
concentration. As a matter of fact, an active form of DAAO has been 
identified in cytosol both in glial cells and neurons (Sacchi et al., 2008; 
Popiolek et al., 2011; Sacchi et al., 2011). In U87 human glioblastoma cells, 
the flavoenzyme shows a different distribution dependent on time after 
transfection: at 24 h, a fraction of active and folded enzyme is largely diffused 
in the cytosol, where it might interact with different proteins; at 48 h and 72 
h after transfection, the signal of the flavoenzyme largely overlapped that of 
peroxisomes (Sacchi et al., 2011).  
Recently, it has been suggested that the flavoenzyme could be mistargeted 
(to cytosol and nuclei) or secreted: rat DAAO is present both in cytosol and 
nuclei of proximal tubule epithelial cells after the treatment with the drug 
propiverine (Luks et al., 2017). A putative nuclear translocation signal (NTS) 
in the primary sequence of hDAAO that could facilitate nuclear import via 
importin 7 after the phosphorylation of an TPx sequence has been identified 
(Chuderland et al., 2008). Moreover, it has been proposed that hDAAO could 
be secreted into the lumen by intestinal epithelial cells in mice (see above) 
(Sasabe et al., 2016). 
hDAAO subcellular localization has been shown to influence its degradation 
pathway. hDAAO is a stable protein with a long half-life (t1/2 ~ 60 h). In U87 
cells, the peroxisomal hDAAO is degraded by the lysosomal/endosomal 
pathway while cytosolic hDAAO is targeted to the proteasome system after 
ubiquitination (Cappelletti et al., 2014). 
 
1.3 Structural properties of hDAAO 
The evidence of the important physiological role played by hDAAO in the 
metabolism of D-Ser has resulted in an increased interest for this 
flavoenzyme: during the past few years, the structure and the biochemical 
properties of hDAAO have been extensively investigated using the 
recombinant enzyme produced in E. coli (Raibekas et al., 2000; Molla et al., 
2006a; Romano et al., 2009) and the crystallographic structure has been 
resolved (Kawazoe et al., 2006, 2007).  
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From a structural point of view, the human enzyme (347 AA, 40.3 kDa) 
contains 11 α-helix and 14 β-strands that fold into two interconnected 
regions: an interface domain, in which a large twisted antiparallel β-sheet 
forms the active-site roof and part of the oligomerization interface, and a FAD 
binding site possessing the Rossman fold motif. The loop following the α-helix 
2 (58-61), the active site loop (216-228) and the loop between β-strands 13 
and 14 (296-303) represents the regions of the protein with the highest 










Figure 8. Detail of the active site. The substrate D-Ser was modeled based on the 
structure of the enzyme in complex with imino-serine (Molla, 2018). 
The substrate is located above the re-side of the cofactor and interacts with  
several residues of the active site (Arg283 and Tyr 228 with the α-COOH 
group, and Gly313 and C(4)=O of the cofactor with the α-NH2 group) (Figure 
8). Moreover, an additional ligand-binding site located at the monomer-
monomer interface has been recently identified by computational and 
labeling studies (Kohiki et al., 2017) (Figure 9A-9B). 
The upper part of the active site, where is located the side chain of the 
substrate is constituted by bulky and hydrophobic residues (Leu51, Gln53, 
Leu215 and Ile230) (Kawazoe et al., 2006). The less-conserved active-site 
residue is Leu51, which is the key position determining the substrate 
specificity. The roof of the active site is formed by the side chain of Tyr224, 
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that is part of a loop (216-228) that could switch during catalysis from an 
open to a close conformation, reducing the turnover, increasing the 
hydrophobicity of the active site and allowing hDAAO to bind larger 



















Figure 9. 3D structure of hDAAO (PDB 2e49). A. A monomer of hDAAO is constituted 
by two domains: the substrate (blue) and the FAD binding domain (red). The large 
arrow indicates the entrance of the active-site while the thin one indicates the 
additional-binding site proposed by (Kohiki et al., 2017). B. hDAAO active-site 
architecture. C. Oligomerization mode of hDAAO. D. Schematic representation of 
the substrate dehydrogenation during the reaction catalyzed by hDAAO. Figure 




hDAAO belongs to the FAD-containing flavooxidases family, of which exhibits 
the well-known properties: it stabilizes the anionic semiquinone, it is able to 
covalently bind sulfite, in anaerobic condition it is fully reduced after  adding  
the substrate, and the FADH2 is highly reactive with oxygen (Pollegioni et al., 
2007). However, hDAAO shows some peculiar features that distinguish it 
from other DAAOs. 
Mammalian DAAOs are different in their oligomerization state: for the 
porcine enzyme (pkDAAO) it is dependent on the concentration in solution 
(in the crystal, the enzyme is a homodimer containing a molecule of 
noncovalently bound cofactor per subunit, whereas in solution it exists as a 
mixture of monomers, dimers, and even higher molecular aggregates in 
equilibrium, depending mainly upon the protein concentration and the 
presence of ligands; the apoprotein is monomeric); rat DAAO is always 
monomeric; hDAAO is a stable head-to-head homodimer (Figure 9C) (80 kDa) 
in both the holo- and the apoprotein form (Mattevi et al., 1996; Molla et al., 
2006b; Pollegioni et al., 2007; Frattini et al., 2011). The rational of this 
characteristic is in a different charge distribution at the dimer interface in 
hDAAO compared to pkDAAO (negatively and positively charged, 
respectively) (Figure 10) due to a higher substitution frequency of the 
residues of the interface region compared to the overall protein (33% vs 15%) 
(Kawazoe et al., 2006). Interestingly, the monomeric ratDAAO shows the 
substitution of three residues at the protein interface (His78, Arg120 and 
Gln234 in human enzyme are replaced by Cys77, Ser119 and Lys233 in 









Figure 10. The monomer-monomer interface of hDAAO is negatively charged while 
that of pkDAAO is positively charged. The surface is colored from blue (positive) to 
red (negative). Figure modified from (Kawazoe et al., 2006). 
 
In particular, Arg120 in the human enzyme highly stabilizes the monomer-
monomer interface (Frattini et al., 2011). Arg120 belongs to α-helix 6. It is 
involved in electrostatic interactions with the carboxylic group of D73 (α-helix 
3) and hydrogen-bonded to the backbone C=O groups of D109 (α-helix 5), 
T110 and V111 (loop between α-helix 5 and β-strand 4) located at the 
interface of the opposite monomer. 
 
1.3.1 FAD binding 
The cofactor, bound in a non-covalent way, is located at the interface of the 
two domains, buried in the protein core in an elongated conformation, with 
the re-face in the inner part of the active site (Kawazoe et al., 2006; Molla, 
2017). While the conformation of the residues located at the re-face of the 
flavin ring is highly conserved, at the si-face the conformation of the 
hydrophobic stretch (47-VAAGL-51) differs between the human and porcine 
enzymes, causing the loss of the H-bond established between Ala49 and N(5) 
of the cofactor and decreasing the strength of the interaction  and the rate 
of flavin reduction (see below) (Figure 11) (Kawazoe et al., 2006). 
The binding of the flavin cofactor to the human enzyme is the weakest among 
known DAAOs (Kd = 8.0 μM), but the presence of a ligand in the active site 
stabilizes the flavin interaction (Kd = 0.3 μM) (Molla et al., 2006; Caldinelli et 
al., 2010). Because of the low interaction with FAD and the in vivo 
concentration of the cofactor (2 - 5 µM), the hDAAO is present in solution as 
an equilibrium of holo- and apoprotein forms, with the latter one 
predominant in absence of an active-site ligand (Caldinelli et al., 2010).   
The holoenzyme reconstitution follows a sequential process: in the first step, 
the apoprotein quickly recovers the activity due to the binding with the 
cofactor; in the second step, slower than the first one, a conformational 











Figure 11. Conformational variability of the hydrophobic stretch (VAAGL, residues 
47–51) at the si-face of the flavin ring of human (carbons in green) and porcine 
(carbons in magenta) DAAO. Figure modified from (Kawazoe et al., 2006). 
 
1.3.2 Kinetic mechanism and substrate preference 
The oxidative deamination catalyzed by hDAAO follows a sequential kinetic 
mechanism, in which the substrate dehydrogenation proceeds by directly 
transferring of an hydride, i.e. the α-hydrogen from the α-carbon of the 
substrate, to the flavin N(5) (Figure 9D). The first reductive-half reaction (the 
conversion of the D-amino acid into the planar imino acid together with the 
flavin reduction) is very fast (117 ± 6 s-1 on D-Ser), more than the turnover 
(6.3 ± 1.4 s-1). The rate limiting step in DAAO catalysis is the product release, 
since the conformational change of the active site loop (217-227) acting as a 
lid and allowing the product/substrate exchange is relatively slow (Molla et 
al., 2006). The rate of the release of the imino acid product from the reduced 
enzyme is very slow (< 1 s-1); therefore, the reoxidation step does not start 
from the free enzyme but from the reduced enzyme-imino acid complex with 
a second-order reaction corresponding to 1.25 x 105 M-1 s-1 (Molla et al., 2006; 
Molla, 2017). 
The human enzyme shows a broad substrate preference due to the plasticity 
of the active site lid: the favorite substrates are bulky hydrophobic D-amino 
acids (D-DOPA, D-Phe, D-Tyr, D-Trp), followed by the small uncharged ones 
(D-Ala, D-Pro, D-Ser). The D-DOPA can be converted into the L-enantiomer 
(then used to synthesize dopamine) by the reactions of DAAO and a 
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transaminase. As shown by (Kawazoe et al., 2007), the apparent maximal 
activity, as well as the catalytic efficiency, is the greatest among tested D-
amino acids (Table 1) but the oxidation of this compound is hampered by the 
observed substrate inhibition effect (Ki 0.5 mM). Very small or acidic amino 
acids are not or are poorly degraded by the flavoenzyme (Table 1) ( Molla et 
al., 2006; Kawazoe et al., 2007).  
 
Table 1. Substrate preference of hDAAO. The apparent kinetic properties 
determined on several D-amino acids. 
 kcat (s-1) Km (mM) kcat/Km (s-1 mM) 
D-DOPA3 21.7 1.5 (Ki 0.5) 14.5 







D-Phe3 15.5 1.2 12.9 
D-Pro1 10.2 8.5 1.2 
D-Ala1 5.2 1.3 4.0 
D-Asp1 6.7 2000 <0.01 
Gly1 0.9 180 <0.01 
1 (Molla et al., 2006); 2 (Caldinelli et al., 2010); 3 (Kawazoe et al., 2007) 
 
1.4 Modulation of hDAAO activity 
The substrate promiscuity of hDAAO supports the hypothesis that this 
flavoenzyme might play different roles in different cells and tissues. The 
flavoenzyme activity must be finely tuned to fulfill what is thought to be its 
most important function in the brain. 
 
1.4.1 By protein interaction 
The functionality of the human enzyme is modulated in vivo by other 
proteins. hDAAO interacts with the Pex5p receptor, which is involved in 
peroxisomal protein import and in the assembly of functional peroxisomes, 




The second hDAAO partner is pLG72, a primate-specific protein (153 
residues, 18.1 kDa) encoded by the G72 gene, which has been associated by 
genome-wide association and meta-studies with schizophrenia and other 
psychiatric disorders (Chumakov et al., 2002; Sacchi et al., 2016; Pollegioni et 
al., 2018). The interaction between the two human proteins was confirmed 
in vitro using the recombinant enzymes: gel-permeation chromatography 
and surface-plasmon experiments demonstrated that hDAAO interacts with 
pLG72, yielding the formation of a 200 kDa complex. The interaction does not 
modify the kinetic parameters of hDAAO or its binding to the cofactor, but 
alters its tertiary structure, causing a time-dependent loss of activity (Sacchi 
et al., 2008; Caldinelli et al., 2010). Recently, low-resolution technique 
experiments (limited proteolysis coupled to mass spectroscopy and cross-
linking analysis) allowed the identification of the structural determinants of 
the proteins involved in forming the interface surface in hDAAO-pLG72 
complex: it has been suggested that the N-terminal region could play an 
important role  in the formation of the complex (Birolo et al., 2016; Sacchi et 
al., 2017).  
The role of pLG72 interaction was investigated at cellular level using U87 cells 
expressing hDAAO and pLG72: D-Ser levels decreased in U87 overexpressing 
hDAAO while the co-expression of pLG72 restored D-Ser concentration, 
confirming that pLG72 acts as a negative effector of the human enzyme 
(Sacchi et al., 2008). On the other hand, pLG72 overexpression in U251 cells 
failed to influence the activity of endogenous hDAAO: in this work hDAAO 
activity was assayed on D-proline as substrate, which is also oxidized by D-
aspartate oxidase (Kvajo et al., 2008). Moreover, pLG72 was found to 
increase hDAAO activity in kidney-like HEK293 cells, while in neuron-like SH-
SY5Y and in astrocyte-like 1321N1 cells there were no significant differences 
in the flavoenzyme activity, suggesting an intriguing cell-specific hDAAO-
pLG72 interaction (Jagannath et al., 2017). In vivo, hDAAO is present in 
peroxisomes and cytosol while pLG72 is localized at mitochondrial level: 
confocal microscopy and FRET analysis showed that after the synthesis, 
hDAAO could interact with pLG72 exposed on the cytosolic side of the outer 
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mitochondrial membrane before the targeting to peroxisomes (Figure 12) 
(Sacchi et al., 2011).  
The degradation pathway of hDAAO and pLG72 was investigated in U87 cells 
expressing the two proteins: the interaction between these proteins 
increases the D-Ser level and decreases the half-life of the human 
flavoenzyme (t1/2 ~ 6 h). Moreover, pLG72 has been proposed to target the 
cytosolic form of hDAAO to the ubiquitin-proteasome system for degradation 
( Sacchi et al., 2008, 2011; Cappelletti et al., 2014). This could represent a 
regulation process of D-Ser levels in the hindbrain, where DAAO is mainly 
glial: the interaction between hDAAO and pLG72 induces enzyme inactivation 
and speeds up its degradation, preserving cytosolic D-Ser and protecting cells 
from oxidative stress by hydrogen peroxide generated by the flavoenzyme 










Figure 12. Proposed role of pLG72 on D-Ser metabolism based on its binding to 
hDAAO (Pollegioni et al., 2018). 
 
Following co-immunoprecipitation experiments in rat cerebellar extracts, the 
proteins bassoon and piccolo, two cytoskeletal matrix components localized 
at the presynaptic active zone, have been proposed as DAAO interacting 
proteins (Popiolek et al., 2011). DAAO was shown to be present in the 
presynaptic “bouton”, where it can metabolize D-Ser, finely tuning its 
concentration within the synapse and eventually influencing NMDAr 
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activation. Intriguingly, a molar excess of bassoon (a condition most likely 
present in the presynaptic active zone) was found to strongly inhibit the 
activity of the extraperoxisomal form of hDAAO (Popiolek et al., 2011). 
Indeed, the detection of the enzyme activity in the forebrain, where it is 
mostly expressed in neurons, has been always difficult, probably due to the 
inhibitory effect of bassoon  (Verrall et al., 2007). 
1.4.2 By hDAAO inhibitors 
Alterations of D-Ser levels due to an abnormal change in hDAAO activity have 
been correlated to several disorders, thus the identification of hDAAO 
inhibitors that could be used as drugs has generated growing interest.  
hDAAO inhibitors can be classified as substrate competitive inhibitors or as 
those that do not compete with the substrate (only ADP and CPZ) (Figure 13) 
(Terry-Lorenzo et al., 2014; Molla et al., 2017). During the past years, more 
than 500 substrate competitive inhibitors have been identified (Gilson et al., 
2016). Analogously to the substrate, these compounds contain a planar 
portion that interact with the core of the active-site; and a second region 
which is placed in the substrate side chain binding pocket. hDAAO inhibitors 
can be divided into several classes (Molla et al., 2017): 
• Classical inhibitors, i.e benzoate, anthranilate and improved 
derivatives, formed by a carboxylic group, that interacts with Arg283, and a 
single aromatic ring, that interacts with Tyr224 (Katane et al., 2013; Sacchi et 
al., 2013). The prototype of this class is the compound 5-methylpyrazole-3-
carboxylic acid. This compound is able to cross the blood-brain barrier in rats, 
increasing D-Ser levels in certain areas of the brain and reversing the effect 
of the dissociative anesthetic PCP (Adage et al., 2008). 
• Second-generation inhibitors, i.e. compounds formed by two 
substituted, heterocyclically fused rings, that bind the residues of the active 
site with additional van der Waals and H-bond interactions (i.e. 3-
hydroxyquinolin-2(1H)-one and CBIO) (Ferraris et al., 2008; Katane et al., 
2013). The main limit of this compound is the low ability to pass the blood-





























Figure 13. Structural formula of hDAAO inhibitors classified based on their 
mechanism of enzyme inhibition (Pollegioni et al., 2018b). 
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• Third-generation inhibitors, i.e. bulky and flexible compounds that 
could interact with the subpocket generated by the conformational change 
of Tyr224 (Kawazoe et al., 2007; Raje et al., 2013; Terry-Lorenzo et al., 2014). 
• Novel-generation inhibitors, that interact with the hDAAO-pLG72 
complex. A high-throughput screening identified compounds which 
inhibitory effect was more potent in the presence of pLG72 (class A 
compounds) and molecules which were 5- to 10-fold less potent in the same 
condition (class C compounds). All these compounds contain the ebsulfur 
substructure (2-phenyl-2,3-dihydro-1,2-benzothiazol-3-one) which can 
interact with the cysteines of hDAAO forming S-S thiol bonds, when the 
protein is partially unfolded due to the presence of pLG72 (Terry-Lorenzo et 
al., 2015).  
1.4.3 By point substitutions 
hDAAO variants corresponding to known single nucleotide polymorphisms 
(SNPs) or sequence conflicts could be divided into two classes based on their 
activity: i) hypoactive and ii) hyperactive (Figure 14) (Sacchi et al., 2018). In 
general, U87 cells overexpressing these hDAAO variants showed a significant 
alteration in D-Ser cellular levels, suggesting an implication in the 
susceptibility to neurodegenerative or psychiatric disorders (Caldinelli et al., 













Figure 14. 3D-Structure of hDAAO (PDB 2e49). The residues mutated are shown as 
sticks in green (hypoactive) and in magenta (hyperactive). FAD is depicted in yellow, 
the product imino-serine in red. Figure prepared with PyMol. 
 
The inactivating substitutions R199W (the variant associated with the onset 
of fALS) and R199Q hDAAO variants show a significant modification in protein 
conformation: altered tertiary conformation of the holoenzyme form, a 
tetrameric oligomeric state at a concentration > 1 mg/mL and a significant 
increase in melting temperature related to protein conformation have been 
reported. The paper from (Cappelletti et al., 2015) provided the rationale for 
the effect of Arg199 substitution: it significantly affected the ability to bind 
the flavin cofactor and the substrate, yielding a significant decrease in 
enzymatic activity (Figure 15); indeed, at 1 mM D-Ser (a concentration similar 
to that observed in physiological conditions in brain) the activity of R199 
variants was negligible (Cappelletti et al., 2015). Arg199 is located on the 
protein surface, near the isoalloxazine ring of the cofactor, at the center of a 
network of secondary structure elements belonging to the interface domain 
(α-helix α10 and β-strands β8 and β12). Moreover, Arg199 interacts with 
Arg283 and Thr280, important for ligand binding (Cappelletti et al., 2015). 
The substitution of glycine located at position 331 with a valine (G331V) 
causes a change in the C-terminal α-helix and produces an hydrophobic 
surface, altering the solubility of the enzyme and promoting protein 
aggregation. Accordingly, human U87 cells expressing this hDAAO variant 
show a significant decrease in cell viability: at cellular level, this variant is 
mistargeted forming cytosolic protein aggregates, which largely colocalize 
with ubiquitin, and resulted in increased protein apoptosis (Caldinelli et al., 
2013). 
The D31H, W209R and R279A hDAAO hyper-active variants showed, on the 
other hand, the opposite effect: the introduced substitutions resulted in a 
significant improved catalytic efficiency (Figure 15) and FAD affinity.  
Among these variants, hDAAO W209R, due to the higher affinity for the 
cofactor binding and the increased amount of the holoenzyme in solution, 
shows a 2-fold increase in the turnover number compared to the wild-type 
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enzyme (Figure 15), in particular with D-Ser and FAD concentrations 
resembling physiological conditions (0.3 mM of D-Ser and 5 µM of FAD), 
suggesting a faster rate of imino acid dissociation from the reoxidized enzyme 
form (Cappelletti et al., 2015). Accordingly, the ability of W209R hDAAO to 
degrade D-Ser is improved in U87 cells transiently expressing this variant. 
Moreover, the excessive production of hydrogen peroxide may affect cell 
viability after stable transfection (Cappelletti et al., 2015). Trp209 is located 
at the monomer-monomer interface but it is not involved in relevant 
hydrophobic interactions with the residues belonging the other monomer. 
The substitution of Trp with an Arg adds an additional electrostatic 
interaction with Glu85, stabilizing the dimeric structure of DAAO (Cappelletti 
et al., 2015). 
Thermal stability, dimeric oligomerization, binding affinity for the inhibitors 
and the ability to interact with pLG72 were not altered in D31H and R279A 
hDAAO variants, while their kinetic efficiency and the affinity for the 
substrate and the cofactor were increased compared to the wild-type 
enzyme. While the substitution of Asp31 may affect protein conformation 
through a general, long-range interactions, the R279A substitution affects 
the FAD binding affinity through the loss of the H-bond with Pro41, thus 
altering the conformation of SAP hDAAO region (Caldinelli et al., 2013). 
 
1.4.4 By post-translation modifications 
A large number of proteins are subjected to post-translational modifications 
(PTMs), thus increasing the actual complexity of the proteome. PTMs consist 
in a modification of the residues of the primary structure and create a much 
larger array of possible protein species (Walsh et al., 2005). In specific 
physiological conditions, PTMs play an important role in regulating many 
biological functions (Walsh et al., 2006), such as protein localization in the 
cell (Fairbank et al., 2012), protein stability (Maeda et al., 2010) and 


















Figure 15. Apparent kinetic parameters of wild-type and hDAAO variants, 
determined at air saturation (0.25 mM oxygen), 25 °C, and pH 8.5 (Pollegioni et al., 
2018b). 
A strict regulation of hDAAO activity by post-translational modifications is 
expected. In particular, at cellular level hDAAO has been proposed to be 
regulated by nitrosylation: in membrane fractions of glioblastoma cells the 
activity of DAAO in U87 cells was enhanced by NO in a dose-dependent 
manner (Shoji et al., 2006). Moreover, also SR appeared to be activated by 
denitrosylation elicited by D-Ser and to be inhibited by NO (Shoji et al., 
2006b). The authors proposed that in astrocytes NO may accelerate D-Ser 
elimination not only by inhibiting SR but also by enhancing DAAO activity, 
thus acting as mediator of D-Ser metabolism. Following D-Ser supply from 
astrocytes to neurons, NO synthesis in neurons may be temporary enhanced. 
In astrocytes switch-off of D-Ser synthesis may mainly be achieved by 
neuron-derived NO, which exhert the aforementioned dual function (Figure 












Figure 16. Regulatory loop between D-Ser and NO metabolism. In astrocytes, NO, 
produced by n/eNOS under normal conditions or by iNOS under inflammatory 
conditions, inhibit SR activity and enhance hDAAO activity. On the other hand, D-Ser 
enhances SR and decreases nNOS activity (Shoji et al., 2006a). 
1.4.5 By protein mistargeting 
hDAAO is a peroxisomal enzyme: it is synthesized in the cytosol and then 
targeted to peroxisomes. The C-terminal PTS1 sequence is recognized by a 
specific receptor, Pex5p, which is involved in protein import to peroxisomes, 
where specific transmembrane transporters mediate the entrance to the 
matrix (Meinecke et al., 2010; Montilla-Martinez et al., 2015). 
Recently, it has been suggested that hDAAO could be mistargeted (to cytosol 
and nuclei) or secreted: rat DAAO has been identified both in cytosol and 
nuclei of proximal tubule epithelial cells following treatment with the drug 
propiverine, an anticholinergic drug used for the treatment of overactive 
bladder syndrome (Luks et al., 2017). The conventional nuclear import is due 
to the presence of a nuclear localization sequence (NLS), which is recognized 
by specific importin which facilitate the passage of proteins through the NPC 
nuclear complex (Tran & Wente, 2006). However, other molecular 
mechanisms permits the entrance of protein to the nucleus. In particular, it 
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has been identified a putative nuclear translocation signal (NTS), constituted 
by three residues (SPS) that could facilitate nuclear import via importin 7 
after the phosphorylation of the signal sequence (Chuderland et al., 2008). 
Recently, it has been identified a putative NTS signal in the primary sequence 
of hDAAO: the T118-P119-R120 sequence (Luks et al., 2017). 
Indeed, it has been also proposed that hDAAO could be secreted into the 
lumen by intestinal epithelial cells in mice (Sasabe et al., 2016). Protein 
secretion is a multistep process (Pigino et al., 2012): after the synthesis, 
proteins translocate into the ER lumen, where they are glycosylated and 
molecular chaperones aid protein folding. The vesicles containing the 
properly folded proteins then access to the Golgi apparatus, where proteins 
are further modified. Successively, the proteins in the secretory vesicles are 
exocytated through a structure called the porosome (Anderson, 2006). 
Proteins that are designated to the secretory pathway contain a signal 
peptide, i.e. a short sequence (usually 16-30 amino acids long) present at the 
N-terminus of newly synthesized proteins (Kapp et al., 2013).  There are many 
proteins which do not use the classical ER-Golgi pathway but follow various 
nonclassical mechanisms. Unconventional protein secretion is largely 
triggered by several conditions, ie. cellular stress and inflammation. 
Unconventional protein secretion includes mechanisms without a signal 
peptide or a transmembrane domain that help translocation across the 
plasma membrane (Rabouille, 2017). 
In the small intestine, DAAO has been proposed to be secreted in the lumen 
of human and mice by goblet cells of the villus epithelium, suggesting a role 






































D-amino acid oxidase is a peroxisomal FAD-dependent enzyme that 
preferentially catalyzes the degradation of small, uncharged D-amino acids 
(Pollegioni et al., 2007). Alterations in DAAO functionality might be highly 
relevant in pathological conditions related to the dysregulation of the 
glutamatergic system. During the past few years hDAAO structural/functional 
relationships have been investigated using the recombinant protein 
produced in E. coli (Molla et al., 2006; Pollegioni et al., 2007; Sacchi et al., 
2012), nevertheless the modulation mechanisms of the enzyme activity 
remain elusive.  
It has been suggested that the flavoenzyme could be mistargeted (to cytosol 
and nucleus) or secreted. Recent reports on rats demonstrated that DAAO is 
present both in cytosol and nuclei of proximal tubule epithelial cells following 
treatment with the drug propiverine (Luks et al., 2017). A putative nuclear 
translocation signal (NTS) in the primary sequence of hDAAO that could 
facilitate nuclear import via importin 7 after the phosphorylation of an TPx 
sequence has been identified (Chuderland et al., 2008). Moreover, it has 
been proposed that the flavoenzyme could be secreted into the lumen by 
intestinal epithelial cells in mice. DAAO has been proposed to play a role in 
controlling the homeostasis of gut microbiota: DAAO protein and activity 
were detected in the proximal and middle small intestine of mice and 
humans, associated to the villus epithelium. A processed form of the mouse 
protein appeared to be secreted in the lumen by goblet cells, likely due to 
the presence of a signal peptide and a predicted cleavage site near the N-
terminus (Sasabe et al., 2016). DAAO was proposed to select the gut 
microbiota facilitating the elimination of pathologic microbial strains. 
Because of the important physiological and pathological role of hDAAO in 
several tissues, this PhD project was aimed to deepen the investigation on 
some of the key biochemical properties of the recombinant enzyme, such as 
its stability (to pH and temperature), the kinetic properties on alternative 
substrates, the effect of various physiological ligands and of the binding of 
the flavin cofactor. Subsequently, we studied the effect of single positions in 
the functionality of the enzyme, focusing on G183R and R120E and R120L 
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hDAAO variants. The first one is the human counterpart of the natural single-
base mutation (yielding the G181R substitution) that in ddY mice inactivates 
the enzyme and that was used to perform behavioral tests to clarify the role 
of DAAO in the mechanisms related to NMDAr transmission. The 
investigation on the two variants at position 120 (of the TPx sequence) aimed 
to clarify the role of this residues on the ligand and FAD binding process to 
the flavoenzyme and of the nuclear translocation due to the presence of the 
NTS sequence. 
Concerning the mistargeting of the flavoenzyme, we started the investigation 
of the role of the DAAO in gut by studying a variant lacking the N-terminal 
signal peptide and by employing bioinformatics, biochemical, microbial, 
cellular and tissue analyses: we suggest that secreted DAAO could not fold 
and maintain the enzymatic activity following the elimination of the N-
terminal sequence and that its ability to select the intestinal microbiota is 
due to the generation of specific antibacterial peptides by proteolytic 
























published: 15 December 2017
doi: 10.3389/fmolb.2017.00088
Frontiers in Molecular Biosciences | www.frontiersin.org 1 December 2017 | Volume 4 | Article 88
Edited by:
Andrea Mozzarelli,
Università degli Studi di Parma, Italy
Reviewed by:
Mariarita Bertoldi,
University of Verona, Italy
Willem J. H. Van Berkel,
Wageningen University and Research,
Netherlands
Robert Stephen Phillips,





This article was submitted to
Structural Biology,
a section of the journal
Frontiers in Molecular Biosciences
Received: 19 September 2017
Accepted: 05 December 2017
Published: 15 December 2017
Citation:
Murtas G, Sacchi S, Valentino M and
Pollegioni L (2017) Biochemical
Properties of Human D-Amino Acid
Oxidase. Front. Mol. Biosci. 4:88.
doi: 10.3389/fmolb.2017.00088
Biochemical Properties of Human
D-Amino Acid Oxidase
Giulia Murtas 1, Silvia Sacchi 1, 2, Mattia Valentino 2, 3 and Loredano Pollegioni 1, 2*
1Dipartimento di Biotecnologie e Scienze della Vita, Università degli Studi dell’Insubria, Varese, Italy, 2 The Protein Factory,
Politecnico di Milano and Università degli Studi dell’Insubria, Milan, Italy, 3 Sezione Adolfo Quilico, Istituto di Chimica del
Riconoscimento Molecolare, CNR, Milan, Italy
D-amino acid oxidase catalyzes the oxidative deamination of D-amino acids. In the
brain, the NMDA receptor coagonist D-serine has been proposed as its physiological
substrate. In order to shed light on the mechanisms regulating D-serine concentration at
the cellular level, we biochemically characterized human DAAO (hDAAO) in greater depth.
In addition to clarify the physical-chemical properties of the enzyme, we demonstrated
that divalent ions and nucleotides do not affect flavoenzyme function. Moreover, the
definition of hDAAO substrate specificity demonstrated that D-cysteine is the best
substrate, which made it possible to propose it as a putative physiological substrate
in selected tissues. Indeed, the flavoenzyme shows a preference for hydrophobic amino
acids, some of which are molecules relevant in neurotransmission, i.e., D-kynurenine,
D-DOPA, and D-tryptophan. hDAAO shows a very low affinity for the flavin cofactor. The
apoprotein form exists in solution in equilibrium between two alternative conformations:
the one at higher affinity for FAD is favored in the presence of an active site ligand. This
may represent a mechanism to finely modulate hDAAO activity by substrate/inhibitor
presence. Taken together, the peculiar properties of hDAAO seem to have evolved in
order to use this flavoenzyme in different tissues to meet different physiological needs
related to D-amino acids.
Keywords: D-serine, D-amino acid oxidase, D-cysteine, substrate specificity, structure-function relationships
INTRODUCTION
D-amino acid oxidase (DAAO, EC 1.4.3.3) is the FAD-containing enzyme that catalyzes the
strictly stereospecific oxidative deamination of the D-isomer of neutral amino acids. Since its
discovery in pig kidney (Krebs, 1935), DAAO has been widely studied as a prototype of FAD-
dependent oxidases (Mattevi et al., 1996; Pilone, 2000). D-Amino acids are oxidized by DAAO
to give the corresponding imino acids (subsequently non-enzymatically hydrolyzed to α-keto acids
and ammonia) and hydrogen peroxide (which is generated during the reoxidation of FADH2 on
molecular oxygen (Scheme 1).
DAAO plays various roles in different organisms: in microorganisms it catalyzes the catabolism
of D-amino acids for cell metabolism, and specific functions have been proposed in nematodes,
insects, and lower vertebrates (Pollegioni et al., 2007; Saitoh et al., 2012). In higher vertebrates, it
Abbreviations: CBIO, 6-chloro-benzo(d)isoxazol-3-ol; CD, circular dichroism; DAAO, D-amino acid oxidase (EC 1.4.3.3);
DOPA, 3,4-dihydroxyphenylalanine; hDAAO, human D-amino acid oxidase; L-NAC, N-acetyl-L-cysteine; NMDAR, N-
methyl-D-aspartate subtype of glutamate receptor.
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SCHEME 1 | Scheme of the reaction catalyzed by DAAO on the physiological substrates D-serine and D-cysteine.
was thought to have a detoxifying function in catabolizing
exogenous D-amino acids. In the last few years, however, a
key role in the metabolism of D-amino acids with specific
physiological function has come into play. In mammals, DAAO
is mainly present in kidney, liver, and brain. In the latter, D-
serine is the most abundant D-amino acid (Weatherly et al.,
2017). D-Serine binds to N-methyl-D-aspartate-type glutamate
receptor (NMDAR) - specifically at the “strychnine-insensitive
glycine modulatory site” (Mothet et al., 2000). In the brain,
NMDARs are involved in main physiological processes such
as development, neuronal cell migration, plasticity, learning
and memory (Wolosker et al., 1999, 2008; Mothet et al., 2000;
Snyder and Kim, 2000; Foltyn et al., 2005; Martineau et al.,
2006). In the central nervous system (CNS) DAAO gene and
protein expression show an opposite content and distribution
when compared with D-serine level (Horiike et al., 1994). The
physiological activity of NMDAR is modulated by D-serine
cellular concentration, which level is partially controlled by
DAAO-induced catabolism (Sacchi et al., 2012).
An excessive production / release of D-serine has been
related to acute and chronic degenerative disorders (such as
stroke, amyotrophic lateral sclerosis, epilepsy, and Parkinson’s,
Alzheimer’s, and Huntington’s diseases); an abnormal decrease
in D-serine concentration was instead reported in psychiatric
disorders (i.e., schizophrenia and bipolar disorders) (Rossi et al.,
2007; Labrie and Roder, 2010; Mustafa et al., 2010; Fuchs et al.,
2011; Lu et al., 2011). Here, the R199W mutation in DAAO,
yielding a loss of enzymatic activity, has been associated with a
familial case of amyotrophic lateral sclerosis (Mitchell et al., 2010)
and association studies have linked DAAO (as well as its main
modulatory partner pLG72) with schizophrenia susceptibility;
(for a review, see Sacchi et al., 2012, 2016).
DAAO is mainly a peroxisomal enzyme (Horiike et al., 1994;
Moreno et al., 1999) although an active DAAO form has been
identified in the cytosol, both in glial cells (Sacchi et al., 2008,
2011) and neurons (Popiolek et al., 2011). Notably, DAAO was
recently reported to be present in cytosol and nuclei of rat
proximal tubule epithelial cells treated with propiverine (Luks
et al., 2017), too, and to be secreted into the lumen by intestinal
epithelial cells (Sasabe et al., 2016).
In past decades, extensive investigations were performed on
pig kidney and yeast DAAOs (Pollegioni et al., 1993, 2007). Later
on, recombinant human DAAO (hDAAO) expressed in E. coli
was purified as active holoenzyme (347 residues), containing
one molecule of non-covalently bound FAD per 40 kDa-protein
monomer. hDAAO shows the spectral properties of the FAD-
containing flavoenzymes (Molla et al., 2006). From a structural
point of view, DAAO tertiary structure is made of two domains,
each generated by several non-contiguous sequence regions: an
interface domain made of a large, twisted, antiparallel β-sheet
and a FAD-binding domain possessing the dinucleotide binding
motif (Kawazoe et al., 2006).
hDAAO possesses a number of distinctive properties: (a)
the weakest interaction with the flavin cofactor among known
DAAOs (Kd = 8 × 10
−6 M). In the presence of an active
site ligand (such as benzoate) a 20-fold tighter interaction
with FAD is apparent (Molla et al., 2006). The flavin molecule
shows an elongated conformation and it is completely buried
in the protein core with the only exception of the isoalloxazine
ring, which is accessible to the solvent. The conformation of
a short hydrophobic stretch (47VAAGL51) near the si-face of
the isoalloxazine ring is significantly different between human
and porcine DAAO and thus was considered responsible for the
comparatively lower FAD affinity of hDAAO (Kawazoe et al.,
2006); (b) it exists in solution as an equilibrium between the
active holoenzyme and the inactive apoprotein; (c) it is a stable
80-kDa homodimer in both the holo- and the apoprotein form
(Molla et al., 2006), whereas all known DAAO apoproteins are
monomeric. In the homodimer, the two subunits show a head-to-
head mode of interaction, as also observed in other mammalian
DAAOs (Mattevi et al., 1996; Pollegioni et al., 2007; Frattini et al.,
2011); however, the dimerization interface is mostly positively
charged in the enzyme from pig kidney (Mattevi et al., 1996)
while in hDAAO it is mainly negatively charged (Kawazoe et al.,
2006); d) its half-life (in vitro as well as at the cellular level) and
activity are negatively affected by pLG72 binding (Sacchi et al.,
2008, 2011; Cappelletti et al., 2014).
The hDAAO reaction follows a sequential kinetic mechanism.
The product release from the reoxidized enzyme represents the
rate-limiting step, as also observed for pig DAAO; the rate
Frontiers in Molecular Biosciences | www.frontiersin.org 2 December 2017 | Volume 4 | Article 88
37
Murtas et al. Human D-Amino Acid Oxidase
of flavin reduction is slower for the human enzyme (Molla
et al., 2006). Small, uncharged D-amino acids seem the preferred
substrates for hDAAO, showing a low substrate affinity and
catalytic efficiency on D-serine, the physiological substrate in the
brain. The volume of hDAAO active site is ∼220 A3. Tyr224 is
part of the active site loop: it has been proposed that it switches
during substrate binding from an open to a closed conformation
and thus to allow the binding of substrates possessing large side
chains (Molla et al., 2006; Kawazoe et al., 2007a,b). Indeed, the
switch of this loop, which improves the efficiency of the hydride
transfer reaction by increasing the hydrophobicity of the active
site, represents the rate-limiting step in the kinetic cycle.
Owing to the important physiological and pathological role
of hDAAO, we decided to deepen the investigation on some of
the key biochemical properties of the recombinant enzyme. The
novel information on hDAAO has been discussed with regard




Recombinant hDAAO was expressed in E. coli cells and purified
as reported inMolla et al. (2006) and Romano et al. (2009); 40µM
of free FAD was present during all purification steps. The final
enzyme preparation was stored in 20mM Tris-HCl buffer, pH
8.0, 100mM NaCl, 10% (v/v) glycerol, 5mM 2-mercaptoethanol,
and 40µM FAD. hDAAO apoprotein was prepared by overnight
dialysis of the holoenzyme against 1M KBr (Molla et al., 2006).
hDAAO concentration was determined based on the extinction
coefficient at 445 nm for the holoenzyme (12.2 mM−1 cm−1) and
at 280 nm for the apoprotein (75.2 mM−1 cm−1).
Activity Assay and Kinetic Measurements
DAAO activity was assayed with an oxygen electrode at air
saturation, pH 8.5 and 25◦C, using 28mMD-alanine as substrate
in the presence of 0.2mM FAD (Molla et al., 2006). The apparent
kinetic parameters were calculated according to a Michaelis–
Menten equation using the initial velocity values determined
at increasing substrate concentrations, i.e. up to 450mM D-
cycloserine, 90mM D-cysteine, 90mM D,L-DOPA and 27.5mM
D-kynurenine. The effect of MgCl2 and CaCl2 (1 or 10mM), of
10µM ATP or GTP and of both divalent ions and nucleotides
was assessed using the standard activity assay.
The same assay was employed to investigate the pH and the
temperature effects on the enzyme activity and stability. For
pH-stability, residual activity was assayed after 30 or 60min of
incubation at different pH-values in a multicomponent buffer
(15mMTris-HCl, 15mMNa2CO3, 15mMH3PO4, 100mMKCl,
and 1% (v/v) glycerol) (Harris et al., 1999); for the effect of
temperature, the incubation was carried out in 10mM potassium
phosphate buffer, pH 8.0, containing 1% (v/v) glycerol, 5mM
2-mercaptoethanol and 40µM FAD. The effect of temperature
on the rate constant of loss of enzymatic activity was fit based
on the Arrhenius equation. To investigate the pH and the
temperature effect on enzyme activity, hDAAO activity was
assayed at: (a) 25◦C, using 200mMD-alanine inmulticomponent
buffer (Harris et al., 2001) containing 40µM FAD at different
pH-values; (b) different temperatures using 28mM D-alanine
in 75mM sodium pyrophosphate, pH 8.5, containing 200µM
FAD. Experimental data for pH dependence were fit based on
the equation for two dissociations (Y = a + b(10pH–pKa1)/(1
+ 10pH–pKa1) + [b – c(10pH–pKa2)/(1 + 10pH–pKa2)]) or three
dissociations (Y = a + b(10pH–pKa1)/(1 + 10pH–pKa1) + [b
– c(10pH–pKa2)/(1 + 10pH–pKa2) + [c – d(10pH–pKa3)/(1 +
10pH–pKa3)]) (Harris et al., 2001).
Spectral Measurements
Circular dichroism (CD) spectra were recorded using a Jasco
J-815 spectropolarimeter (Jasco Co., Cremella, Italy) in 10mM
Tris-HCl, pH 8.0, 1% (v/v) glycerol, and 40µM FAD. The cell
path length was 0.1 cm for measurements in the 200- to 250-nm
region (0.1mg protein/mL) and 1 cm for measurements in the
250–350 nm range (0.4mg protein/mL) (Caldinelli et al., 2010).
Protein fluorescence spectra were measured at 1µM protein
concentration (0.04 mg/mL) in 20mM Tris-HCl buffer, pH 8.0,
100mM NaCl, 10% (v/v) glycerol, 5mM 2-mercaptoethanol,
and 40µM FAD for the holoenzyme and in 50mM sodium
pyrophosphate, pH 8.3 for the apoprotein; spectra were recorded
using a Jasco FP-750 instrument and were corrected for the
buffer contribution. Protein fluorescence spectra were recorded
between 300 and 400 nm, with excitation at 280 nm. The ligand
dissociation constants (Kd) were estimated by titrating 1µM
enzyme with increasing amounts of FAD, benzoate, or CBIO
and following the protein fluorescence quenching at 330–340 nm
(Molla et al., 2006). The Kd-values for FAD to the hDAAO
apoprotein moiety was determined in free form and in complex
with benzoate (7 or 70µM). In all cases, Kd-values were
determined using an hyperbolic plot.
RESULTS
Effect of pH and Temperature on hDAAO
Activity and Stability
The activity of hDAAO onD-alanine and D-serine increases with
pH, reaching a maximal value at pH 10 and 9.5, respectively,
and decreases quickly at higher values (Figure 1A). Concerning
the pH effect on stability, the activity values determined after
30 or 60min show that hDAAO is fully stable in a pH range of
4–10 (Figure 1B); experimental values were fitted based on the
equation for two dissociations: estimated pKa’swere 2.5± 0.1 and
11.1± 0.1.
To investigate the temperature dependence of the initial rate
of the reaction catalyzed by hDAAO, the enzymatic activity was
assayed at different temperature values on 28mM D-alanine
(a saturating substrate concentration), at pH 8.5, and in the
presence of 200µM FAD by measuring the O2 consumption.
As shown in Figure 2A, the optimal temperature of hDAAO
activity is 45◦C. The effect of temperature on the enzyme stability
was evaluated assaying the residual activity after 30 or 60min
of incubation. The flavoenzyme was fully stable after 60min of
incubation at 45◦C and fully inactivated at ≥65◦C (Figure 2B).
Melting temperatures were 55.2 and 54.9◦C after 30 and 60min
of incubation, respectively, higher than Tm’s determined from
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Figure 1 | Effect of pH on the activity (A) and stability (B) of hDAAO. (A) The activity was assayed on D-Ala (, ——) or D-Ser (, ---), at 25◦C and air saturation; the
value at pH 8.0 was reported as 100%. Data points were interpolated based on the equation for three dissociations (pKas of 5.7, 9.6, 10.2 and of 5.6, 7.9, 10.5 for
D-alanine and D-serine, respectively). (B) The residual activity of hDAAO was assessed after 30 (, ——) or 60 (, ---) min of incubation at 4◦C at the indicated pH
values, and is related to the value determined at time = 0min for each condition. Data points were fitted based on the equation for two dissociations. Each value was
mean ± SD, n = 3; when not shown error bars are smaller than the symbol used.
Figure 2 | Effect of temperature on the activity (A) and stability (B) of hDAAO. (A) Activity values are reported as specific activity determined at a saturating D-alanine
concentration (28mM). The specific activity at 25◦C (9.5 U/mg protein) corresponds to a kcat-value of 6 s
−1. (B) The residual activity of hDAAO was assessed after
30 (, ——) and 60 (, ---) min of incubation at pH 8.0 in 10mM potassium phosphate buffer, 1% (v/v) glycerol, 5mM 2-mercaptoethanol and 40µM FAD, and is
related to the value determined at time = 0min for each condition. The rate constant for the enzyme inactivation at different temperatures were calculated and used
for the Arrhenius plot reported as inset of (B). Each value was mean ± SD, n = 3.
changes in protein fluorescence (Caldinelli et al., 2010). This
indicates that loss of enzymatic activity follows the alteration in
secondary and tertiary structure, a behavior previously reported
for DAAO from yeast (Caldinelli et al., 2004). The rates of
inactivation at each temperature were determined assaying the
enzyme activity up to 20 h. The Arrhenius plot reporting the
logarithm of rates of inactivation (ln k) plotted against inverse
temperature (1/T) gives a straight line in the 25–55◦C range (inset
of Figure 2B) pointing to the absence of temperature-induced
conformational transitions. From this plot, an activation energy
of 119.4 kJ/mol was calculated.
Modulation of hDAAO Activity
In order to shed light on putative regulation mechanisms
of hDAAO, the effect of selected physiologically relevant
compounds on the flavoenzyme activity was evaluated. The
activity and the far-UV CD spectrum of hDAAO are slightly
modified by calcium ions at 1 or 10mM final concentration
(Figure 3A), while magnesium ions do not modify both the
protein conformation and the hDAAO activity. Adding 10µM
ATP or GTP alter the far-UV CD spectrum of hDAAO,
which is similarly affected by the simultaneous presence of
10µM nucleotide triphosphate and 10mM magnesium ions
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Figure 3 | Comparison of far-UV CD spectra of hDAAO holoenzyme (0.1 mg/mL, black) in the presence of: (A) 1 and 10mM calcium ions (red and blue, respectively);
(B) of 10mM magnesium ions (blue), 10µM ATP (red), and of both compounds (green).
(Figure 3B). These ligands do not alter the far-UV CD spectrum
of the flavoenzyme (not shown). Notably, we previously
demonstrated that pLG72, the specific hDAAO modulator
(Sacchi et al., 2008), also interacts with nucleotide triphosphates
although no ATPase/GTPase activity was assayed (Sacchi et al.,
2017). Indeed, hDAAO activity on D-alanine (at 2 or 28mM final
concentration) is not modified by the simultaneous presence of
10mMmagnesium ions and ATP or GTP (10µM).
The reducing agent N-acetyl-cysteine (L-NAC, a derivative of
the amino acid L-cysteine, an antioxidant and anti-inflammatory
agent, which has the ability to modulate NMDAR activity)
(Kumar, 2015) at 1 or 10mM concentration, does not affect
hDAAO activity even when added to the enzyme preparation
60min before the assay.
Flavin Binding
We previously set up a simple procedure to prepare the
apoprotein form of hDAAO by dialysis in the presence of 1M
KBr (∼70% yield) (Molla et al., 2006). From activity assays
and protein fluorescence changes, a Kd-value of 8µM for
the FAD-apoprotein complex was estimated, which is in good
agreement with the value reported by Raibekas et al. (2000).
Flavin interaction was significantly strengthened by benzoate
binding (Kd = 0.3µM) (Molla et al., 2006; Caldinelli et al.,
2010). Here, we decided to investigate the effect of the active-
site ligand benzoate on hDAAO flavin binding by following the
protein fluorescence quenching during titration of apoprotein
with HPLC-purified FAD.
In the absence of an active-site ligand, the quenching in
protein fluorescence intensity vs. FAD concentration is biphasic:
a saturation is apparent up to ∼2µM FAD, corresponding to
∼50% of the change in fluorescence intensity, and a second
saturation is evident up to ∼80µM FAD (Figure 4). The
corresponding dissociation constants were 0.43± 0.02µMand>
30µM, respectively. Using an amount of benzoate corresponding
to the Kd-value for its binding to hDAAO (7µM), the change
in fluorescence intensity was again biphasic but the first phase
accounted for >70% of the total change. Kd-values of 0.43 ±
0.02µM and 19.1 ± 2.8µM were calculated for the first and the
second phase, respectively. Notably, using an amount of benzoate
corresponding to 10-fold the Kd for its binding to hDAAO
(i.e., 70µM), the intensity change in fluorescence was mainly
fitted using a single saturation equation with a Kd-value of 0.48
± 0.02µM (Figure 4). The observed increase in the intensity
amplitude associated to the first phase indicates that benzoate
binding favors a protein conformation with a higher affinity for
the cofactor.
The holoenzyme reconstitution process was also investigated
by adding increasing concentrations of apoprotein to ∼1µM
of FAD and following the decrease in flavin fluorescence at
528 nm (excitation at 450 nm). In the absence of benzoate, the
fluorescence change at increasing apoprotein concentration was
still biphasic and yielded a Kd,1 = 0.67± 0.07µM(corresponding
to ∼40% of the total change) and a Kd,2 = 4.0 ± 0.9µM. In the
presence of 70µM benzoate the fluorescence intensity change
was essentially monophasic: Kd-value was estimated as 0.40 ±
0.04µM.
Taken together, these analyses show that the apoprotein
form of hDAAO exists in solution as an equilibrium of two
conformations differing in FAD binding affinity: an active-site
ligand such as benzoate favors the form at higher affinity.
Substrate Specificity
All the known DAAOs show a broad substrate specificity
with significant differences depending on the source (Pollegioni
et al., 2007; Sacchi et al., 2012). Here, we reviewed published
data and accomplished the range of investigated D-amino
acids. hDAAO is mainly active on neutral, hydrophobic and
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Figure 4 | Analysis of FAD binding to hDAAO apoprotein in the absence () and presence of 7µM () or 70µM () of benzoate assessed as protein fluorescence
quenching. (A) Shows the fit of the values, expressed as percentage of the total change, corresponding to the first saturation phase of the protein fluorescence
change (up to 2µM of cofactor concentration). The curves reported in (B) correspond to the best fit for the second phase of saturation. Measurements were
performed at 15◦C.
slightly polar D-amino acids: the highest catalytic efficiency was
apparent with D-cysteine while the same parameter for the
brain physiological substrate D-serine was 44-fold lower (see
Table 1). The preference of hDAAO for D-cysteine is of utmost
relevance (see Discussion). Glycine and D-serine are alternative
coagonists that bind to the strychnine-insensitivemodulatory site
of NMDAR (Mothet et al., 2000). hDAAO is also able to oxidize
glycine but the apparent Km for this small substrate (∼1,000-
fold higher than its physiological concentration) hinders its real
degradation by the flavooxidase, especially under physiological
conditions.
hDAAO shows a preference for aromatic D-amino acids: the
highest maximal activity was determined for D-tyrosine and was
high for D-phenylalanine and D-tryptophan as well (Table 1).
Notably, hDAAO oxidizes D-kynurenine, i.e., the D-enantiomer
of the intermediate found in L-tryptophan degradation pathway:
the apparent Km-value (0.7mM) resembles the one determined
for D-cysteine. The product of hDAAO-induced D-kynurenine
oxidation is kynurenic acid, which is known to inhibit NMDAR
by binding to the modulatory glycine site. hDAAO also oxidizes
D-cycloserine, an amino acid that acts as NMDAR modulator
(Kumar, 2015). A specific argument must be made for the D-
enantiomer of 3,4-dihydroxyphenylalanine (DOPA), which can
be converted into the L-enantiomer (then used to synthesize
dopamine) by the reactions of DAAO and a transaminase.
As shown by (Kawazoe et al., 2007b), the apparent maximal
activity, as well as the catalytic efficiency kcat/Km ratio, is the
greatest among tested D-amino acids (Table 1) but the oxidation
of this compound is hampered by the observed substrate
inhibition effect (KI = 0.5mM). For sake of comparison, we
performed the kinetics on D-DOPA preparations whose purity
was evaluated by chiral HPLC: the kcat-value for D-DOPA is the
highest among the tested compounds and the Km is ∼6mM,
thus resulting in a lower catalytic efficiency than that of D-
tyrosine. A main difference with previous results concerns the
substrate inhibition effect that was observed at a significantly
TABLE 1 | Analysis of the substrate specificity of human DAAO.
kcat (s
−1) Km (mM) kcat/Km
(mM−1 x s−1)
SMALL-MEDIUM SIZE AMINO ACIDS
D-Alaninea 5.2 ± 0.1 [10]c 1.3 ± 0.2 [1]c 4.0
D-Serinea 3.0 ± 0.1 [4]d 7.5 ± 0.5 [1]c [3.9]d 0.4
Glycinea ∼ 0.9 ∼ 180 0.005
D-Cysteine 8.6 ± 0.2 0.6 ± 0.1 14.6
D-Prolinea 10.2 ± 0.1 8.5 ± 1.0 1.2
D-Cycloserine 0.77 ± 0.05 83.5 ± 15.0 0.009
HYDROPHOBIC AMINO ACIDS
D-Tyrosined 14.8 1.1 13.5
D-DOPA 40.5 ± 5.1
[21.7]d
6.0 ± 1.3 (KI = 41.3)
[1.5 (KI = 0.5)]
d
6.75 [14.4]d
D-Phenylalanineb 6.6 ± 0.1 [15.5]d 2.7 ± 0.2 [1.2]d 2.4
D-Tryptophanb 3.2 ± 0.1 1.5 ± 0.1 2.1
D-Kynurenine 0.09 ± 0.01 0.7 ± 0.4 0.14
ACIDIC AMINO ACIDS
D-Aspartatea 6.7± 1.2 ∼ 2000 0.0035
D-Glutamate b. d. b. d.
N-Methyl-D-
aspartate
b. d. b. d.
a Molla et al., 2006.
b Frattini et al., 2011.
c Raibekas et al., 2000.
d Kawazoe et al., 2007b (at pH 8.3).
b.d., below detection.
The apparent kinetic parameters were determined by the oxygen-consumption assay at
21% oxygen saturation, pH 8.5, and at 25◦C.
higher D-DOPA concentration (Ki = 41.3mM, Table 1). No
difference in kinetic parameters was apparent when the D,L-
racemic mixture was used (not shown), suggesting that L-
DOPA did not compete with the D-enantiomer for hDAAO
binding.
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The acidic D-amino acids NMDA and glutamate are not
oxidized by hDAAO (at 100 and 500mM final concentration)
while D-aspartate is a very poor substrate: although the maximal
activity is quite high (6.7 s−1), the catalytic efficiency is
strongly affected by the high apparent Km (in the molar range,
see Table 1). At physiological concentrations (0.3–0.5mM)
(Weatherly et al., 2017) the activity of hDAAO on D-Asp is
negligible.
We observed that the activity of hDAAO on 100mM D-
serine (the physiological substrate in brain) is partially inhibited
by the presence of the L-isomer at concentrations higher than
10mM (not shown): half of the activity measured on D-serine
only was assayed when ∼500mM L-serine was simultaneously
present. The kinetics of D-serine oxidation by hDAAO was thus
investigated at increasing L-serine concentrations: as shown by
the double reciprocal plot reported in Figure 5, the L-isomer
does not alter the apparent maximal rate but does increase the
apparent Km-value. Thus, L-serine acts as competitive inhibitor:
a KI of 26.2mM was estimated (see the inset in Figure 5). At
physiological concentrations (≤2mM in brain tissues and in
blood) (Weatherly et al., 2017), L-serine should not affect the
activity of the flavoenzyme on D-serine.
The ability of L-serine to bind at the hDAAO active site like
the corresponding D-enantiomer is further confirmed by the
observed reduction of FAD following anaerobic addition of the
L-amino acid: 14µM of hDAAO was reduced by 1mM L-serine
in >60min. A similar behavior was apparent when employing L-
alanine or L-valine (not shown) but not NMDA, which is not a
substrate of hDAAO.
Ligand Binding
In past years, we focused on the ability of hDAAO to bind
small-size molecules (Molla et al., 2006; Caldinelli et al., 2010).
The drug chlorpromazine was demonstrated to compete with
FAD for the binding to hDAAO apoprotein (Iwana et al., 2008;
Sacchi et al., 2008): its binding generated a protein conformation
more sensitive to thermal unfolding and proteolysis than the
native holoenzyme (Caldinelli et al., 2010). Indeed, a plethora
of investigations focused on identifying and characterizing
substrate competitive inhibitors, in particular for their potential
use as drug to treat schizophrenia and neuropathic pain
(Sacchi et al., 2013). By structural bioinformatics, high-
throughput screening, and three-dimensional structural studies,
a number of DAAO inhibitors have been identified. These
compounds have been classified into three distinct chemotypes
(Lange et al., 2011): (i) hetero(bi)cyclic carboxylic acids, as
5-methylpyrazole-3-carboxylic acid, 4H-furo[3,2-b]pyrrole-5-
carboxylic acid, and 4H-thieno[3,2-b]pyrrole-5-carboxylic
acid; (ii) compounds based on benzo[d]isoxazol-3-ol,
such as 6-chlorobenzo[d]isoxazol-3-ol (CBIO); and (iii) 3-
hydroxyquinoline-2-(1H)-one (a strong hDAAO inhibitor, IC50
= 4 nM) and its analogs. For a review focusing on properties and
pharmacokinetics of DAAO’s inhibitors see (Sacchi et al., 2013).
Here, we decided to investigate the ability of selected
compounds to alter hDAAO conformation by following the
quenching of protein fluorescence. A decrease in protein
fluorescence is apparent at increasing CBIO concentrations: a Kd
Figure 5 | Double reciprocal plot of kinetics of D-serine oxidation by hDAAO in
the presence of increasing concentrations of L-serine. Ki-value for L-serine
was estimated by fitting the Km/Vmax values calculated at different L-serine
concentrations (see inset).
Figure 6 | Effect of CBIO binding to the fluorescence emission spectrum of
hDAAO after adding increasing concentrations of ligand (up to 35µM, see
arrow). The inset shows the fitting of the fluorescence intensity change at
331 nm (expressed as percentage of maximal change) vs. CBIO
concentration. Measurements were performed at 15◦C.
of 0.24 ± 0.05µM was calculated (Figure 6, inset), suggesting
that the induced conformational changes might result in the
loss of function. This value is in good agreement with the IC50
= 188 nM determined from enzyme’s inhibition assays (Ferraris
et al., 2008). Similarly, benzoate also decreased the protein
fluorescence intensity at ∼320–340 nm but a biphasic change
was apparent: a first saturation is observed using low benzoate
concentrations (≤20µM, Kd = 0.33 ± 0.04µM) and a second
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saturation, associated to ∼80% of fluorescence change, was
observed at higher ligand concentrations (Kd = 2.59± 0.68mM),
see Figure 7. For benzoate binding, a Kd-value of 5–7µM was
determined following the formation of a shoulder at 484 nm
in the absorbance spectrum (Raibekas et al., 2000; Molla et al.,
2006), a value of 9.5µM following the CD signal at ∼270 nm
(Caldinelli et al., 2010), and a KI of 7µM following enzyme
inactivation (Kawazoe et al., 2006). On the other hand, no change
in protein fluorescence was observed with glycine (up to 50mM),
ATP (up to 20mM), NMDA (up to 50mM), or D-glutamate (up
to 50mM).
DISCUSSION
In this work, we biochemically characterized hDAAO in greater
depth. Because of its relevant physiological role in the brain
related to modulation of the concentration of the NMDAR
coagonist D-serine, we were interested to know how hDAAO
activity is modulated, taking into consideration both physical-
chemical effects and ligands.
The pH and temperature dependence of hDAAO activity and
stability was established. The human flavoenzyme shows a good
activity on both D-alanine and D-serine in the 6–10 pH range, as
well as a good stability (Figure 1). hDAAO is fully stable up to
45◦C, a value corresponding to the optimum for the enzymatic
activity (Figure 2). Altogether, changes in pH and temperature
in the physiological range do not seem a way to modulate the
function of this enzyme.
We demonstrated that the flavoenzyme activity is not altered
by calcium ormagnesium divalent ions and/or nucleotides as well
as by the reducing agent L-NAC. In aged mice, the expression of
serine racemase (the enzyme responsible for D-serine synthesis)
is reduced, whereas no change in DAAO activity was observed
(Sato et al., 1996): the chronic treatment of senescent rats with L-
NAC to prevent oxidative damage preserved D-serine levels and
serine racemase expression, yielding to intact NMDAR activation
(Haxaire et al., 2012).
We clarified the substrate acceptance of hDAAO,
showing its preference for hydrophobic amino acids: some
of them are molecules relevant in neurotransmission as
they are intermediates of dopamine biosynthetic pathways
(Kawazoe et al., 2007a,b) (see Table 1). Notably, the best
substrate is D-cysteine: it was proposed to be converted by
DAAO in brain and kidney to 3-mercaptopyruvate, which
then generates pyruvate and H2S by 3-mercaptopyruvate
sulfurtransferase (Shibuya et al., 2013). H2S plays different, main
physiological roles in neuromodulation, vascular tone regulation,
cytoprotection against oxidative stress, angiogenesis, and anti-
inflammation; (for a review, see Kimura, 2015). D-Cysteine,
originating from food (Friedman, 2010), could thus represent
the physiological substrate of hDAAO in specific tissues.
D-Cycloserine is a partial agonist and positive modulator
of NMDAR, which binds to the strychnine-sensitive glycine-
binding modulatory site: it acts as an antagonist at high doses
and as an agonist at low doses (Kumar, 2015). It is oxidized by
hDAAO but with a low efficiency because of a very high Km-
value. Concerning NMDAR modulators, hDAAO is also able to
oxidize both glycine and D-aspartate, but again with a very low
kinetic efficiency (at least 100-fold lower than the efficiency of
D-serine oxidation).
DOPA is a further molecule of relevance for
neurotransmission. We confirmed that D-DOPA is oxidized
by hDAAO with the highest kcat-value (∼40 s
−1): the Km
we determined is 4-fold higher than the value previously
reported (Kawazoe et al., 2007b). Most interestingly, we
demonstrated that D-DOPA is less efficient in enzyme inhibition
than previously reported (Ki is 41.3mM) and that L-DOPA
does not compete with the D-form for hDAAO active-site
binding. In contrast, some L-amino acids can bind in the
hDAAO active site, thus acting both as competitive inhibitors
(KI for L-serine is 26.2mM) and, with a very low efficiency,
Figure 7 | Analysis of benzoate binding to hDAAO holoenzyme. (A) Change in protein fluorescence intensity at increasing benzoate concentrations (expressed as
percentage of maximal change). (B). Detail of the first saturation phase of the protein fluorescence quenching at a ligand concentration up to ∼20µM. Measurements
were performed at 15◦C in 20mM TrisHCl buffer, pH 8.0, 150mM NaCl, 5% (v/v) glycerol and 5mM 2-mercaptoethanol.
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as substrates (by slowly reducing the flavin cofactor under
anaerobic conditions).
Concerning the binding of hDAAO inhibitors, a different
situation is apparent for benzoate vs. CBIO. While for the latter
compound the Kd-value determined following the quenching
of protein fluorescence agrees with the Kd, IC50, and Ki-
values reported in the literature, a process characterized by
two phases is apparent for benzoate binding. This observation
indicates that two protein conformations in equilibrium with
different affinity for the ligand or that two ligand binding sites
exist. We demonstrated that benzoate interacts with both the
holo- and the apoprotein forms of hDAAO (Caldinelli et al.,
2009). Noteworthy, a recent investigation combining in silico
docking simulation and labeling experiments using 4-bromo-3-
nitrobenzoic acid highlighted the presence of a second ligand
binding site, located in a cleft between monomers (Kohiki et al.,
2017).
Concerning flavin binding, we previously demonstrated that
an active-site ligand stabilizes the apoprotein-FAD interaction
(Molla et al., 2006; Caldinelli et al., 2010) pushing the holoenzyme
formation. Here, we clearly demonstrated that, in solution,
hDAAO apoprotein exists in two alternative conformations
with different flavin affinity: the equilibrium is shifted toward
the one at higher avidity by the presence of the competitive
inhibitor benzoate, reaching a Kd-value similar to that of rat
or pig DAAOs (Frattini et al., 2011). It is noteworthy that the
reconstitution process leading to the active holoenzyme is a
biphasic, sequential process; first, the apoprotein binds FAD
and gains catalytic activity—and this step is 20-fold faster when
benzoate is bound (Caldinelli et al., 2010)—and then a slower
secondary conformational change follows, which stabilizes the
protein (Caldinelli et al., 2009). Although no crystal structure
of hDAAO in the absence of an active-site ligand has been
solved, our biochemical evidence suggests that, in addition to
the known conformation of the hydrophobic region 47VAAGL51
at the si-face of the isoalloxazine ring of FAD observed in the
hDAAO-benzoate complex, a second conformation should exist
that possesses a lower affinity for the flavin cofactor. This is an
important issue since the holoenzyme stability both increases
the half-life of the protein and affects the cellular D-serine level
(Caldinelli et al., 2010).
Taken together, these findings strengthen our belief that, in
the case of hDAAO, evolution adopted sophisticated regulatory
strategies. Because of the weak interaction between FAD and
hDAAO apoprotein and of the physiological concentration
of the cofactor in human brain tissues, the flavoenzyme
is largely present in the apoprotein, inactive form. The
flavin binding and the kinetic properties (hDAAO possesses
a low catalytic efficiency and substrate affinity) seem to
be evolved to generate an enzyme that controls D-serine
concentration in brain, avoiding an excessive degradation of
the neuromodulator. The fact that the presence of a ligand
in the active site promotes a conformational switch toward
a protein form able to bind more avidly the cofactor might
represent a mechanism finely modulating hDAAO activity:
the free enzyme, significantly present in solution as inactive
apoprotein, is rapidly turned into the flavinylated, active
holoenzyme by the presence of the substrate. This, in turn,
would represent an effective way to keep the concentration of
specific D-amino acids in distinct tissues in the physiological
range. In conclusion, hDAAO possesses a number of peculiar
properties that distinguish it from homologs from diverse
sources. Such properties make this flavoenzyme an interesting
protein that can be used by different tissues to meet various
physiological needs related to the catabolism of different D-
amino acids.
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A B S T R A C T
In the brain, the enzyme D-amino acid oxidase (DAAO) catalyzes the oxidative deamination of D-serine, a main
positive modulator of the N-methyl-D-aspartate subtype of glutamate receptors (NMDAR). Dysregulation in D-
serine signaling is implicated in the NMDAR dysfunctions observed in various brain diseases, such as amyo-
trophic lateral sclerosis, Alzheimer's disease, schizophrenia. A strain of ddY mice lacking DAAO activity due to
the G181R substitution (DAAOG181R mice) and exhibiting increased D-serine concentration as compared to wild-
type mice shows altered pain response, improved adaptative learning and cognitive functions, and larger hip-
pocampal long-term potentiation. In past years, this mice line has been used to shed light on physiological and
pathological brain functions related to NMDAR. Here, we decided to introduce the corresponding substitution in
human DAAO (hDAAO). The recombinant G183R hDAAO is produced as an inactive apoprotein: the substitution
alters the protein conformation that negatively affects the ability to bind the flavin cofactor in the orientation
required for hydride-transfer during catalysis. At the cellular level, the overexpressed G183R hDAAO is not fully
targeted to peroxisomes, forms protein aggregates showing a strong colocalization with ubiquitin, and sig-
nificantly (7-fold) increases both the D-serine cellular concentration and the D/(D + L)-serine ratio. Taken to-
gether, our investigation warrants caution in using DAAOG181R mice: the abolition of enzymatic activity is
coupled to DAAO aggregation, a central process in different pathological conditions. The effect due to G181R
substitution in DAAO could be misleading: the effects due to impairment of D-serine degradation overlap with
those related to aggregates accumulation.
1. Introduction
D-Amino acid oxidase (DAAO, EC 1.4.3.3) is a well-known, FAD-
dependent enzyme which catalyzes the stereospecific oxygen-depen-
dent deamination of D-amino acids to give the corresponding α-keto
acids, ammonia, and hydrogen peroxide [1,2]. In the human brain, the
main physiological function of this flavoenzyme is degradation of D-
serine. This D-amino acid binds to the glycine-modulatory site of the N-
methyl-D-aspartate subtype of glutamate receptors (NMDARs) and, in
addition to glutamate, conditions receptor activation [3–5]: D-Serine
acts as the main endogenous coagonist in different brain areas [5–9].
Furthermore, D-serine has been proposed to be mainly synthesized and
released by neurons and subsequently taken up by astrocytes. In the
latter cells, which contain low levels of the enzyme serine racemase (EC
5.1.1.18, catalyzing both synthesis and degradation of D-serine), DAAO
plays a central role in terminating D-serine signaling [10,11]. Accord-
ingly, DAAO should play a main role in regulating D-serine levels and
thus may affect the NMDAR-dependent physiological functions
involved in cognitive abilities, such as learning and memory [12,13].
Dysregulation in D-serine signaling is implicated in the NMDAR dys-
functions observed in various diseases: a) D-serine is increased in the
spinal cord of patients affected by familial and sporadic amyotrophic
lateral sclerosis (ALS): the R199W substitution in human DAAO
(hDAAO) associated with familial ALS strongly affects the enzyme ac-
tivity, promotes the accumulation of ubiquitinated protein aggregates,
and causes primary motor neuron death [14–16]; b) D-serine level is
altered in Alzheimer's disease [17,18]; c) activated astrocytes may
provide D-serine to enable receptor activation and thus allodynia [19];
and d) D-serine levels are lower in the cerebrospinal fluid and serum of
patients suffering from schizophrenia [20–22]: increased levels of
DAAO expression and activity have been observed concomitantly
[23–25].
A strain of ddY mice lacking DAAO activity in kidney homogenates
was identified in 1983 [26]; the enzyme was inactivated by a single-
base mutation, yielding the G181R substitution [27]. C57BL/6J mice
carrying the DAAO G181R mutation (DAAOG181R mice) showed a
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chronic reduction of DAAO activity throughout life: these mice were
viable and did not demonstrate any obvious change in reproductive
capacity and in NMDAR-related molecular systems but did show en-
hanced NMDAR activity in vivo [28]. D-Serine concentration was in-
creased in whole brain of DAAOG181R mice, as well as in different,
specific brain regions (with the most significant increase in cerebellum)
as compared to wild-type mice [29].
The DAAOG181R mice were used for a number of behavioral tests
[30–32]. DAAO inactivation in these mutant mice likely promoted
adaptative learning in response to changing conditions (i.e., improved
memory for a new target location in the acquisition phase following a
single platform location). Indeed, DAAOG181R mice showed an increase
rate of extinction (a form of learning that acts to suppress, but not to
erase, previously learned responses) in the Morris water maze task,
similar to that observed following administration of 600 mg D-serine/kg
in wild-type animals [29]. Moreover, in the Grin1D481N mice carrying a
mutation in the GluN1 subunit of NMDAR (which decreases glycine
affinity), and displaying schizophrenic-related behavioral deficits, the
DAAOG181R mutation modestly elevated brain levels of D-serine
(~20%), resulted in an improvement in social approach and spatial
memory retention reversal of abnormally persistent latent inhibition
and partial normalization of startle responses [33], and reversed an-
xiolytic effects of diminished NMDAR function [34]. Despite these in-
triguing findings, the effect of the G181R mutation on DAAO bio-
chemical properties was not investigated further.
Since these mice lines are used to shed light on the role played by
the catabolism of D-serine in physiological and pathological human
brain functions related to NMDAR, we introduced in the human fla-
voenzyme the corresponding mutation that abolished enzymatic ac-
tivity in the mouse counterpart, i.e., G183R substitution. This conserved
residue belongs to α-helix α9, which is close to the pyrophosphate and
ribityl groups of the FAD cofactor (see Fig. 1). Here, the main bio-
chemical properties of such a hDAAO variant were compared to those of
the wild-type counterpart, and its effect on cellular D-serine levels,
protein subcellular localization, and apoptosis were also investigated.
2. Materials and methods
2.1. Expression and purification of recombinant G183R hDAAO variant
The G183R hDAAO variant was generated by a mutagenesis reac-
tion using the QuickChange Site-Directed Mutagenesis kit (Agilent
Technologies, Santa Clara, CA, USA) and the pET11b-hDAAO expres-
sion vector encoding the wild-type enzyme as a template [35]. The
recombinant G183R hDAAO variant was expressed in E. coli BL21 (DE3)
Star cells (Invitrogen, Carlsbad, CA, USA), as reported for the wild-type
enzyme [35]. The highest G183R hDAAO production level was ob-
tained by growing the cells overnight at 37 °C after adding 0.6 mM
IPTG at the late exponential phase of growth. The recombinant G183R
hDAAO was purified from the crude extract obtained by sonication and
centrifugation by a single chromatography step on a nickel-chelating
column (Hi-Trap chelating HP column; GE Healthcare, Uppsala,
Sweden) using the following elution buffer: 50 mM sodium pyropho-
sphate, pH 7.2, 0.5 M imidazole, 5% (v/v) glycerol and 5 mM 2-mer-
captoethanol [35,36]. The final hDAAO preparation was equilibrated in
20 mM Tris-HCl, pH 8.0, 100 mM NaCl, 10% (v/v) glycerol, and 5 mM
2-mercaptoethanol.
In order to push holoenzyme reconstitution, the purified G183R
protein (2 mg protein/mL solution added of 200 μM FAD) was dialyzed
against 20 mM Tris-HCl, pH 8.0, 100 mM NaCl, 10% (v/v) glycerol,
40 μM FAD, and 5 mM 2-mercaptoethanol for 20 h at 4 °C, and stored in
the same buffer.
The hDAAO activity was assayed on 28 mM D-alanine as substrate in
75 mM sodium pyrophosphate, pH 8.5, containing 200 μM FAD, at air
saturation and 25 °C by measuring the O2 consumption with an oxygen
electrode [35].
pLG72 was prepared as reported in [37] and stored in 20 mM
Tris–HCl, pH 8.5, 100 mM NaCl, 5% (v/v) glycerol, 5 mM 2-mercap-
toethanol, and 0.1% (v/v) N-lauroylsarcosine (NLS).
2.2. Spectral analysis
UV–Visible absorbance spectral analysis was performed in 20 mM
Tris–HCl, pH 8.0, 100 mM NaCl, 10% (v/v) glycerol, and 5 mM 2-
mercaptoethanol. The concentration of the purified enzyme was cal-
culated using the extinction coefficient at 280 nm (72.5 mM−1 cm−1),
which was determined by measuring the absorbance spectrum of the
protein completely denatured in 6 M urea [38] and assuming an ex-
tinction coefficient as calculated by ExPASy Bioinformatic Resource
Portal using the ProtParam tool (http://web.expasy.org/protparam/).
Circular dichroism (CD) spectra were recorded in 20 mM Tris–HCl,
pH 8.0, 150 mM NaCl, 5% (v/v) glycerol, and 40 μM FAD (for the ho-
loenzyme form only) by using a Jasco J-815 spectropolarimeter (Jasco
Co., Cremella, Italy) on a mixture containing a protein at 0.4 mg/mL for
measurements above 250 nm and at 0.1 mg/mL for measurements in
the 200- to 250-nm region [39].
Protein fluorescence spectra were recorded in a FP-750 instrument
(Jasco Co.) at 1 μM (0.04 mg/mL) protein concentration in 50 mM so-
dium pyrophosphate, pH 8.3. Protein emission fluorescence spectra
were recorded between 300 and 400 nm, with excitation at 280 nm.
The binding constants for FAD, chlorpromazine (CPZ), 6-chloro-benzo
(d)isoxazol-3-ol (CBIO), benzoate, anthranilate, FMN, and riboflavin
were estimated by titrating hDAAO apoprotein with increasing amounts
of ligands and by analyzing the quenching of tryptophan emission at
340 nm [35]. The binding constant for FAD to the apoprotein moiety
was estimated using either the free form or the benzoate-complex
(obtained by adding 50 mM benzoate).
Temperature-ramp experiments (from 20 to 75 °C, at 0.5 °C/min)
were performed in 20 mM Tris–HCl, pH 8.0, 100 mM NaCl, 5% (v/v)
glycerol, 5 mM 2-mercaptoethanol, and 40 μM FAD (for the ho-
loenzyme form only), using a Peltier temperature controller and by
measuring the fluorescence protein change at 340 nm or the CD signal
at 220 nm, as reported in [40].
2.3. Size-exclusion chromatography
The oligomeric state of G183R hDAAO variant and its interaction
with pLG72 (at 40 and 20 nmol, respectively) were investigated by size-
exclusion chromatography on a Superdex 200 Increase column using an
AKTA chromatographic system (GE Healthcare) in 20 mM Tris–HCl,
pH 8.5, 150 mM NaCl, 5% (v/v) glycerol, 40 μM FAD, and 5 mM 2-
mercaptoethanol. In the presence of pLG72, 0.06% (v/v) NLS was
added to the elution buffer [35]. The presence of pLG72 and hDAAO in
the peak corresponding to the complex was confirmed by SDS–PAGE
and Western blot analyses by using anti-hDAAO (1:4000; Davids Bio-
technology GmbH, Regensburg, Germany) and anti-pLG72 (1:500;
Santa Cruz Biotechnology Inc., Dallas, TX, USA) antibodies [41].
2.4. Expression of G183R hDAAO variant in U87 glioblastoma cells
The expression construct encoding the G183R hDAAO variant was
generated using the Quickchange Site-Directed Mutagenesis kit and the
pEYFP-hDAAO-C3 plasmid as template, which encodes for a chimeric
hDAAO fused to the C-terminal end of the enhanced yellow fluorescent
protein (EYFP) [41,42].
Human U87 glioblastoma cells (ATCC) were maintained in DMEM
supplemented with 10% (w/w) fetal bovine serum, 1 mM sodium pyr-
uvate, 2 mM L-glutamine, penicillin/streptomycin, and amphotericin B
(Euroclone S.p.A., Pero, Italy) at 37 °C in a 5% CO2 atmosphere; cells
were transfected using the FuGENE HD transfection reagent (Promega
Co., Madison, WI, USA) and 2 μg of pEYFP–G183R-hDAAO-C3 con-
struct, as reported in [41,42]. The EYFP-hDAAO expression level was
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monitored by conventional epifluorescence microscopy imaging (ex-
citation at 470 nm; Zeiss AXIOVERT 200; Zeiss, Oberkochen, Germany)
and by Western blot analysis in parallel (see above). The transfected
cells were used for further experiments or to select stable clones upon
adding 0.4 mg/mL G418 to the growth medium.
Immunostaining and confocal analyses were performed as reported
in [41,42]. U87 cells were plated on round glass coverslips (2.5 × 105
cells each), incubated for 24 h at 37 °C and 5% CO2, and transfected
with pEYFP-G183R-hDAAO-C3 construct. At 24, 48, and 72 h after
transfection, the coverslips were washed with PBS (10 mM dibasic
sodium phosphate, 2 mM monobasic potassium phosphate, 137 mM
NaCl, and 2.7 mM KCl, pH 7.4) and fixed with 4% (v/v) p-formaldehyde
and 4% (w/v) sucrose in 0.1 M sodium phosphate buffer, pH 7.4, for
15 min at room temperature. The fixed cells were permeabilized and
blocked in PBS supplemented with 0.2% (v/v) Triton X-100 and 4% (v/
v) horse serum, and subsequently stained using primary rabbit poly-
clonal anti-PMP70 (peroxisomal membrane protein 70, 1:200; Sigma-
Aldrich, Saint Louis, MO, USA) or mouse monoclonal anti-ubiquitin
antibody (F-11, 1:150; Santa Cruz Biotechnology Inc.), followed by
secondary anti-rabbit Alexa 647 and anti-mouse Alexa 546 antibodies
Fig. 1. Structure of human DAAO (PDB 2DU8). (A) The
position of the residue G183 mutated in this work is shown
in red. FAD is depicted in yellow. (B, C) Detail of the G183R
substitution. The wild-type residue is shown in green (B),
the mutated residue is shown in red (C). (D) Detail of the
additional interactions established by R183 in the hDAAO
variant. The numbers refer to the distance in Å. Figure
prepared with PyMOL.
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(1:1000; Molecular Probes, Eugene, OR, USA). Immunostained cover-
slips were imaged as reported in [41,42]. Immunofluorescence in U87
cells expressing the EYFP-hDAAO G183R variant was analyzed using an
inverted laser-scanning confocal microscope (TCS SP5, Leica Micro-
systems, Wetzlar, Germany) equipped with a HCX PL APO lambda blue
63.0 × 1.40 NA OIL UV objective. Images were acquired using the
Leica TCS software in a sequential mode to avoid interference between
each channel (emission windows fixed in the 520–538, 551–626 and
650–727 range for EYFP, Alexa 546 and Alexa 647, respectively)
without saturating any pixel. Z-stack sections acquisition (15/cell) was
carried out by selecting the optimized acquisition parameters. Controls
were performed by omitting primary antibodies. The displayed images
represent Z-stack projections of sections obtained with the open source
image software Fiji (average intensity).
2.5. HPLC analysis
Cellular D- and L-serine levels were determined by HPLC chroma-
tography [41,42]: 2.5 × 105 U87 cells expressing EYFP-hDAAO en-
coding wild-type or G183R variant were resuspended in 1 mL of ice-
cold 5% (w/v) trichloroacetic acid, sonicated, and centrifuged (45 min
at 13,000 rpm). The soluble fraction was extracted with ether, neu-
tralized, and derivatized with o-phthaldialdehyde/N-acetyl-L-cysteine
in borate buffer. D- and L-serine were resolved by HPLC chromatography
using a 5-μm Waters C8 (4.6 × 250 mm) reversed-phase column (Wa-
ters Co., Milford, MA, USA). Identification and quantification of D- and
L-serine were based on retention times and peak areas, compared to
those associated with external standards.
2.6. Caspase-Glo 3/7 assay
U87 cells were seeded in 96-well plates at a density of 104 cells/
well, incubated for 24 h at 37 °C and 5% CO2, and transiently trans-
fected with 0.1 μg of the plasmid pEYFP-hDAAO-C3 encoding wild-
type, W209R [16], or G183R hDAAO variants using the FuGENE HD
transfection reagent. After 48 h of incubation, caspase-3 and caspase-7
activity was measured using the Caspase-Glo 3/7 Assay kit (Promega
Co., Madison, WI, USA). According to the manufacturer's instructions,
100 μL of the Caspase-GloW 3/7 reagent was added to each well and the
cells were incubated for 4 h at 25 °C. The light emission produced by
the substrate cleavage, aminoluciferin release, and the subsequent lu-
ciferase reaction were measured by a plate reader (Infinite 200, Tecan,
Mannedorf, Switzerland): the value recorded at 2 h was used to assess
caspase activity. The same measurements were performed by adding
1 mM D-serine to cells 24 h after transfection. Nontransfected U87 cells
and DMEM medium were used as controls and were analyzed in
parallel.
3. Results
3.1. Expression of hDAAO G183R in E. coli and its purification
First, the G183R hDAAO variant was expressed in E. coli cells as N-
terminal His-tagged protein, employing the same conditions used for
the wild-type enzyme [35], but the yield in terms of purified protein
was too low (1 mg/L of fermentation broth) for an in-depth biochemical
characterization. In order to improve the expression level of hDAAO
G183R in a soluble form, the following parameters were investigated by
employing a simplified factorial design approach [43]: the growth
medium (LB, 1.5x LB or TB), the OD600 nm value at the moment IPTG
was added (2.5 or 6), the time of cell collection (0, 1, 2, 5 or 16 h), the
growth temperature after the induction of protein expression (20, 25, or
37 °C), the flask fermentation volume (350, 500, or 700 mL), and the
aeration level. Best conditions in terms of protein expression are re-
ported in Suppl. Table 1.
The G183R variant was purified by HiTrap chelating chromato-
graphy using the procedure previously set up for the wild-type enzyme
[35], yielding a protein preparation with a 95% of purity as judged by
SDS-PAGE analysis and an overall yield of 5.4 mg of pure protein/L of
fermentation broth corresponding to 0.2 mg protein/g cells (Suppl.
Table 2).
3.2. Biochemical properties of G183R hDAAO
Activity assays performed under standard conditions as well as in
the presence of a large excess of exogenous FAD (200 μM) show that
purified G183R hDAAO was fully inactive (Suppl. Table 2). A similar
result was obtained after incubating the enzyme for 1 or 16 h with
100 μM FAD to push holoenzyme reconstitution before the activity
assay. Indeed, the absorbance spectrum of the G183R hDAAO pre-
paration showed that the variant was purified as apoprotein, i.e.,
lacking the typical absorbance peaks at 450 and 380 nm associated with
the bound FAD cofactor (Fig. 2).
In order to push holoenzyme reconstitution, the purified G183R
hDAAO – to which 200 μM FAD was added – was extensively dialyzed
against 40 μM FAD: the resulting preparation showed the typical ab-
sorbance spectrum of FAD containing flavoenzymes (see spectrum 2 in
Fig. 2). The activity assay performed in the presence of an excess of FAD
showed that the reconstituted hDAAO G183R holoenzyme was com-
pletely inactive.
The oligomeric state of G183R hDAAO was investigated by size-
exclusion chromatography. Similarly to the wild-type flavoenzyme,
both the apoprotein and the reconstituted holoenzyme form of hDAAO
G183R showed an elution volume corresponding to a 80-kDa homo-
dimeric state at a protein concentration of 1 and 10 mg/mL (Suppl.
Fig. 1 and Suppl. Table 2).
The protein conformation of the G183R variant was analyzed by
circular dichroism spectroscopy. The far- and the near-UV CD spectra of
the holoenzyme form were significantly altered for the G183R variant
compared to the wild-type hDAAO (Fig. 3A, B). On the contrary, the
secondary and tertiary structure of the apoprotein form was only
slightly modified following the G183R substitution, as made apparent
by the CD spectra in Fig. 3C, D and by the similar protein fluorescence
spectra (not shown). Furthermore, the CD spectra recorded for the re-
constituted holoenzyme form of G183R variant closely resembled the
ones for the apoprotein form, while for the wild-type hDAAO the near-
UV CD spectra significantly differed for the holo- and the apoprotein
forms [39,40].
Thermal stability of hDAAO G183R was investigated by tempera-
ture-ramp experiments analyzing the changes in tryptophan fluores-
cence at 340 nm (for tertiary structure modifications) and in the CD
signal at 220 nm (for secondary structure alterations). In all cases, the
Fig. 2. Comparison of the absorbance spectrum of 35 μM G183R hDAAO variant in
apoprotein (1), as isolated at the end of the purification procedure, and in holoenzyme
form (2), following incubation with a large excess of free FAD.
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melting temperature was 3–6 °C higher for the G183R variant than for
wild-type hDAAO (Table 1).
3.3. Binding properties
Dissociation constants of the apoprotein form of G183R hDAAO
variant for FAD (both the free form and the benzoate complex), FMN,
riboflavin, chlorpromazine (CPZ, a FAD-competitive inhibitor of
hDAAO, used as an antipsychotic drug in schizophrenia treatment)
[44], 6-chloro-benzo(d)isoxazol-3-ol (CBIO, a hDAAO inhibitor that
binds to the enzyme active site) [45], benzoate (a substrate-competitive
inhibitor that increases the affinity for the cofactor of the wild-type
enzyme) [35], and anthranilate were estimated by titrating 1 μM of the
enzyme with increasing amounts of ligand and by analyzing the
quenching of tryptophan emission at 340 nm. Titration of the G183R
variant with FAD in the absence and presence of 50 mM benzoate is
shown in Suppl. Fig. 2: in the latter case the emission maximum is
shifted from 340 nm for the apoprotein to ~320 nm at the end of the
titration.
Compared to the wild-type hDAAO, the most significant alterations
in the G183R variant were apparent for the binding of FAD in the
presence of benzoate (~ 1000-fold weaker) and for the binding of an-
thranilate (~ 150-fold weaker). Kd values are reported in Table 2.
Fig. 3. Comparison of CD spectra of wild-
type (——) and G183R (—) hDAAO variants.
(A, C) Far-UV CD spectra of holoenzyme (A)
and apoprotein (C) forms of hDAAO variants
(0.1 mg/mL). (B, D) Near-UV CD spectra of
holoenzyme (B) and apoprotein (D) forms of
hDAAO variants (0.4 mg/mL).
Table 1
Comparison of melting temperatures of wild-type and G183R hDAAO variants as de-




Wild-type G183R Wild-type G183R
Protein fluorescence (at
340 nm)
53.1 ± 1.0 59.1 ± 1.5 57.7 ± 0.3 61.0 ± 1.7
CD (at 220 nm) 58.8 ± 1.0 63.2 ± 0.4 57.0 ± 1.0 62.4 ± 0.3
Values are reported as mean ± SD (n = 3). Table 2
Comparison of binding properties of wild-type and G183R hDAAO variants. For the latter
variant, the apoprotein form was used. The Kd values were determined following the
quenching of protein fluorescence.
Dissociation constant (Kd)
Wild-type G183R
FAD, free form (μM) 7.9 ± 2.0a 8.4 ± 1.9
Benzoate complex (μM) 0.3 ± 1.0a 235.0 ± 25.9
FMN (μM) 12.0 ± 0.6 56.6 ± 4.2
Riboflavin (mM) 1.0 ± 0.1 0.8 ± 0.1
CPZ (μM) 5.0 ± 0.1b 9.3 ± 0.2
Benzoate (mM) 1.8 ± 0.5 6.5 ± 0.4
CBIO (μM) 369 ± 64 628 ± 25
Anthranilate (μM) 2.7 ± 0.6 386.1 ± 30.4
Values are reported as mean ± SD (n = 3).
a [35].
b [41].
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Notably, after adding a large excess of benzoate or anthranilate to
G183R hDAAO-reconstituted holoenzyme, no alteration of the visible
absorbance spectrum was apparent, as was observed for the wild-type
enzyme [35]. The alteration observed for the latter enzyme gives strong
evidence of ligand binding at the active site of DAAO since it corre-
sponds to the π-π interaction between the aromatic ring of the ligand
and the isoalloxazine ring of FAD [2,46].
The interaction between G183R hDAAO and the modulator pLG72
was investigated by size-exclusion chromatography using a mixture
containing a 2:1 molar ratio of hDAAO and pLG72, a condition leading
to the 200-kDa complex formation for the wild-type enzyme [41]. The
G183R hDAAO variant interacted with pLG72, also yielding the 200-
kDa complex: in addition to the peak at an elution volume of 14.1 mL,
corresponding to G183R hDAAO, a peak at 12.4 mL, corresponding to
the complex, was apparent (Fig. 4).
3.4. Expression of hDAAO G183R in U87 cells
The effect of the G183R substitution in the human flavoenzyme was
studied at the cellular level by analyzing its subcellular localization and
by measuring cellular D-serine concentration. For this purpose the
hDAAO variant was expressed in human U87 glioblastoma cells using a
pEYFP-hDAAO-C3 construct that encodes for a chimeric hDAAO fused
to the C-terminus of EYFP [41,42]. The subcellular localization of
G183R hDAAO was analyzed in cells both stably and transiently ex-
pressing the flavoenzyme variant by immunostaining and confocal
microscopy analyses. The signal for the wild-type enzyme was mainly
cytosolic at 24 h from transfection and largely compartmentalized to
peroxisomes at 48 and 72 h from transfection [42]. Similarly to the
wild-type enzyme, in U87 cells transiently transfected EYFP-hDAAO
G183R mainly showed a cytosolic distribution at 24 h from transfec-
tion; while at 48 and 72 h from transfection, differently to hDAAO wild-
type, the chimeric protein fluorescence signal only partially overlapped
with PMP70 one, indicating an incomplete peroxisomal targeting. In-
deed, the same cells formed cytosolic protein aggregates and showed a
high ubiquitin signal intensity (Fig. 5A). Notably, aggregate-containing
cells often showed an altered (fused) morphology for peroxisomes, as
previously observed in cells expressing the G331V hDAAO variant [36].
The images acquired from U87 cells stably expressing the G183R
hDAAO variant resembled those of U87 cells 72 h after transient
transfection. EYFP-hDAAO G183R was partially compartmentalized to
peroxisomes: its distribution was largely cytosolic and overlapped to
the signal corresponding to ubiquitin (Fig. 5B).
The effect of the G183R substitution on D-serine cellular levels was
studied on U87 cells stably expressing the wild-type or the variant
hDAAO by HPLC chromatography (Suppl. Fig. 3). The D-serine cellular
concentration and the D/(D + L)-serine ratio were significantly higher
(~7-fold) in the selected U87 clone stably expressing the fully inactive
G183R hDAAO variant than in the control clone expressing the wild-
type enzyme (Table 3).
Since hDAAO is known to be partially cytosolic and that the G183R
variant is prone to aggregation (see above), we investigated the acti-
vation of apoptosis induced by expression of hDAAO on U87 cells
transiently expressing the wild-type, W209R (a hDAAO variant showing
an improved activity) [16] or G183R variants of the flavoenzyme by
assaying the activity of caspase 3 and 7. Caspase activity was lower in
cells expressing the inactive G183R variant than in cells expressing the
active wild-type or W209R hDAAOs (see Fig. 6, left). The level of
apoptosis in cells expressing the G183R hDAAO was unchanged when
exogenous 1 mM D-serine was added to the medium, while a significant
decrease in luminescence signal was apparent for cells expressing the
active hDAAO variants (Fig. 6, right). Taken together, the induction of
apoptosis is likely related to both the activity and the aggregation
ability of the overexpressed hDAAO variant.
4. Discussion
Considering the low levels of serine racemase in astrocytes, the
“serine shuttle model” [10,11] indirectly assigns to DAAO a key role in
regulating D-serine concentration in these cells: this flavo-oxidase exerts
a neuromodulatory function by terminating D-serine signaling and thus
may affect the NMDAR-dependent physiological functions involved in
key cognitive abilities [12,13]. As stated in the Introduction section, a
dysregulation in D-serine signaling is implicated in the NMDAR dys-
function observed in a number of pathological conditions.
Structural and functional studies have highlighted the peculiar
biochemical properties of hDAAO [35,40,41,47,48]: it only weakly
binds the FAD cofactor, shows a stable homodimeric state, and its ac-
tivity and half-life are specifically regulated by pLG72 binding. Not-
withstanding the high sequence identity with the mouse counterpart
(80.6%), we propose that hDAAO evolved to tightly control D-serine
concentration in the brain and thus to finely tune NMDAR-related
processes.
Since the ddY mice lacking DAAO activity has been used to shed
light on physiological and pathological brain functions related to
NMDAR, we decided to introduce the corresponding substitution in
human DAAO and to investigate the main properties of the protein
variant.
The recombinant G183R hDAAO is produced as inactive apoprotein.
Abolition of catalytic activity is not only due to the low binding affinity
for the cofactor since the reconstituted holoenzyme did not recover the
ability to oxidize D-serine. Furthermore, CD spectra of reconstituted
G183R hDAAO holoenzyme resemble those recorded for the apoprotein
form, and the variant protein shows a higher thermal stability than the
wild-type hDAAO. By following the changes in protein fluorescence
during the titration with different ligands, it was made clear that the
G183R substitution only alters the binding of the FAD and its analogues
FMN, riboflavin, and CPZ, as well as the substrate-competitive in-
hibitors benzoate and CBIO (< 3.5-fold) to a limited extent (< 4.5-
fold). In any case, the absence of a perturbation in the 400- to 500-nm
range of the flavin absorbance spectrum during benzoate and anthra-
nilate titration points to ligand positioning in G183R hDAAO not par-
allel to the isoalloxazine ring, as usually observed for substrate-com-
petitive aromatic inhibitors [47,48]. Taken together, the biochemical
characterization indicates that the substitution of G183 with an argi-
nine alters hDAAO conformation and negatively affects the ability to
bind the flavin cofactor in the orientation required for hydride-transfer
during catalysis, a conformation that is further modified when the
substrate or a substrate analogue is bound in the active site [35,40]. The
25-fold tighter interaction of the apoprotein with FAD observed in the
Fig. 4. Analysis of pLG72 binding to G183R hDAAO (20 and 40 nmol, respectively). Size-
exclusion chromatography was used to investigate the 200 kDa hDAAO-pLG72 complex
formation (——). Elution profile of G183R hDAAO (—).
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presence of benzoate for the wild-type hDAAO [35] translates into a 30-
fold lower affinity in the G183R variant. The conserved G183 residue
belongs to α-helix α9, which is close to the pyrophosphate and ribityl
groups of FAD (see Fig. 1A, B). By substituting it with an arginine,
additional electrostatic and hydrogen bond interactions can be estab-
lished with surrounding residues side chains and -CO and -NH backbone
groups that are in close contact with the moiety of FAD (Fig. 1C, D). The
ensuing alteration in protein conformation alters the binding and or-
ientation of the cofactor, thus affecting the interaction of the iso-
alloxazine ring with the substrate/competitive inhibitor.
At the cellular level, the overexpressed G183R hDAAO is partially
targeted to peroxisomes and forms protein aggregates showing a strong
colocalization with ubiquitin. Indeed, its overexpression significantly
increases both the D-serine cellular concentration and the D/(D + L)-
serine ratio (7-fold). We demonstrated that the increase in D-serine does
not alter the concentration of L-serine (Table 3): in agreement with the
preferential neuronal localization of serine racemase [49], in glial cells
the two enantiomers cannot efficiently convert each other and thus the
excess of D-serine will be stored. Notably, in contrast to what is ob-
served for the R199W hDAAO related to ALS [15,50] and the G331V
Fig. 5. Confocal analysis of the subcellular
localization of EYFP-hDAAO G183R variant
in transiently (A) and stably (B) transfected
U87 human glioblastoma cells. The dis-
tribution pattern of EYFP-hDAAO G183R as
well as the immunofluorescence of the per-
oxisomal marker PMP70 and ubiquitin is
reported in gray scale in the single channel
panels. In the merge panels the signal for
chimeric protein fluorescence (yellow
channel) is overlaid to the signals corre-
sponding to peroxisomes (blue channel) and
ubiquitin (red channel). Images represent Z-
stack projections of 15 sections. Insets show
a high magnification detail of a single cell.
Scale bars correspond to 5 μm (panels) and
2 μm (insets).
Table 3
Quantitative analysis of EYFP-hDAAO G183R expression levels, D-serine levels and D-/(D
+ L)-serine ratio in U87 cells clones stably expressing wild-type or G183R EYFP-hDAAO
variants. Expression levels are reported as the pEYFP-hDAAO/actin signal intensity ratio.
hDAAO
Wild-type G183R
Relative DAAO expression (pEYFP-hDAAO/actin) 1.43 1.16
D-Serine (pmol)a 1.8 ± 0.5 13.3 ± 1.4
L-Serine (pmol)a 48.5 ± 16.2 45.0 ± 1.6
D-/(D + L)-Serine (%) 3.6 ± 0.2 28.2 ± 8.3
a Values refers to 2.5 × 105 cells and are reported as mean ± SD (n = 5).
Fig. 6. Caspase activity in untrasfected (black) and in transiently transfected U87 cells
expressing wild-type (dark gray), G183R (white) or W209R (light gray) EYFP-hDAAOs.
Caspase activity was assayed at 48 h after transient transfection of EYFP-hDAAO and
compared to that detected in control cells (untrasfected U87 cells). The protease activity
was measured as relative light units by lysing the cells in the presence of Caspase-Glo 3/7
substrate. The samples on the right were added of 1 mM D-serine at 24 h after transfec-
tion. The values as reported as the mean ± standard deviation.
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variant related to schizophrenia susceptibility [36], where formation of
protein aggregates is coupled to strong induction of apoptosis, G183R
hDAAO overexpression did not result in enhanced apoptosis.
In conclusion, the ability of the G183R hDAAO to bind the FAD
cofactor is strongly affected and its ability to degrade D-serine is fully
abolished. As such, the G183R substitution resembles the effect of the
R199W substitution related to a familial case of ALS [15,16,50]: the
substitution altered the protein conformation, yielding loss of enzy-
matic activity and protein aggregation at the cellular level, which re-
sulted in an abnormal increase in cellular D-serine concentration. A si-
milar situation was observed in aged mice lacking DAAO activity,
where ubiquitin-positive aggregates were observed in motoneurons of
the ventral root in the spinal cord, which was associated to axonal
degeneration with muscle atrophy [51].
Taken together, our investigation warrants caution in using mice
lacking DAAO activity because of the G181R single-point mutation. The
effect due to this substitution in hDAAO could be misleading: the effects
due to impairment of D-serine degradation overlap with those related to
aggregate accumulation.
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Substitution of Arginine 120 in
Human D-Amino Acid Oxidase
Favors FAD-Binding and Nuclear
Mistargeting
Giulia Murtas*, Silvia Sacchi and Loredano Pollegioni
Dipartimento di Biotecnologie e Scienze della Vita, Università degli Studi dell’Insubria, Varese, Italy
The peroxisomal enzyme human D-amino acid oxidase (hDAAO) is attracting attention
owing to its role in degrading D-serine, the main co-agonist of N-methyl D-aspartate
receptors in brain, and its involvement in brain functions and diseases. Here, we focused
on arginine 120, a residue located at the protein interface, 20 Å from the assumed
second ligand-binding site, showing a different orientation of the side chain in the
hDAAO-benzoate complex, and corresponding to Ser119 in rat DAAO, which is part
of a putative nuclear translocation signal (NTS). By substituting Arg120 in hDAAO with
a glutamate (to mimic the active NTS) or a leucine (to eliminate the positive charge)
the protein conformation, thermal stability, and kinetic properties are slightly altered,
while the dimeric structure and the ligand-binding properties are unchanged. The most
relevant alteration in Arg120 variants is the strongest interaction with FAD. Nevertheless,
the activity assayed at low D-serine and FAD concentrations (resembling physiological
conditions) was quite similar for wild-type and Arg120 hDAAO variants. These results
resemble the ones obtained substituting another residue located at the interface region
(i.e., theW209R variant), indicating that substitutions at the monomer-monomer interface
mainly affects the FAD binding in hDAAO. Indeed, U87 glioblastoma cells transiently
transfected for hDAAO variants show that substitution of Arg120 favors mistargeting:
the increase in cytosolic localization observed for the variants promotes nuclear targeting,
especially for the R120E hDAAO, without affecting cell viability. Notably, mistargeting to
the nucleus is an innate process as it is apparent for the wild-type hDAAO, too: whether
such a process is related to specific pathologic processes is still unknown.
Keywords: flavoprotein, D-serine, mistargeting, structure-function relationships, peroxisome
INTRODUCTION
Human D-amino acid oxidase (hDAAO, EC 1.4.3.3) is a FAD-dependent enzyme, which catalyzes
the oxidative deamination of neutral D-amino acids into the corresponding α-keto acids, ammonia,
and hydrogen peroxide (Pollegioni et al., 2007; Sacchi et al., 2012; Murtas et al., 2017). In the brain,
the main physiological substrate of this flavoenzyme is D-serine (D-Ser). D-Ser binds the glycine
site of the N-methyl-D-aspartate type of the glutamate receptors (NMDAr) regulating its activity
(Mothet et al., 2000; Li et al., 2013; Le Bail et al., 2015). A number of experimental results suggests
that dysregulation of processes tuning D-Ser concentrations and thus of NMDAr-dependent
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neurotransmission is involved in the mechanisms that concur
to trigger various diseases such as amyotrophic lateral sclerosis,
Alzheimer’s disease, schizophrenia, etc. (Chumakov et al., 2002;
Verrall et al., 2007; Billard, 2008; Madeira et al., 2008; Wolosker
et al., 2008; Collingridge et al., 2013; Curcio et al., 2013; Murtas
et al., 2017). Astrocytes express DAAO, the enzyme responsible
for D-Ser degradation and thus ultimately modulate NMDAr-
dependent physiological functions (Wolosker, 2011).
During the past few years, hDAAO structural-functional
relationships have been studied in depth using the recombinant
protein produced in E. coli (Kawazoe et al., 2006; Molla et al.,
2006; Pollegioni et al., 2007; Caldinelli et al., 2009, 2010; Romano
et al., 2009; Sacchi et al., 2012; Murtas et al., 2017) and cell
lines overexpressing the enzyme (Sacchi et al., 2008, 2011; Li
et al., 2013). Nevertheless, several aspects in the modulation
of the enzyme activity remain elusive (Pollegioni et al., 2018).
DAAO is known as a peroxisomal enzyme (Moreno et al., 1999;
Sacchi et al., 2008; Cappelletti et al., 2014) that is targeted
to this organelle due to the C-terminal PTS1 sequence. In
peroxisomes, the cytotoxic product hydrogen peroxide generated
by the DAAO reaction is eliminated by specific enzymes, such
as catalase. U87 glioblastoma cells transiently overexpressing
hDAAO showed that the flavoenzyme is cytosolic before being
delivered to peroxisomes: a time course of protein import
was reported in Sacchi et al. (2008, 2011). Recent reports on
rats demonstrated that DAAO is present both in cytosol and
nuclei of proximal tubule epithelial cells following treatment
with the drug propiverine (Luks et al., 2017a). In the nucleus,
DAAO is ubiquitinated, sumoylated, and degraded through
the nuclear proteasomal system (Luks et al., 2017a,b). The
mistargeting of the enzyme could be due to the presence of an
NTS (TPx sequence corresponding to 117T-P-S119) that, after
phosphorylation of Ser119, might activate the translocation to
the nucleus (Chuderland et al., 2008; Luks et al., 2017a). Ser119
of rat DAAO (rDAAO) corresponds to Arg120 in the hDAAO
sequence. Notably, deletion of the C-terminal peroxisomal
targeting signal 1 (PTS1) in both hDAAO and rDAAO resulted in
a diffused nuclear and cytosolic distribution of the flavoenzyme
(Luks et al., 2017b): nuclear localization was higher for rDAAO
probably because a serine is phosphorylated more frequently
than an arginine or was due to the different molecular masses
of the two homologous enzymes (40 vs. 80 kDa for rDAAO
and hDAAO, respectively). Substitution of the putative tripeptide
for nuclear translocation with the EPE sequence fully abolished
nuclear import, independently of the presence of the PTS1 signal
(Luks et al., 2017b).
In hDAAO, the binding of an active site ligand facilitates FAD-
apoprotein interaction to yield the active holoenzyme (Caldinelli
et al., 2010; Murtas et al., 2017), this representing a main
regulatory mechanism of its activity. R120 is located at the
monomer-monomer interface (Figure 1A) and it has been also
Abbreviations: CBIO, 6-chloro-benzo(d)isoxazol-3-ol; CD, circular dichroism;
DAAO, D-amino acid oxidase (EC 1.4.3.3); D-Ala, D-alanine; D-Cys, D-cysteine;
D-Ser, D-serine; EYFP, enhanced yellow fluorescent protein; hDAAO, human
D-amino acid oxidase; NMDAr, N-methyl-D-aspartate subtype of glutamate
receptor; NTS, nuclear translocation signal.
proposed to play a role in ligand binding. Binding of benzoate
(an active site ligand) to hDAAO is a biphasic process (Murtas
et al., 2017). Indeed, the FAD-binding to hDAAO apoprotein in
the absence of an active site ligand is also biphasic, while a single
phase of saturation is apparent in the presence of 70µMbenzoate
(Murtas et al., 2017). For both FAD and benzoate binding no
evidence of cooperativity between the first and second binding
process was observed, which indicates the presence of two
alternative protein conformations. A second benzoate binding
site located in a cleft between the monomers was proposed
(Kohiki et al., 2017): it is constituted by the residues belonging to
FIGURE 1 | Structure of hDAAO. (A) Details of the monomer-monomer
interface of hDAAO. The second putative benzoate binding site proposed by
Kohiki et al. (2017) is depicted in yellow. (B) Alternative orientations of R120 in
hDAAO in the free form (blue, pdb 2E48) and in complex with benzoate
(magenta, pdb 2DU8), with imino-DOPA (green, pdb 2E82), and with
imino-serine (orange, pdb 2E49). (C) Details of the interaction of R120 with
residues of the facing subunit (the two protomers are depicted in a different
color).
Frontiers in Molecular Biosciences | www.frontiersin.org 2 November 2019 | Volume 6 | Article 125
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the loop between β-strands 8 and 9 (residues 205-211) and those
between β-strands 10 and 11 (residues 231-236); see Figure 1A.
The overlay of the solved structures of hDAAO (in detail, 2DU8
in complex with benzoate, 2E82 in complex with imino-DOPA,
2E49 in complex with imino-serine, and 2E48, the substrate-
free holoenzyme) does not show any difference in the residues
belonging to the putative second binding site and pinpoints the
orientation of R120 in the structure of hDAAO in complex with
benzoate (Figure 1B) as being the only difference. R120 is located
at the protein interface at 20 Å from the residues of the second
binding site (Figure 1A).
Owing to the relevant physiological and pathological role
of hDAAO, we expressed and biochemically characterized two
variants at position 120 generated to mimic the activation of
the NTS (by modifying the TPx sequence) and to verify its
involvement in ligand binding and protein functionality.
MATERIALS AND METHODS
Preparation and Expression of hDAAO
Variants in Escherichia coli
Mutagenesis reactions to prepare His-hDAAO R120E and R120L
variants were performed on the pET11b-His-hDAAO wild-type
expression plasmid (Molla et al., 2006) using the QuickChange
site-directed mutagenesis kit (Stratagene, Santa Clara, CA, USA).
Previous studies showed that the His-tag at the N-terminal end
of hDAAO did not alter its activity or stability (Molla et al.,
2006; Romano et al., 2009). Recombinant wild-type and R120
hDAAO variants were expressed in BL21 (DE3) Star E. coli cells
and purified as reported in Molla et al. (2006) and Romano et al.
(2009); 40µM of free FAD was present during all purification
steps. The final enzyme preparations were stored at −20◦C
in 20mM Tris-HCl buffer, pH 8.0, 100mM NaCl, 10% (v/v)
glycerol, 40µM FAD, and 5mM 2-mercaptoethanol (added for
long-term storage). Final enzyme preparations have a purify
degree >95% as judged by SDS-PAGE analysis. The enzyme
concentration was determined spectrophotometrically by using
the extinction coefficient at 445 nm (12.2 mM−1 cm−1) (Molla
et al., 2006).
Activity Assay and Kinetic Measurements
DAAO activity was assayed with an oxygen electrode at pH 8.5,
air saturation, and 25◦C, using 28mMD-alanine as the substrate
in the presence of 0.2mM FAD (Molla et al., 2000, 2006). The
kinetic parameters were determined on different D-amino acids,
employing increasing substrate concentrations (Molla et al.,
2000, 2006). The apparent kinetic parameters were calculated
using the initial reaction rate according to a Michaelis–Menten
equation using the Kaleidagraph software (Synergy Software,
Reading, PA, USA).
Spectral Measurements
Ligand and FAD-binding to hDAAO were investigated by
following the quenching of protein fluorescence (0.3mg
protein/mL) (Molla et al., 2000; Caldinelli et al., 2009; Murtas
et al., 2017). Protein fluorescence spectra were recorded between
300 and 400 nm, with excitation at 280 nm using a Jasco FP-750
instrument (excitation slit of 10 nm; emission slit of 5 nm) in
10mM potassium phosphate, pH 8.0, 1% (v/v) glycerol, 5mM
2-mercaptoethanol, and 40 µM FAD.
Circular dichroism (CD) spectra were recorded in 10mM
Tris-HCl, pH 8.0, 1% (v/v) glycerol, and 40µM FAD by using
a Jasco J-815 spectropolarimeter and analyzed employing a
dedicated software (Jasco Co., Cremella, Italy). Cell path length
was 1 cm formeasurements above 250 nm (at 0.4mg protein/mL)
and 0.1 cm for measurements in the 190- to 250-nm region (at
0.1mg protein/mL) (Caldinelli et al., 2009, 2010).
Temperature-ramp experiments were performed in
10mM potassium phosphate, pH 8.0, 1% glycerol, 5mM
2-mercaptoethanol, and 40µM FAD. A software-driven,
Peltier-equipped fluorimeter was used to measure the
fluorescence protein changes at 340 nm and Peltier-
equipped CD spectropolarimeter to follow the CD
signal at 220 nm: a temperature gradient of 0.5◦C/min
(Caldinelli et al., 2009, 2010).
Oligomeric State
The molecular mass in solution of hDAAO variants (0.1–10
mg/mL protein) was investigated by means of gel-permeation
chromatography on a Superdex 200 Increase column, using
an Akta chromatographic system (GE Healthcare, Uppsala,
Sweden), at room temperature and in 20mM Tris–HCl,
pH 8.5, 150mM NaCl, 5% glycerol, 40µM FAD, and 5
mM 2-mercaptoethanol.
Cell Cultures and Transfection
Human U87 glioblastoma cells (ATCC) were cultured in
DMEM supplemented with 10% fetal bovine serum, 1mM
sodium pyruvate, 2mM L-glutamine, 1% non-essential amino
acids, 1% penicillin/streptomycin, and 1% amphotericin B
(Euroclone), at 37◦C in 5% CO2. The cells were transfected
either with the pEYFP-hDAAO-C3 construct (for the expression
of the wild-type enzyme downstream of the enhanced yellow
fluorescent protein, EYFP) (Sacchi et al., 2008, 2011), the
pEYFP-hDAAO(R120L)-C3, or the pEYFP-hDAAO(R120E)-C3
expression vectors. The latter constructs were obtained by
mutagenesis using the QuikChange Lightning Site-Directed
Mutagenesis Kit (Agilent), and the following primers: 5′-
ATTTCGGAAGCTGACCCCCGAGGAGCTGGATATGTTCCC
AG-3′ and 5′-CTGGGAACATATCCAGCTCCTCGGGGGTCA
GCTTCCGAAAT-3′ for the R120E substitution, and 5-
TTCGGAAGCTGACCCCCTTAGAGCTGGATATGTTCC-3′
and 5′-GGAACATATCCAGCTCTAAGGGGGTCAGCTTCCG
AA-3′ for the R120L substitution.
For transient transfection, 2 × 104 cells were seeded into
eight-well chamber slides (Sarstedt). At 24 h after seeding, cells
were transfected with 2 µg plasmid DNA using a 4:1 ratio of
FuGENE transfection reagent (Promega) to DNA. Then, 12.5
µL of transfection mix was added to 500 µL medium per well.
Protein expression levels were monitored by using a fluorescence
microscope (Olympus IX51) equipped with a FITC filter and by
Western blot analysis using an anti-hDAAO antibody (Davids
Biotechnologie) (Sacchi et al., 2008, 2011).
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Immunostaining and Confocal Microscopy
At 24, 48, and 72 h after transfection, cells were washed twice with
PBS and fixed with ice-cold 4% p-formaldehyde and 4% sucrose
for 10min at room temperature. After fixation, cells were washed
twice with PBS and blocked by incubation in PBS supplemented
with 0.2% Triton X-100 and 4% horse serum for 30min at room
temperature. Peroxisomes were stained using rabbit polyclonal
anti-PMP70 (peroxisomal membrane protein 70, Sigma), diluted
1:500 in PBS, 0.1% Triton X-100, and 4% horse serum overnight
at 4◦C; they were then washed twice in PBS and 1% horse serum
and incubated for 1 h at room temperature (light protected)
with goat anti-rabbit Dylight 550 secondary antibodies (Abcam)
diluted 1:400 in PBS, 0.1% Triton X-100, and 1.5% horse serum.
Cells were then extensively washed in PBS and nuclei were
stained with DRAQ5TM (Thermo Scientific) and diluted 1:500
in PBS for 10min at room temperature in the dark. Cells
were washed three times with PBS and stored in PBS at 4◦C
until imaging.
Immunostained cells were imaged using an inverted laser
scanning confocal microscope (TCS SP5, Leica Microsystems),
equipped with a 63.0 × 1.25 NA plan apochromatic oil
immersion objective. Confocal image stacks were acquired
using the Leica TCS software with a sequential mode to
avoid interference between each channel and without saturating
any pixel. Cells in 10–15 non-magnified optical fields were
analyzed for each condition (i.e., different EYFP-hDAAO
expression constructs at different times after transfection). The
fluorescence signal corresponding to the overexpressed EYFP-
hDAAO variants was monitored by excitation at 514 nm (yellow
channel); the peroxisomal and nuclear cellular compartments
were imaged by excitation at 546 nm (red channel) and 647 nm
(blue channel), respectively.
RESULTS
Design of R120 hDAAO Variants
Analysis of the hDAAO primary sequence for nuclear
localization (e.g., by NucPred or cNL Mapper) and for the
presence of nuclear localization sequences (e.g., by Moseslab,
NLSdb by RostLab, or SeqNLS) does not predict hDAAO
targeting to the nucleus. A putative nuclear translocation signal
for rDAAO (117T-P-S119) was recently proposed (Luks et al.,
2017b): this might facilitate nuclear import through importin
7 after phosphorylation of such a sequence. In hDAAO, this
tripeptide corresponds to the 118T-P-R120 sequence.
R120 belongs to α-helix 6 and is involved in electrostatic
interactions with the carboxylic group of D73 (α-helix 3) and
hydrogen-bonded to the backbone C=O groups of D109 (α-
helix 5), T110, and V111 (loop between α-helix 5 and β-strand
4) located at the interface of the opposite monomer (Figure 1C).
Indeed, and as stated in the Introduction section, the R120 side
chain possesses two alternative orientations, one of which is
observed in the benzoate-bound complex only. R120 is located
at the monomer-monomer interface (Figure 1B); therefore, a
connection between protomer interaction and the binding of the
ligand and/or the cofactor is feasible.
Based on these considerations, and to shed light on
benzoate binding, monomer-monomer interaction, and nuclear
translocation, we designed two hDAAO variants differing
at position 120 aimed at eliminating the positive charge
(introducing a Leu) or at mimicking the negative charge of
a phosphorylated serine present at the active NTS in rDAAO
(introducing a glutamate). A serine at position 120 was not
introduced since no evidence is reported of phosphorylation in
hDAAO (Murtas et al., 2017).
Biochemical Properties of R120E and
R120L hDAAO Variants
hDAAO R120E and R120L variants were expressed in E.
coli following the same conditions used for expressing the
wild-type enzyme and were purified by HiTrap chelating
chromatography as previously reported (Molla et al., 2006). The
protein preparations have a purity degree of 95% and the overall
purification yield is 2.5- to 4-fold lower than the wild-type
hDAAO (Table 1).
The R120E and R120L hDAAO variants show the typical
absorbance spectrum of FAD-containing flavoenzymes in the
oxidized form (Figure 2A): absorbance maxima at 448, 384, and
279 nm and an Abs279nm/Abs448nm ratio of 10.4 and 11.2 for
R120E and R120L variants, respectively, which are close to the
value of 10.6 reported for the wild-type enzyme (Molla et al.,
2006).
The far-UV CD spectra show a different signal for
hDAAO R120E as compared to the wild-type enzyme and the
R120L variant, indicating a lower α-helix content (Figure 2B).
Concerning the tertiary structure, the near-UV CD spectra of
hDAAO R120E and R120L are slightly altered in the 250-
to 290-nm region, corresponding to the signal for aromatic
residues, in comparison to the wild-type enzyme (Figure 2C).
Accordingly, the protein fluorescence spectra for both of the
variants at position 120 show a lower emission intensity of the
peak at 330 nm, particularly for the R120E hDAAO (Figure 2D),
strengthening the evidence that aromatic residue exposure has
been altered.
Overall, the substitution of R120 results in a slight alteration in
the conformation (secondary and tertiary structure) of hDAAO,
which is most apparent for the R120E variant.
TABLE 1 | Comparison of selected properties of recombinant wild-type, R120E,




Purified protein (mg/L fermentation broth) 7.0 2.8 1.8
Specific activity (U/mg protein) 12.0 21.0 17.6
Holoenzyme content (%) 80 100 100
Thermal stability (TM,
◦C)
CD (at 220 nm) 57.0 ± 1.0 46.1 ± 0.1 47.6 ± 0.1
Protein fluorescence (at 340 nm) 57.7 ± 0.3 52.7 ± 0.1 54.2 ± 0.1
aMolla et al. (2006) and Caldinelli et al. (2009).
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FIGURE 2 | Spectral properties of hDAAO variants in the holoenzyme form. Wild-type (black), R120E (red) and R120L (blue) hDAAO variants. Comparison of: (A)
UV-visible absorbance spectra in the oxidized form; (B,C) far-UV CD spectra (0.1 mg/mL, B), and near-UV CD spectra (0.4 mg/mL, C); (D) protein fluorescence
spectra (0.3 mg/mL).
Kinetic Properties
The activity assays performed in the absence of exogenous
cofactor or the presence of an excess of FAD result in similar
values indicating that purified R120E and R120L hDAAO are
present in solution as holoenzyme, this being different from the
wild-type enzyme, which is partially present in the apoprotein
form in the absence of exogenous FAD (Table 1; see below).
Notably, the R120E and R120L hDAAO variants show higher
specific activity than the wild-type enzyme in the standard assay
(on 28mM D-alanine, Table 1).
The apparent kinetic parameters were calculated according
to a Michaelis–Menten equation using the initial velocity values
determined at increasing D-amino acid concentrations and a
fixed O2 concentration (air saturation) at pH 8.5 and 25◦C, in
the presence of 0.2mM FAD to avoid apoprotein formation for
wild-type hDAAO. Three D-amino acids were used: D-Ala is
the reference substrate for DAAOs (Pollegioni et al., 2007), D-
Ser is considered the main substrate for hDAAO in the brain
(based on the concentration and physiological role) (Sacchi et al.,
2012; Murtas et al., 2017; Weatherly et al., 2017), and D-Cys is
the putative preferred substrate in specific tissues (Shibuya et al.,
2013; Murtas et al., 2017). Both variants show a 2-fold higher
apparent kinetic efficiency (kcat/Km) for D-Ala than the wild-
type hDAAO (due to a higher kcat ; Table 2). On the other hand,
using D-Ser as a substrate, all the enzyme variants show similar
kinetic efficiency, although both apparent kcat and Km values are
significantly higher in the R120-substituted variants (2.5- and
3.5-fold for the R120E and R120L, respectively; Table 2). An
inhibition effect is observed at very high D-Cys concentration for
both R120 variants (Ki > 200mM), which is absent for wild-type
hDAAO. Moreover, the kinetic efficiency of the R120L variant is
2-fold higher than the wild-type hDAAO on this substrate due to
an increase in the apparent kcat value.
In order to assess the effect of the kinetic properties of R120
hDAAO variants on the oxidation of D-Ser under conditions
similar to the physiological ones, the enzymatic activity was
assayed on 0.3 or 1mM D-Ser in the absence of free FAD
or in the presence of 2.5µM (corresponding to the maximal
estimated concentration in the brain) or 40µMFAD (a saturating
cofactor concentration) (Cappelletti et al., 2015). In all cases, the
conditions affected the activity only slightly (Figure 3). At low
D-Ser and FAD concentrations higher activity is measured for
the R120L variant, while at 1mM D-Ser and 40µM FAD, the
wild-type hDAAO is the most active variant.
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TABLE 2 | Comparison of the apparent kinetic properties of wild-type, R120E, and R120L hDAAO variants.
D-Ala D-Ser D-Cys
hDAAO kcat (s
−1) Km (mM) kcat/Km (mM
−1 s−1) kcat (s
−1) Km (mM) kcat/Km (mM
−1 s−1) kcat (s
−1) Km (mM) kcat/Km (mM
−1 s−1)
wild-typea 5.2 ± 0.1 1.3 ± 0.2 4.0 3.0 ± 0.1 7.5 ± 0.5 0.4 8.6 ± 0.2 0.6 ± 0.1 14.6
R120E 12.6 ± 0.1 1.4 ± 0.1 8.9 8.5 ± 0.4 17.6 ± 3.5 0.5 9.9 ± 0.5 0.6 ± 0.1 16.5
R120L 17.3 ± 0.3 2.0 ± 0.3 8.5 11.3 ± 0.4 26.7 ± 4.5 0.4 15.6 ± 0.7 0.7 ± 0.1 22.6
Conditions: air saturation, 25◦C, pH 8.5.
aMolla et al. (2006) and Murtas et al. (2017).
FIGURE 3 | Effect of the concentration of the FAD on the activity of hDAAO
variants at low substrate concentrations (resembling physiological conditions).
Wild-type (black bars) R120E (red bars) and R120L (blue bars) hDAAO
variants. The activity was assayed at 0.3 or 1mM D-Ser and at three different
FAD concentrations: 0, 2.5 or 40µM. Activity values are reported as the mean
± SD (n = 3).
Ligand and FAD-Binding
The interaction of R120 hDAAO variants with the classical
inhibitor benzoate and with CBIO, the prototype of the new
class of hDAAO inhibitors, was investigated following the protein
fluorescence signal. Similar to what was observed for the wild-
type hDAAO (Murtas et al., 2017), benzoate binding is a biphasic
process for R120 variants. The main change observed was a ∼3-
fold higher Kd for the second phase of binding for the R120E
variant, i.e., ∼8 vs. 2.6mM for the wild-type hDAAO (Table 3).
Differently from benzoate, the binding of CBIO is a monophasic
process for wild-type and variants of hDAAO.
The Kd for FAD was estimated for the R120 hDAAO variants
based on the quenching of the apoprotein fluorescence during
FAD titration, both in the absence and presence of the active
site ligand benzoate. Similar to the wild-type enzyme, FAD-
binding is a biphasic process for both R120 variants in the
absence of benzoate (Figure 4A): the fluorescence intensity










Wild-typeb 0.43 ± 0.02c [40%] 0.48 ± 0.02 0.33 ± 0.04c 0.24 ± 0.05
≥30d [60%] 2,590 ± 680d
R120E 0.05 ± 0.01c [65%] 0.61 ± 0.08c [65%] 0.16 ± 0.01c 0.30 ± 0.05
32 ± 3d [35%] ≥ 30d [35%] 7,985 ± 755d
R120L 0.05 ± 0.01c [60%] 0.07 ± 0.01c [75%] 0.27 ± 0.12c 0.35 ± 0.04
23.1 ± 1.0d [40%] ≥20d [25%] 6,205 ± 40d
Kd values were determined by monitoring the quenching of protein fluorescence.
When the FAD binding process to the apoprotein moiety is biphasic, the amplitude of
fluorescence change for each phase is reported in square parentheses.
a In presence of 70 µM benzoate.
bMurtas et al. (2017).
cKd values corresponding to the first saturation phase.
dKd values corresponding to the second saturation phase.
change associated with the first phase accounts for 60–65% of
the overall change. The main difference concerning the wild-
type hDAAO is a 10-fold lower dissociation constant for the
first phase (Kd1) of cofactor binding to the apoprotein of
R120 variants (Table 3). Significant alterations are also apparent
when FAD binding to hDAAO apoprotein is performed in the
presence of a saturating benzoate concentration (i.e., 70µM,
Figure 4B): this is a monophasic process for the wild-type
hDAAO and a biphasic event for the R120 variants. Indeed,
a tighter binding of the first process is apparent for the
R120L variant only, while similar Kd1 values are determined
in the presence of benzoate for the wild-type and the R120E
variants (Table 3).
Taken together, these findings indicate that R120 substitution
modifies the interaction of hDAAO apoprotein with the
flavin cofactor.
Oligomeric State and Protein Stability
Wild-type hDAAO is a stable homodimer (Molla et al.,
2006). R120 is located at the interface between monomers
(Figure 1A) and, therefore, the oligomeric state of hDAAO
R120E and R120L holoenzymes was investigated by gel-
permeation chromatography. Both variants elute as a dimer in
the 0.1–10 mg/mL protein concentration range (elution volume
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of ∼13.7mL, corresponding to a molecular mass of 80 kDa,
not shown).
The stability of hDAAO secondary and tertiary
structures was investigated by performing temperature-
ramp experiments and analyzing the CD signal at 220 nm
and the tryptophan fluorescence at 340 nm, respectively. The
melting temperature values determined for the R120E and
R120L variants are 3.5–5◦C lower than those of wild-type
hDAAO when the changes in tertiary structure are analyzed
and ∼10◦C lower when the secondary structure stability is
studied (Table 1).
Subcellular Localization
U87 glioblastoma cells were transiently transfected with a pEYFP-
hDAAO-C3 plasmid encoding for EYFP-hDAAO chimeric
proteins harboring R, E, or L at position 120 of the flavoenzyme.
The presence of the fluorescence tag at the N-terminal end was
previously demonstrated to not alter the activity, subcellular
distribution, or degradation pathway of wild-type hDAAO
(Sacchi et al., 2008, 2011; Li et al., 2013). A similar amount
of transfected cells (expressing EYFP-hDAAO protein) was
obtained for all three constructs (Table 4). The percentage of
cells showing a cytosolic, peroxisomal, and nuclear localization
of the flavoenzyme was determined by comparing the yellow
fluorescence signal of EYFP-hDAAO variants with those of the
markers PMP-70 (for peroxisomes) and DRAQ5TM dye (for
nuclei, Figure 5). The amount of cytosolic wild-type EYFP-
hDAAO decreased with time after transfection (28% of the signal
is cytosolic at 72 h vs. 94% at 24 h), as did the amount of
nuclear signal (Table 4 and Figure 6). The presence of glutamate
at position 120 of hDAAO to mimic a phosphorylation state
favors the mistargeting by increasing the number of cells with
an EYFP nuclear signal as compared to wild-type hDAAO.
This is accompanied by a lower percentage of cells displaying
a peroxisomal signal for the EYFP-tagged protein. Introducing
an uncharged residue at position 120 (R120L variant) also
FIGURE 4 | Analysis of FAD binding to hDAAO variants assessed as protein fluorescence quenching at ∼340 nm. Wild-type (black), R120E (red), and R120L hDAAO
(blue) apoprotein. Fit of the values, expressed as percentage of the total change, corresponding to: (A) the first saturation phase of the protein fluorescence change
(up to 2µM of cofactor) in the absence of benzoate; (B) in the presence of 70µM of benzoate.
TABLE 4 | Confocal analysis of the cellular distribution of hDAAO variants in U87 cells transiently transfected with different pEYFP-hDAAO expression constructs.
hDAAO variants Hours after transfection Cells number T (%) hDAAO cellular distribution (% of transfected cells)
C C/P P N A
Wild-type 24 551 24.3 69.4 13.4 17.2 14.4 18.7
48 599 17.4 21.2 26.9 51.9 9.6 15.4
72 781 16.0 10.4 18.4 71.2 4.0 5.6
R120L 24 628 20.7 93.1 3.8 3.1 20.8 41.5
48 497 24.9 59.7 21.0 19.4 20.2 22.6
72 511 19.4 45.5 21.2 34.3 13.1 35.6
R120E 24 515 24.9 86.7 7.8 6.3 36.7 29.7
48 549 24.4 56.7 14.9 28.4 27.6 31.3
72 801 19.2 40.3 18.2 41.6 24.0 18.2
The cells were fixed at different times after transfection and peroxisomes were immunostained using an anti-PMP70 antibody. The total number of cells in each field was determined by
counting the nuclei, counterstained using the DRAQ5TM far red fluorescent dye. T, transfected cells; C, cytosol; C/P, mixed, cytosol and peroxisomes; P, peroxisomes; N, nucleus; A,
large cytosolic aggregates detected.
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FIGURE 5 | Confocal analysis of U87 cells expressing hDAAO variants. Cells
were transiently transfected with the pEYFP-hDAAO-C3,
pEYFP-hDAAO(R120L)-C3, and pEYFP-hDAAO(R120E)-C3 constructs. (A–C)
Distribution of the overexpressed EYFP-hDAAO in different cellular
compartments: (A) the EYFP-hDAAO signal (in yellow) is largely diffused in the
cytosol and also clearly detectable within the nucleus (in blue). No overlapping
with the peroxisomal stain (in red) is apparent; (B) the EYFP-hDAAO
fluorescence is still present in the cytosol (and in the nucleus, in this case), but
a punctuate distribution overlapping to the peroxisomal stain is evident; (C) the
EYFP-hDAAO is fully compartmentalized, as indicated by the almost complete
overlapping of the corresponding signal with peroxisomal stain. Note that no
EYFP-hDAAO is detectable in the nucleus. (D) Time course after transfection
of the subcellular distribution of EYFP-hDAAO variants in U87 transfected
cells. Scale bars: (A–C) 5µm; (D) 50µm.
negatively affects peroxisomal targeting and modifies, to a
limited extent, the percentage of cells with an EYFP-hDAAO
nuclear signal as compared to the cells expressing the wild-type
hDAAO (Figure 5). The substitution of R120 also appears to
increase the propensity of hDAAO to form cytosolic aggregates
(Table 4). Notably, in all cases, the cells showing nuclear
FIGURE 6 | Time course of the subcellular distribution of EYFP-hDAAO
variants in transiently transfected U87 cells investigated by immunostaining
and confocal analysis. The cells were fixed at different times after transfection
(24, 48, and 72 h) and immunostained with an anti-PMP70 antibody to
specifically label the peroxisomes. Nuclei were counterstained using the red
fluorescent probe DRAQ5TM and counted to obtain the total number of cells.
Data are reported as the fraction of transfected cells (at different times after
transfection) in which the EYFP-hDAAO variants signal is largely observed in
the cytosol, or is completely compartmentalized within the peroxisomes, or is
detected in the nucleus. Black bars, EYFP-hDAAO wild-type; blue bars,
EYFP-hDAAO R120L; red bars, EYFP-hDAAO R120E. Values represent mean
± SEM.
localization of hDAAO also possess a signal largely diffused
in the cytosol.
The number of viable cells following transfection is similar
for wild-type and R120 hDAAO variants, indicating that
mistargeting does not affect cell viability.
DISCUSSION
The elucidation of the structure-function relationships in
hDAAO represents a way to deep inside the modulation of
the D-serine level in the human brain. Here we studied two
enzyme variants at position 120. From a biochemical point
of view, substituting R120 in hDAAO slightly alters protein
conformation, kinetic properties, and ligand binding, while the
dimeric quaternary structure is unchanged. The tertiary structure
is largely preserved: only for the R120E hDAAO does alteration
in the near-UV CD and fluorescence spectra suggest that the
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orientation of aromatic residues has changed and is coupled to
a decrease in the α-helix content. Indeed, both the R120E and
R120L variants show a decrease in Tm, which is more evident
following the signal related to the secondary structure (Table 1):
the substitution of R120 likely alters the electrostatic interactions
with the facing residues belonging to α3 and α6 and the loop
connecting α5 and β4 on the other monomer (Figure 1C).
Notably, the substitution of R120 in hDAAO does not alter the
affinity for the classical inhibitor benzoate (resulting in a biphasic
binding process) and for CBIO (showing a monophasic process;
Table 3). This result excludes a connection between R120 and the
ligand-binding process, especially related to the second putative
benzoate binding site.
Concerning the apparent kinetic properties, while both of
the variants at position 120 possess a higher kinetic efficiency
for D-Ala and D-Cys due to a higher kcat than the wild-type
enzyme, a similar kinetic efficiency value is apparent on D-Ser as
the increase in maximal activity is counteracted by an increased
Km value. D-Ser is the physiological substrate of hDAAO in the
brain: the low kinetic efficiency of the human flavoenzyme on
this substrate seems to be evolved to control its cerebral level
without resulting in a drastic decrease that could negatively affect
NMDAr functionality (Caldinelli et al., 2009, 2010; Murtas et al.,
2017; Pollegioni et al., 2018). The possibility that hDAAO kinetic
properties could be affected by post-translational modification
processes is a topic that deserves further investigations.
The most relevant change in hDAAO following the
substitution of R120 is the strongest interaction with the
flavin cofactor. The presence in solution of two apoprotein
forms showing a different affinity for FAD is still evident for
R120 variants, but the most avid form (accounting for ∼ 60-65%
of the total change in protein fluorescence following FAD-
binding) possesses a 10-fold lower Kd than the corresponding
form of wild-type hDAAO (Table 3). This could be significant
at the cellular level as wild-type hDAAO at physiological FAD
concentration (∼2µM) is in equilibrium between the apoprotein
inactive form and the active holoenzyme. In any case, the activity
values for wild-type and R120 hDAAO variants were quite
similar at low D-Ser and FAD concentrations, resembling the
physiological conditions (Figure 3). Furthermore, we previously
reported that benzoate binding shifts the hDAAO apoprotein
into the single conformation for FAD more avidly (Caldinelli
et al., 2009, 2010; Murtas et al., 2017). This ligand-induced
conformation change is abolished for R120 variants: FAD-
binding to hDAAO variants is biphasic both in the absence and
in the presence of the active-site ligand.
The properties of W209R hDAAO, corresponding to the SNP
rs11347906 (Cappelletti et al., 2015), resemble those of R120
variants: the residue W209 is also located at the monomer-
monomer interface, is part of the second binding site identified
by Kohiki et al. (2017), and its substitution results in an increased
activity onD-Ala, a 4-fold tighter FAD-binding with no change in
ligand-binding properties (Cappelletti et al., 2015). The similarity
in biochemical properties between R120E/L andW209R hDAAO
variants suggests that the reported alterations are due to the
structure-function relationships of this specific region, which is
close to the interface between monomers.
Concerning the investigation of hDAAO subcellular
localization, and since phosphorylation of arginine is unusual,
we substituted R120 with glutamate (to mimic the active NTS
sequence) or a leucine (to eliminate the positive charge). Our
studies based on U87 glioblastoma cells transiently transfected
for hDAAO variants show that substitution of R120 alters the
subcellular localization of the flavoenzyme; the increase in
cytosolic localization, observed at all times after translocation,
favors nuclear targeting, especially for the R120E hDAAO
(Figures 5, 6). Indeed, the wild-type enzyme is also mistargeted
to the nucleus, suggesting that it is a usual process for hDAAO.
Nuclear passive diffusion promotes the transport of proteins
of <40 kDa (corresponding to the size of DAAO monomer)
although proteins at higher mass also accumulate in the nucleus
(Luks et al., 2017b). R120 is located at the protein interface
between monomers and electrostatically interacts with D73
on the opposite chain (Figure 1C). The substitution of the
arginine in position 120 does not affect the generation of a
soluble, dimeric holoenzyme: the altered subcellular localization
of R120 hDAAO variants does not arise from a change in
molecular mass. Finally, the expression of catalytically active
hDAAO variants at position 120 does not alter the viability of
U87 transfected cells. This is significant and can be explained
in two different ways: (i) mistargeted (cytosolic and nuclear)
hDAAO is inactive; (ii) no hydrogen peroxide is generated by
mistargeted hDAAO because of the absence of its substrate, i.e.,
the D-amino acids.
Results from mutagenesis at position 120 and previous
studies on the W209R hDAAO variant (Cappelletti et al.,
2015) indicate that single point substitutions at the monomer-
monomer interface affect biochemical properties, especially the
affinity for FAD, but do not affect ligand binding. Indeed, our
results reveal thatmistargeting to the nucleus is an innate process,
as it is apparent for the wild-type enzyme too (Table 4), which
does not affect cell viability. Whether hDAAO mistargeting
is involved in physiological processes or related to specific
pathological states is still unknown (Pollegioni et al., 2018).
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Introduction 
The FAD-dependent enzyme D-amino acid oxidase (DAAO, EC 1.4.3.3) 
catalyzes the oxidative deamination of uncharged and basic D-amino acids 
[Pollegioni et al., 2007]. In mammals DAAO is widely distributed in different 
organs and is expressed by many cell types. The highest expression is 
apparent in proximal tubules of the kidney, while it is also present in the 
hepatocytes, in astrocytes of the hindbrain, in neutrophils, and in the goblet 
cells and enterocytes of the small intestine; for a review see [Pollegioni et al., 
2007; Koga et al., 2017]. Accordingly, DAAO plays different roles. 
In the central nervous (CNS) system DAAO regulates the level of D-serine 
(D-Ser), the main co-agonist of synaptic N-methyl-D-aspartate type of 
glutamate receptors (NMDAR) [Mothet et al., 2000; Collingridge et al., 2013]. 
NMDAR disfunction due to alteration in D-Ser levels concurs to the 
development of various neurological and psychiatric disorders including 
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amyotrophic lateral sclerosis, Alzheimer’s disease, schizophrenia, drug abuse 
[Lin et al., 2018; Billard 2008; Madeira et al., 2008; Wolosker et al., 2008; 
Wolosker 2011; Collingridge et al., 2013]. In liver and kidney, DAAO is 
responsible for the detoxification and degradation of D-amino acids 
originating from the cell wall of intestinal bacteria, from diet and endogenous 
racemization. In kidney the enzyme is expressed in proximal tubule cells and 
is associated with renal damage due to the nephrotoxicity caused by the 
production of H2O2 during the elimination of D-Ser and D-proparglyglycine 
mediated by DAAO [Konno et al., 2000, Maekawa et al., 2005; Nakade et al., 
2018]. In kidney and brain, it has been recently proposed that DAAO could 
take part in a new pathway (DAAO/3-MST) linked to hydrogen sulfide (H2S) 
production [Shibuya et al., 2013]. In neutrophils and intestinal mucosa, DAAO 
shows an antimicrobial activity by generating hydrogen peroxide from the 
deamination of D-amino acids originating from bacteria [Sasabe et al., 2016; 
Sasabe and Suzuki, 2018]. 
In the intestine, it has been suggested that goblet cells secrete a 
processed form of the mouse DAAO, likely due to the presence of a signal 
peptide and a predicted cleavage site near the N-terminus [Sasabe et al., 
2016]. DAAO could thus control the homeostasis of gut microbiota [Sasabe 
et al., 2016]: DAAO protein and activity were detected in the proximal and 
middle small intestine of mice and humans, associated to the villus 
epithelium [Sasabe et al., 2016]. This investigation proposed that the 
selection of dangerous microbes such as Staphylococcus aureus and Vibrio 
cholera is due to the hydrogen peroxide generated by DAAO activity on 
intestinal D-amino acids, originating from food or microbial cell wall. 
Based on structural details suggesting that DAAO could not properly fold 
and maintain its enzymatic activity following the elimination of the N-
terminal sequence which is part of the Rossman fold, i.e. the motif required 
for flavin binding, in this work we employed biochemical, microbial, cellular 
and tissue analyses to re-evaluate the role of the flavoenzyme in antibacterial 
activity and gut homeostasis. We here report that the microbiota selection 
ability of DAAO is mainly due to the generation of specific antimicrobial 
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peptides and not by the generation of hydrogen peroxide, as previously 
proposed. 
 
Materials and Methods 
Bioinformatics analysis 
The sequences of mammalian DAAOs (from human, mouse, rat and porcine) 
were analyzed with different bioinformatics servers for the presence of a 
signal peptide and a cleavage site for protein secretion: 
i) SignalP 3.0 Server, which predicts the presence and location of signal 
peptide cleavage sites in amino acid sequences based on a combination of 
several artificial neural networks and hidden Markov models [Bendsten et al., 
2004a]; 
ii) SignalP 4.1 Server, an improved version of the previous server, which does 
not consider the hidden Markov model and is able to discriminate between 
signal peptides and transmembrane regions [Petersen et al., 2011]; 
iii) SecretomeP 2.0 Server, which produces ab initio predictions of non-
classical, not signal-peptide triggered protein secretion. The method queries 
many other feature prediction servers to obtain information on various post-
translational and localization aspects of the protein, which are integrated 
into the final secretion prediction [Bendsten et al., 2004b]; 
iv) Signal-3L server, which determines the presence of a signal peptide and 
cleavage site and selects a final unique site in concertation with its evolution 
conservation score [Shen and Chou, 2007]; 
v) Signal-3L 2.0 Server, an improved version of the previous server [Zhang et 
al., 2017]. 
 
Molecular dynamics of hDAAO 
The 3D structure of the substrate-free form of the human DAAO (PDB 2E48) 
was used as a starting point for molecular dynamics (MD) simulation 
performed using the GROMACS package, version 4.6.7. The deleted variant 
was obtained from the-structure of full-length hDAAO through the deletion 
of the first N-terminal 16 residues. For the full length hDAAO, the system was 
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solvated in a cubic box (volume equal to 670 nm3, 8.5 nm x 7.5 nm x 10.5 nm) 
with 20000 water molecules, while for the deleted form a dodecahedral box 
was used (volume of 610 nm3) and solvated with 18000 water molecules, 
with the aim to decrease the system dimensions and to increase the rate of 
the simulation. To neutralize the overall charge, an adequate number of Na+ 
ions was added. The system was minimized again with the Steepest Descent 
method, followed by equilibration of the restrained protein (1000 kJ mol-1 
nm-2 isotropic force applied to each heavy atom of the protein) in the NVT 
ensemble (up to 200 ps). In each system the equilibration phase was 
composed of an inverted simulated annealing starting with an initial 
temperature of 10 K and rising up to 300 K in 200 ps, keeping the heavy atoms 
of protein restrained in the same way as in the apoprotein systems. In 
production phase, each system was simulated for 100 ns in unrestrained 
conditions in NVT ensemble. Electrostatics was treated with the cutoff 
method for short-range interactions and with the Particle Mesh Ewald 
method for the long-range ones (rlist = 1.1 nm, cutoff distance = 1.1 nm, VdW 
distance = 1.1 nm, PME order = 4). A time step of 2 fs was set using bonds-
constraining algorithm LINKS. The constant temperature conditions were 
provided by using V-rescale thermostat, which is a modification from 
Berendsen’s coupling algorithm. The AMBER99SB-ILDN force field was used 
for the simulations. 
The Root Mean Square Deviation of atomic positions (RMSD, the measure of 
the average distance between the atoms) was used as a quantitative 
measure of similarity to compare the stability of the systems (full-length vs. 
deleted variant) in presence or in absence of the flavin cofactor with respect 
to the initial reference structure. The Root Mean Square Fluctuation (RMSF, 
the measure of the deviation between the positions of a residue averaged 
over time) was calculated to compare the fluctuations of every single 
residues in the systems. 
 
Antimicrobial peptides  
The sequences of murine and human DAAO were analyzed by an in silico tool 
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[Pane et al., 2017] which allows to detect the presence and the accurate 
position of a potential cryptic antimicrobial peptide (CAMP) inside a protein, 
based on antimicrobial “Absolute Scores” (AS) which depend on 
hydrophobicity, net charge and length of a peptide. Putative antimicrobial 
peptides identified inside the sequence of mouse DAAO, 
257IWKSCCKLEPTLKNARIVGELTGFRPVRPQVRL289 (IWK) and 
313GLTIHWGCAMEAANLFGKILEEKKLSRLPPSHL345 (GLT) were synthesized by 
Aurogene s.r.l. (Roma, Italy). 
Far-UV circular dichroism (CD) spectra of DAAO-generated peptides were 
recorded in 10 mM sodium phosphate buffer pH 7.0 by using a Jasco J-815 
spectropolarimeter (Jasco Co., Cremella, Italy). The cell path length was 0.1 
cm for measurements in the 190 to 250 nm region (0.1 mg peptide/mL), as 
reported in [Caldinelli et al., 2009]. The effect of sodium dodecyl sulphate 
(SDS, 0.1-40 mM), 2,2,2-trifluoroethanol (TFE, 5-50% v/v) and 
lipopolysaccharides from E. coli (LPS, 0.1-1 mg/mL) was analyzed by titrating 
the peptides with increasing concentrations of these compounds and 
recording the far-UV CD spectra. CD-spectra were analyzed using the Selcon3 
method by DichroWeb [Whitmore and Wallace, 2008] to estimate secondary 
structure content. 
MIC (Minimum Inhibitory Concentration) analyses were performed on Gram-
positive and Gram-negative bacteria by broth microdilution method for 
antimicrobial peptides previously described [Pane et al., 2017] with minor 
modifications. In details, assays were carried out in Nutrient Broth 0.5x 
(Difco, Detroit, Mich.) using sterile 96-well polypropylene microtiter plates 
(cat. 3879, Costar Corp., Cambridge, MA). Bacterial strains were grown in 
Luria-Bertani (LB) medium (Becton, Dickinson) overnight at 37 °C and then 
diluted in Nutrient Broth at a final concentration of ~ 5x105 CFU/mL per well. 
IWK and GLT peptides were suspended in 5 mM sodium acetate buffer, pH 5. 
Peptide concentrations were determined by spectrophotometric analysis 
using the extinction coefficients calculated by the ProtParam tool 
(http://web.expasy.org/protparam/) [Gasteiger et al., 2005]. Twofold serial 
dilutions of peptides were carried out in the test wells to obtain 
70
 
concentrations ranging from 100 μM to 0.2 μM. Plates were incubated 
overnight at 37 °C. MIC value was taken as the lowest concentration at which 
growth was inhibited. Three independent experiments were performed for 
each MIC value. The peptide antibiotic polymyxin B and vancomycin (Sigma, 
St. Louis, MO) were tested as control. MIC values were measured on: 
Pseudomonas aeruginosa PAO1, Acinetobacter baumanii ATCC 17878, 
Escherichia coli ATCC 25922, Salmonella typhimurium ATCC 14028, 
Salmonella enteriditis 706 RIVM (kindly provided by Prof. E. Veldhuizen, 
Utrecht University, Holland), Staphylococcus aureus ATCC 6538P and 
Enterococcus faecalis ATCC 29212. 
The Minimum Bactericidal Concentration (MBC) was determined from the 
broth dilution of MIC tests by subculturing cell mixtures on agar plates. The 
MBC was defined as the lowest concentration of antibacterial agent that kills 
≥ 99.9% of bacterial cells. According to a widely accepted criterion, peptides 
were considered bactericidal if their MBC was no more than four times the 
MIC.  
To assess the effect of antimicrobial peptides on lactobacilli, Lactobacillus 
acidophilus ATCC 4356, Lactobacillus casei ATCC 393, Lactobacillus 
fermentum ATCC 14931 and Lactobacillus rhamnosus ATCC 7469 (from 
American Type Culture Collection) were used. Before performing 
antimicrobial susceptibility testing, cultures were streaked on Lactobacilli 
MRS agar (MRS) and incubated for 24 h at 37 °C in an anaerobic chamber (BD 
Difco). Antimicrobial susceptibility testing was performed according to the 
ISO 10932/IDF 233 standard (ISO, 2010). Erythromycin and Vancomycin 
(Sigma-Aldrich, USA) were dissolved for preparing stock solutions of 1000 
µM. IWK and GLT peptides were dissolved as above at a concentration of 400 
µM. Typically, a 2-fold serial dilution of stock solutions was performed in 
Lactobacilli MRS broth to obtain solutions in the concentration range of 0.2–
100 µM. Bacterial inocula were prepared by suspending colonies, from 24 h 
incubated Lactobacilli MRS agar plates, into 2 mL of 0.85% NaCl solution. 
Subsequently, inocula were adjusted to have an OD625nm of 0.25 and diluted 
1:200 in Lactobacilli MRS broth for inoculation of microdilution plates by 
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adding 50 µL of diluted inoculum to each well containing 50 µL of an antibiotic 
solution. In these conditions, the bacterial inoculum was around 3-8 ×105 
CFU/mL in the wells. After incubating the plates under anaerobic conditions 
at 37 °C for 48 h, MIC values were read as the lowest concentration of the 
antimicrobial agent at which visible growth was inhibited. 
 
Preparation and expression of hDAAO deletion variant in Escherichia coli 
The cDNA encoding for the N-terminal deleted variant, namely hDAAO(Δ1-
16) lacking the secretion signal peptide, was prepared by PCR using the 
pET11b-His-hDAAO plasmid as the template and the following primers: 5’-
CACCATATGCTCTGCATCCATGAGCGC-3’ (annealing downstream to the 
canonical starting codon, starting from the one coding for Leu17 and 
containing the NdeI restriction site, underlined) and 3’-
ATGGATCCTCTTCAGAGGTGGGATGGTG-5’ (annealing downstream the stop 
codon, in bold, and containing the BamHI restriction site, underlined). The 
amplified insert was then subcloned in the pET11b plasmid. 
For the co-expression of the N-terminal deleted variant with the His-tagged 
full-length hDAAO, the pET-Duet-1 vector (Novagen) was used. The His-
hDAAO wild-type [Molla et al., 2006] was subcloned into the multiple cloning 
site 1; the PCR reaction was carried out using the pET11b-His-hDAAOwt as 
template and the following primers: 5’-
cacCCATGGATGCATCACCATCACCATCACATG-3’ (annealing downstream to 
the canonical starting codon of the His-hDAAO wild-type, in bold, and adding 
a NcoI restriction site, underlined) and the 3’-
atAAGCTTTCTTCAGAGGTGGGATGGTGGCAT-5’ (annealing downstream to 
the canonical stop codon, in bold, and adding a HindIII restriction site, 
underlined). The amplified fragment was inserted into the pET-Duet vector 
between the NcoI-HindIII sites. The deleted strep-tagged hDAAO(Δ1-16) 
variant was subcloned into the multiple cloning site 2; the gene was amplified 
using the pET11b-hDAAO(Δ1-16) as a template using the following primers: 
5’-cacCATATGCTCTGCATCCATGAGCGCTAC-3’ (annealing downstream to the 
canonical starting codon of hDAAO(Δ1-16), in bold, and adding a NdeI 
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restriction site, underlined) and 3’-
atCTCGAGTCTTCACTTTTCGAACTGCGGGTGGCTCCAGAGGTGGGATGGTGGCA
TTCTGGA-5’ (annealing downstream to the canonical stop codon, in bold, and 
adding a XhoI restriction site, underlined, and the strep-tag, italic). The 
amplified fragment was inserted into the pET-Duet vector between NdeI and 
XhoI sites. 
Recombinant hDAAO wild-type and deleted variants were expressed in 
BL21(DE3)Star E. coli cells and purified as reported in [Molla et al., 2006; 
Romano et al., 2009]; 40 µM of free FAD was present during all purification 
steps. The deleted variant was purified by using the procedure previously set 
up for the untagged wild-type enzyme consisting of ammonium sulfate 
precipitation at 35% saturation, followed by dialysis of the pellet, and anionic 
exchange chromatography on DEAE Sepharose FF at pH 8.0 (as well as using 
different resins and buffers). 
The co-expressed deleted variant and full-length hDAAO (which were 
expected to produce heterodimers) were purified using the same protocol 
set-up for the His-tagged wild-type enzyme (HiTrap Chelating 
chromatography) [Molla et al., 2006] or the protocol suggested for the 
purification of strep-tagged protein (Strep-Trap HP chromatography, in 
TrisHCl pH 8.0 or PBS pH 7.4 using desthiobiotin in the elution buffer) for the 
strep-tagged hDAAO(Δ1-16). 
The final enzyme preparations were stored in 20 mM Tris-HCl buffer, pH 8.0, 
100 mM NaCl, 10% (v/v) glycerol, 40 µM FAD and 5 mM 2-mercaptoethanol. 
The enzyme concentration was determined spectrophotometrically by using 
the extinction coefficient at 445 nm (12.2 mM-1 cm-1).  
DAAO activity was assayed with an oxygen electrode at pH 8.5, air saturation 
and 25 °C, using 28 mM D-alanine as substrate in the presence of 0.2 mM 
FAD [Molla et al., 2006]. 
 
Isolation of luminal, mucosal and epithelial layers in the small intestine 
Slightly modified versions of protocol described in [Vaishnava et al., 2011] 
were used to isolate luminal and mucosal layers in the small intestine of 
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Wistar rats (5-6 months old) and C57BL/6J mice (5-7 months old). The 
protocol reported in [Roche, 2001] was followed for isolation of the epithelial 
layer. Freshly dissected rat or mouse small intestines were partitioned into 
three parts: proximal, medial and distal samples. Then each part was further 
subdivided into three pieces: i) the ‘luminal content’ corresponded to the 
washing out with 2 mL of ice-cold sterile PBS; ii) the tissue pieces were 
opened longitudinally and placed in 15 mL tubes with 2 mL of ice-cold 
sterilized PBS. Tubes were inverted 20 times and vortexed for 10 s, the liquid 
was then collected in a fresh tube and defined as ‘mucosal content’; iii) 
finally, the ‘epithelial layer’ was recovered. The remaining tissue pieces were 
cut into 3–5 mm square patches, collected in a tube with 10 mL of phosphate 
buffer saline (PBS) containing 0.5 mM DTT and 5 mM EDTA, and incubated 
with constant shaking at 37 °C for 20 min. Epithelial cells were collected by 
pipetting for ten times and the sample was filtered through a 70 μm cell 
strainer to remove tissue fragments; cells were pelleted by centrifugation at 
6000 g at 4 °C for 10 min [Sasabe et al., 2016]. As negative control, we used 
C57BL/6J DAAO-/- knock out mice which do not express the flavoenzyme 
[Pritchett et al., 2015]. 
All experiments on animals were conducted in accordance with Italian (Decr. 
Leg. 4.03.2014 n. 26) and French directives on animal experimentation and 
local ethical committee approvals and following the Directive 2010/63/EU of 
the European Parliament and of the Council of 22 September 2010 on the 
protection of animals used for scientific purposes and to the Council of 
Europe Convention for the Protection of Vertebrate Animals used for 
Experimental and other Scientific Purposes (ETS123). 
 
Immunoprecipitation and Western blot analyses 
The presence of DAAO in the different gut samples was investigated by 
Western blot analyses using different antibodies: anti-hDAAO, diluted 1:3000 
(Davids Biotechnologie); anti-hDAAO C-terminal, diluted 1:3000 (Davids 
Biotechnologie); anti-hDAAO N-terminal, diluted 1:250 (Davids 
Biotechnologie); anti-hDAAO diluted 1:1000 (Abcam); anti-hDAAO, diluted 
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1:500 (Rockland); anti-mDAAO C-terminal, diluted 1:500 (Santa Cruz 
Biotechnology). Epithelial cells were homogenized in lysis buffer (150 mM 
sodium chloride, 1% NP-40, 50 mM Tris, pH 8.0, and a protease inhibitor 
cocktail), luminal and mucosal contents isolated from the small intestine 
were sonicated and centrifuged. Protein level in supernatants was quantified 
using Bradford reagent. A cerebellar lysate was used as a positive control for 
the presence of DAAO. Supernatants were subjected to SDS–PAGE and 
proteins were transferred to PVDF membranes. Blots were blocked in 4% 
skim milk in Tris-buffered saline (TBS) with 0.1% Tween-20 at 4 °C, overnight. 
The membranes were incubated with primary antibodies diluted in TBS with 
0.05% Tween-20 and 2% skim milk at room temperature for 2 hours, 
subsequently washed in TBS with 0.1% Tween-20 and 4% skim milk (3 x 5 
min), then incubated with secondary antibodies conjugated with horseradish 
peroxidase for 1 h (diluted in TBS with 0.05% Tween-20 and 2% skim milk). 
The membranes were washed in TBS with 0.1% Tween-20 (2 x 5 min) and TBS 
(2 x 5 min) and bound antibodies were detected with ECL plus WB detection 
solution (GE Healthcare) by a Li-Core system. 
For immunoprecipitation analyses, the samples were precleared with 50 μL 
of mProtein A Sepharose (GE Healthcare, Chicago, Illinois, USA) for 1 hour at 
4 °C with rotation. 5 μg of anti‐DAAO antibodies were cross‐linked to 50 μL 
of Dynabeads Protein G using 20 mM dimethyl pimelimidate dissolved in 0.2 
mM triethanolamine, pH 8.2 (for 60 min at room temperature with rotation). 
The excess of cross‐linker was removed and the Dynabeads were incubated 
for 15 min at room temperature under rotation with 50 mM Tris‐HCl, pH 7.5, 
and then washed with PBS containing 0.1% Tween. The precleared samples 
were added to the Dynabeads–antibody complexes and incubated overnight 
at 4 °C with rotation. The supernatant (post‐IP sample) was collected by 
separating the beads on the magnet. The beads were extensively washed 
with PBS and finally suspended in 50 μL of a nonreducing SDS-PAGE sample 
buffer (IP sample) and boiled. Subsequently, 20 μL of the IP samples were 
analysed by SDS-PAGE and Western blot. Recombinant hDAAO was used as 




In order to verify the presence of DAAO in the small intestine, tissue samples 
were analysed by mass spectrometry. 160 µg (40 x 4 lanes) of total proteins 
from different gut fractions were separated by SDS-PAGE and stained with 
colloidal Coomassie; the bands of interest (i.e. at the selected molecular mass 
values) were cut, and stored in 5% acetic acid for the identification by nLC-
MS/MS. Each band was cut and digested in situ by trypsin sequence grade 
upon extraction with TCA (trichloroacetic acid) and acetonitrile (CH3CN), 
reduction with 45 mM dithiothreitol and malkylation with 100 mM 
iodoacetamide. MS/MS analysis was carried out by a LTQ-Orbitrap Velos 
(Thermo FisherScientific), as previously described [Dell’Orco et al., 2016]. 
Data Base search was performed using the Sequest search engine of 
Proteome Discoverer 1.4 (Thermo Fisher Scientific) against the Rodentia 
Uniprot sequence database. Only peptides with Xcorr 1.5 and Confidence 
FDR ≤ 0.05 were kept for the identification. 
 
Native PAGE 
With the aim to verify the presence and the mass of an active DAAO in the 
intestinal fractions, 60 µg of total proteins of the tissues were analysed by 
native electrophoresis (non-denaturating, 7.5% acrylamide resolving gel, 4 °C 
at 20 mA). Gels were stained with Blue Coomassie or for DAAO activity based 
on the reduction of iodonitrotetrazolium salt, i.e by incubating at 37 °C the 
gel in 35 mM sodium pyrophosphate, pH 8.5, 0.2 mM FAD, 28 mM D-Ala, 0.18 
mM iodonitrotetrazolium dissolved in ethanol [Piubelli et al., 2003]. Controls 
were performed by adding the DAAO specific inhibitor CBIO in the assay 
solution (negative controls), as well as using the recombinant hDAAO or mice 
cerebellum samples (positive controls). 
 
Results 
Prediction of signal sequence in DAAO 
The sequences of mammalian DAAOs (human, mouse, rat and porcine) were 
analyzed in silico with various bioinformatics programs, including the SignalP 
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3.0 used by [Sasabe et al., 2016], in order to reveal the presence of a signal 
peptide and a cleavage site for protein secretion, see Materials and Methods. 
While the SignalP 4.1 Server predicted a signal sequence and a cleavage site 
between positions 16 and 17 at the N-terminus of the pig DAAO only (score 
value of 0.455 vs. a cutoff value of 0.450), three alternative bioinformatics 
tools predicted the same signal peptide for all the mammalian DAAOs 
analyzed and the Signal-3L predicted the presence of this signal peptide in 
mouse and rat DAAOs only (Fig. 1A and Supplementary Data 1 and Suppl. 
Table 1). Accordingly, the hDAAO(Δ1-16) variant lacking the N-terminal 16 
residues was designed (see below). 
The prediction analysis for the presence of antimicrobial peptides (CAMP) 
in the DAAO sequence suggested the presence of two cryptic cationic 
peptides: 257IWKSCCKLEPTLKNARIVGELTGFRPVRPQVRL289 and 
313GLTIHWGCAMEAANLFGKILEEKKLSRLPPSHL345 in the murine sequence 
(corresponding to 264RLEPTLKNARIIGERTGFRPVRPQIRLEREQLR297 and 
315GLTIHWGCALEAAKLFGRILEEKKLSRMPPSHL347 in the human enzyme, Fig. 
1A). The antimicrobial absolute score, AS values, were calculated for all 
possible peptides of length between 12 and 40 residues. The highest AS was 
found for a 33-residues long peptide starting at position 257 
(257IWKSCCKLEPTLKNARIVGELTGFRPVRPQVRL289, named IWK). The plot in 
Suppl. Fig. 1, shows the AS values for all the possible peptides of 22 or 33 
residues in mouse DAAO sequence and highlights that the figure for this 
peptide is higher than two of the three threshold scores. Downstream the 
potential antimicrobial region 257-289, at the C-terminus of DAAO, an 
additional region was observed containing two relative maxima with AS = 4.5 
(for the 22 residue window) and AS = 3.3 (for the 33 residue window) 
corresponding to peptides 324AANLFGKILEEKKLSRLPPSHL345 and 
313GLTIHWGCAMEAANLFGKILEEKKLSRLPPSHL345, respectively. Even if the 
scores of these peptides are below the threshold scores, we selected peptide 
313-345, named GLT, for further characterization because in the crystal 
structure of hDAAO this region is structured as a long and amphipathic -




Expression of hDAAO(Δ1-16) and strep-hDAAO(Δ1-16) variants 
At first, hDAAO(Δ1-16) was produced in E. coli BL21DE3Star cells using the 
conditions reported for the wild-type enzyme [Molla et al., 2006]: the 
resulting expression level in the crude extract (< 1 mg/L fermentation broth) 
was too low for a biochemical characterization. In order to increase the 
expression yield of the soluble hDAAO variant, the following parameters 
were investigated: the E. coli strain, the cultivation broth, the OD600nm at the 
moment of IPTG addition, the time of cell collection, the growth temperature 
after the induction of protein expression, the presence of the inhibitor 
benzoate (as active site ligand designed to stabilize the enzyme 
conformation) and the two-step protocol for the inhibition of protein 
synthesis [De Marco et al., 2007]. Best conditions are reported in 
Supplementary Data 2 and Suppl. Table 2. 
The untagged hDAAO(Δ1-16) variant was purified employing the 
procedure used for the wild-type enzyme [Molla et al., 2006]. However, 
about 50% of the total recombinant hDAAO variant is lost in the ammonium 
sulfate precipitation step and part is eluted in the flow through of the DEAE 
Sepharose FF column (~ 25%): the resulting overall purification yield is 
extremely low (< 20%) corresponding to 0.04 mg of pure hDAAO variant/L 
fermentation broth. Indeed, no DAAO activity was detected in the crude 
extract or in the final enzyme preparation also in the presence of a saturating 
exogenous FAD concentration, i.e. 0.2 mM. 
In order to facilitate the production of the deleted variant, and since 
hDAAO is a stable homodimer in solution, it was co-expressed with the wild-
type hDAAO using the pET-Duet plasmid as tagged proteins, i.e. His-hDAAO 
wild-type and strep-hDAAO(Δ1-16). No DAAO enzymatic activity was 
detected in the crude extract of BL21(DE3)pLysS E. coli cells harbouring the 
pET-Duet vector. Neither a HiTrap chelating chromatography nor a StrepTrap 
column (using desthiobiotin in the elution buffer) allowed binding of the 
recombinant proteins: in both cases, the two protein forms eluted in the 
flow-through (not shown). None of the conditions reported in Suppl. Table 3 
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allow to produce a suitable amount of Δ1-16-deleted hDAAO: the 
recombinant protein poorly binds to different resins and seems highly 
unstable and inactive. We concluded that elimination of 16 residues at the 
N-terminal end of hDAAO significantly hampers protein folding, FAD binding 
and stability. 
 
MD simulation analysis 
We next used molecular dynamics simulations to compare the stability of the 
tertiary structure of full-length (PDB 2E48) with the model of Δ1-16 deleted 
hDAAO variant (Fig. 1B), in presence and in absence of the flavin cofactor. 
Actually, wild-type hDAAO exists in solution in equilibrium between the 
apoprotein and the holoenzyme forms because of the weak FAD binding 
[Molla et al., 2006; Caldinelli et al., 2009]. The Root Mean Square deviation 
(RMSD) during the time of simulation (100 ns) is higher for the Δ1-16 variant 
compared to the full-length enzyme, in particular in the absence of FAD (Fig. 
2A). The Root Mean Square Fluctuation (RMSF), calculated to compare the 
extent of fluctuations of each single residue of the system, is still significantly 
higher for the Δ1-16 hDAAO (Fig. 2B). In the absence of the cofactor, the Δ1-
16 variant resulted more unstable than the full-length protein: the regions 
characterized by highest instability are those located close to the flavin 
cofactor (residues from 17 to 50, residues from 135 to 210 and residues from 
260 to 320, Fig. 2C). Altogether, experimental and in silico analyses suggest 
that elimination of part of the Rossman fold, and especially of the GXGXXG 
Wierenga sequence [Rossmann 1974, Wierenga 1983], strongly affects the 
overall fold of the flavoenzyme hampering FAD binding and catalytic activity. 
 
Tissue analysis on rat and mouse intestine 
At first, the presence of DAAO in tissue fractions from mouse and rat small 
intestine (luminal, mucosal content and epithelial layer of proximal, medial 
and distal small intestine) was investigated by Western blot analysis using 
five different commercial anti-hDAAO antibodies. In a previous investigation 
[Sasabe et al., 2016] an home-made produced and affinity chromatography 
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purified polyclonal anti-mouse DAAO antibody and an polyclonal anti-human 
DAAO antibody (from Everest Biotech, which is no more commercially 
available) were used. Among the five commercially available antibodies we 
here selected the two antibodies giving reproducible results in preliminary 
experiments and that could provide information about the lost region, i.e. 
the anti-N-terminal and anti-C-terminal hDAAO antibodies (from Davids 
Biotechnologie). The regions recognized by these antibodies are indicated in 
Fig. 1A. The elimination of the putative N-terminal translocation sequence 
should convert the 38.7-38.8 kDa full-length rat or mouse DAAO into a 37.3-
37.5 kDa fragment which is still recognized by both the antibodies we used. 
The lack of recognition by the anti-N-terminal antibody requires the 
elimination of 120 residues at the N-terminal end, corresponding to a 13.5 
kDa decrease in mass. The elimination of a sequence ≥ 20 residues at the C-
terminus will give a DAAO form not recognized by the anti-C-terminal hDAAO 
antibody. 
The analysis of rat intestine samples resulted in aspecific recognition 
patterns, see Suppl. Data 3 and Suppl. Table 4. On mice samples, the main 
signals recognized by anti-C-terminal hDAAO antibodies corresponds to 
bands at 70 kDa in mucosal proximal and distal samples, at 40 kDa in mucosal 
distal and luminal (proximal, median and distal) samples, and at 27 kDa in 
mucosal proximal and distal samples, see Table 1, Supplementary Data 4 and 
Suppl. Fig. 2A. The band at ~ 40 kDa, that should correspond to the full-length 
mice DAAO, was recognized by both anti-hDAAO antibodies in mucosal distal, 
and luminal medium and distal regions. Faint bands at ~ 100 kDa (in distal 
mucosal), 70, 45 and ~ 35 kDa (in epithelial layer samples), and at 18 kDa (in 
proximal and distal mucosal samples) were also observed depending on 
sample concentration and preparation (see the samples indicated by asterisk 
in Table 1). An anti-C-terminal mDAAO antibody recognized bands at 55, 35 
and 27 kDa in mucosal proximal and distal samples: the band at lower 
molecular mass was also recognized by the anti-C-terminal hDAAO antibody 
(see Table 1, Supplementary Data 4 and Suppl. Fig. 3). 
The main signals corresponding to anti-N-terminal antibody recognition 
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corresponds to bands at 40 kDa in distal samples from mucosal and luminal 
portions (and, with a lower intensity, from proximal and medial samples), at 
35 kDa in proximal and medial samples form mucosal and luminal fractions, 
and at ≤ 20 kDa in epithelial samples (in details at 20 and 18 kDa in the medial 
and at 15 kDa in all samples of the epithelial fraction). These results should 
arise from a specific recognition since the apparent mass values agree with 
protein fragments harboring the regions recognized by the two antibodies. 
Notably, bands at ≤ 20 kDa are recognized only in the epithelial layer: the 20 
kDa-band in proximal epithelial layer corresponds to 5.7 ng / µg total 
proteins. Faint bands at 55 kDa (in mucosal samples), 45 kDa (in epithelial 
layer samples), 20 kDa (in medial and distal epithelial layer samples) were 
also detected based on sample concentration and preparation (see the 
samples indicated by the asterisk in Table 1). 
These results differ from what is reported in [Sasabe et al., 2016]: the 
presence of the full-length ~ 39 kDa form of mouse DAAO in the epithelial 
layer samples is not apparent in our studies, while only bands at < 20 kDa 
molecular mass are apparent. On the other hand, the presence of a ~ 35-37 
kDa protein form lacking the N-terminal sequence in the intestinal content is 
confirmed in proximal and medium regions of mucosal and luminal samples. 
Notably, bands at ~ 30 and 20 kDa, too small to preserve the enzymatic 
activity, were also apparent in the analyses reported by [Sasabe et al., 2016]. 
In order to confirm the presence of mouse DAAO in the most interesting 
samples, the bands at 40 and 35 kDa in the mucosal distal and proximal 
regions and the ~ 27 kDa band in the mucosal distal and proximal samples 
were analyzed by mass spectrometry (Fig. 3). In the band at 40 kDa of the 
distal mucosal content the presence of DAAO was confirmed with three 
different peptides (corresponding to sequences 23-33, 115-141, 233-252, 
equal to the 4% of the whole protein contents). No peptides derived from 
DAAO were identified in the ~ 35 kDa band from proximal mucosal sample. 
In the band at 27 kDa of the distal mucosal content four different DAAO-
generated peptides (i.e. sequences 1-32, 116-141, 158-171, 233-263) were 
also identified. Three different peptides derived from DAAO were detected 
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in the ~ 27 kDa band of the proximal mucosal content, corresponding to 29% 
of the total amount of the proteins (i.e. sequences 101-140, 233-259, 295-
335). Altogether, DAAO is released in mouse gut, where it is largely 
proteolyzed.  
In order to verify the specificity of the recognized bands in intestinal 
tissues, we followed the recommendations recently reported by [Mothet et 
al., 2019], i.e. we performed the same Western blot analyses as above on 
intestinal tissues from a full DAAO null constitutive mutant mice strain 
(DAAO-/-) [Schweimer et al., 2014]. The Western blot analysis revealed bands 
at 27 kDa in mucosal medial samples (and faint bands at 45 kDa in epithelial 
samples and at 70 and 35 kDa in proximal epithelial samples) using the anti-
C-terminal hDAAO antibody (Suppl. Fig. 4A) and a band at ~ 20 kDa in 
proximal epithelial sample by the anti-C-terminal hDAAO antibody (Suppl. 
Fig. 4B). The anti-C-terminal mDAAO antibody recognized similar signals in 
samples isolated from wild-type and DAAO-/- mice (Table 1 and Suppl. Fig. 
4A). The 40 kDa, ~ 35 kDa and ~ 27 kDa bands in proximal and distal mucosal 
layers were subjected to MS analysis: no peptides deriving from DAAO were 
identified in samples from DAAO-/- mice. This analysis on samples from DAAO-
/- mice demonstrates that DAAO’s aspecific recognition is apparent in 
Western blot analysis of gut samples, pointing to the need of mass 
spectrometry to confirm the presence of the flavoenzyme. 
Despite the purified recombinant hDAAO was immunoprecipitated with 
the tested antibodies, endogenous DAAO was not isolated from the mouse 
intestinal samples. Notably, zymograms performed following native-PAGE on 
whole mice gut tissue show a band at low electrophoretic mobility, 
significantly different from the one corresponding to the reference 
recombinant hDAAO and from the signal observed using a mice cerebellum 
sample (Suppl. Fig. 5) Indeed, this band is present even when the gel was 
incubated in the presence of the 6-chloro-1,2-benzisoxazol-3(2H)-one (CBIO), 
an inhibitor of hDAAO. The altered migration of hDAAO in native-PAGE of 
crude samples is probably due to its composition since also the recombinant 
hDAAO added to mucosal proximal mouse intestine sample did not migrate 
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as the pure protein alone. Anyway, the lack of inhibition of activity signal by 
CBIO points to the presence of aspecific signals. 
 
Antimicrobial peptides 
Investigating the primary structure of mDAAO using the method described in 
[Pane et al., 2017] suggests the presence of two antimicrobial peptides 
corresponding to 257-289 (IWK) and 315-347 (GLT) regions, see Fig. 1A. 
Conformation of DAAO antimicrobial peptides was analyzed by far-UV CD. 
Both the peptides are mostly unstructured and show slightly different 
spectra (Fig. 4, black lines): notably, they assume an ordered helical 
conformation (minima at around 210 and 220 nm) in the presence of SDS (1 
mM) or TFE (30% v/v), two membrane mimicking agents, and of LPS from E. 
coli (0.1 and 0.25 mg/mL for GLT and IWK, respectively) (Fig. 4). DichroWeb 
confirmed the experimental results: both the peptides are initially 
“unordered” and assume an helical conformation during the titration (α-helix 
content > 70%). 
In order to shed light on their putative role in the observed microbial 
selection in the gut, the antimicrobial activity of the two polypeptides and of 
a mixture containing both peptides at 1:1 a molar ratio was tested on two 
Gram-positive and five Gram-negative bacteria (Table 2). Both peptides 
showed bactericidal or bacteriostatic activity on the tested bacteria, the only 
exception was S. enteriditis. Notably, in some cases an additive effect of the 
two peptides is apparent (Table 2) reaching MIC values in the low micromolar 
range. Noteworthy, both peptides show a strong and additive bacteriostatic 
activity on E. faecalis with the mixture of the two peptides being already 
active at about 3 M. 
Four lactic acid bacteria (LAB) strains belonging to species Lactobacillus 
acidophilus, Lactobacillus casei, Lactobacillus fermentum, Lactobacillus 
rhamnosus were tested for their susceptibility to IWK and GLT peptides. The 
results of antimicrobial susceptibility testing of four Lactobacillus strains 
using broth microdilution are listed in Table 3. The tested strains do not show 
any significant difference in their antibiotic resistance profile. All strains were 
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resistant to vancomycin and susceptible to erythromycin. None of the four 
lactobacilli tested showed susceptibility to IWK and GLT peptides in vitro at 
the highest tested concentration of 100 µM. 
 
Conclusions 
We are aware that, despite the key role played by hDAAO in some important 
physiological processes, much remains to be unraveled concerning the 
modulation of its functional properties; a fine and careful regulation through 
post-translational modification(s) and alternative subcellular targeting is 
expected and not yet proved. DAAO is known to be largely peroxisomal 
[Moreno 1999, Sacchi 2008, Cappelletti 2014] even if a cytosolic form has 
been observed [Sacchi 2008, Sacchi 2011], largely corresponding to the neo-
synthetized protein which is cytosolic before reaching the peroxisomes. 
Recent reports on rats demonstrated that DAAO is present both in cytosol 
and nuclei of proximal tubule epithelial cells following treatment with the 
drug propiverine [Luks et al., 2018]. Indeed DAAO was also reported to be 
secreted in the intestine: it has been proposed that the flavoenzyme might 
play a role in controlling the homeostasis of gut microbiota through the 
production of H2O2 [Sasabe et al., 2016]. DAAO protein and activity were 
detected in the epithelium of proximal and middle small intestine of mice and 
humans. A processed form of the protein appeared to be secreted in the 
lumen by goblet cells, due to the presence of a signal peptide and a predicted 
cleavage site near the N-terminus [Sasabe et al., 2016]. 
However, despite bioinformatics analysis by several softwares (Suppl. Table 
1) confirm the presence of the signal peptide, the fact that the putative signal 
peptide belongs to the Rossmann fold motif, which contains the Wierenga 
sequence (GxGxxG) required for the binding to the cofactor (Fig. 1B), suggests 
that the processed enzyme might not be folded and active. Our experiments 
on recombinant hDAAO show that the enzyme form lacking the residues from 
1 to 16 is unstable and inactive. This conclusion is supported by molecular 
dynamics studies, highlighting a higher instability of the deleted hDAAO, 
especially in the absence of FAD, compared to the full-length counterpart. 
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Accordingly, we propose that any active hDAAO present in the lumen might 
retain the N-terminal sequence required for cofactor binding and essential 
for the enzymatic activity. Native-PAGE does not suggest the presence of an 
active DAAO in the mice gut: the band identified in the zymogram shows a 
low electrophoretic mobility and is not inhibited by a strong DAAO inhibitor 
(see Suppl. Fig. 5). Notably, our results agree with a recent assay of DAAO 
activity in mice tissues which did not identify any enzymatic activity in small 
intestine (whole intestine as well as proximal, middle and distal fractions) 
[Kim et al., 2019]. 
In order to clarify this issue (and the putative secretion pattern), Western blot 
analyses were performed on small intestine samples from rat and mouse 
using different antibodies. We excluded three commercial anti-hDAAO 
antibodies as well as the results gathered on the rat tissues since the 
recognized bands seem largely due to unspecific recognition. By using anti-
N-terminal and anti-C-terminal hDAAO antibodies (from Davids 
Biotechnologies), bands at 40 and 35 kDa were apparent in the mucosal and 
luminal content of mouse small intestine, as well as bands at lower molecular 
mass which can arise from processing of the full-length enzyme (Table 1). 
Concerning the bands at 40 (in mucosal distal fraction) and at ~ 27 kDa (in 
mucosal distal and proximal fractions) both contains DAAO-originating 
peptides, Fig. 3. The 27 kDa-band arises from cleavage of ~ 100 residues at 
the N-terminus of DAAO. The same analysis were performed on DAAO-/- mice 
tissues as a negative control: again bands at 40, 35 and at lower molecular 
mass were apparent in Western blot, but MS analysis did not identify DAAO-
generated peptides. We conclude that i) commercial anti-DAAO antibodies 
recognize aspecific bands in gut samples; ii) DAAO is present in the mucosal 
fraction of mouse gut, where it is largely proteolyzed. We can not exclude 
that the use of Germ Free C57BL/6 mice [Sasabe et al., 2016] instead of 
untreated C57BL/6 mice, as in our case, can induce a different expression of 
DAAO. 
The antimicrobial AS score, a tool that has already allowed the identification 
of several cryptic CAMPs inside human, plant and archaeal proteins [Bosso et 
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al., 2017; Gaglione et al., 2017; Notomista et al., 2015; Pane et al., 2016; Pane 
et al., 2018; Pizzo et al., 2018], identified two internal regions in DAAO 
sequence as CAMP (see Table and Fig. 1A). The corresponding peptides 
showed antimicrobial activity on various Gram-positive and Gram-negative 
bacteria (Table 2), but not on Lactobacilli species which represent the 
commensal microbiota (Table 3). Interestingly, these peptides assumed a 
secondary structure in presence of detergents and LPS from E. coli.  
Our study confirms that hDAAO activity is finely tuned through post-
translational modifications to fulfil different physiological functions in 
different tissues. At the same time, our results modify the mechanism by 
which DAAO is able to select the gut microbiota. DAAO seems to act 
indirectly, by the generation of antimicrobial peptides, instead of a direct 
action due to its catalytic activity and mediated by H2O2. 
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Fig. 1. A) Comparison of primary structure of mouse, rat, porcine and human DAAO. 
The putative secretion signal is marked in red, the regions recognized by anti-N-
terminal and anti-C-terminal hDAAO antibodies are in violet and underlined, and 
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putative antimicrobial sequences are in light blue and green. The regions recognized 
by the anti-DAAO antibodies used in [Sasabe et al., 2016] are highlighted in green 
and yellow. The peptides identified by MS analysis following SDS-PAGE are 
highlighted in grey. B) Comparison of the structure of full-length hDAAO (PDB 2DU8, 
green) and of the model of the Δ1-16 hDAAO variant (blue). The deleted N-terminal 












































Fig. 2. A) Protein RMSD from the starting structure are represented as a function of 
simulation time: full-length wild-type hDAAO in absence and in presence of FAD (in 
black and red) and Δ1-16  deleted variant in absence and in presence of the cofactor 
(in green and blue). B) The per residue RMSF are represented as a function of the 
residue number (same colours as in panel A). C) Model of the 3D structure of the 
Δ1-16 deleted variant without FAD. The sequences characterized by highest 




Fig. 3. Western blot and MS analysis of distal (A) and proximal (B) mucosal contents 
of mouse intestinal samples. The bands recognized by two different antibodies were 
analysed by MS for the presence of DAAO: the peptides identified are reported (right 





Fig. 4. Comparison of far-UV CD spectra of DAAO antimicrobial peptides: GLT (A, C, 
E) and IWK (B, D, F) peptides (0.1 mg/mL, black) in the presence of: (A, B) 0.1 and 1 
mM SDS (green and blue, respectively); (C, D) of 5 and 30% TFE (green and blue, 
respectively), (E, F) 0.1 and 0.25 mg/mL LPS (green and blue respectively). In green 
is shown the spectrum at the lowest concentration added during the titration; in 
blue is reported the spectrum at the concentration at which the peptides show 
secondary structure.  
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Table 1: Schematic recognition pattern obtained using different antibodies in 
Western blot analyses on mouse intestinal tissues (see Suppl. Data 4). The bands 
indicated in bold have been analyzed by MS: the underlined samples contain DAAO-







 -hDAAO-Cterm (DaBio) 
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18 epithelial  
layer distal  
***  mucosal 





* < 0.1 ng DAAO/µg total proteins 
** 0.1-0.5 ng DAAO/µg total proteins 
*** 0.5-1 ng DAAO/µg total proteins 
**** > 1 ng DAAO/µg total proteins 
  








70    epithelial 
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 18 mucosal distal *    
 15 mucosal distal *    
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Table 2: Antimicrobial activity expressed as MIC and MBC values of two putative 

























IWK 25 50 2 x   
GLT 100 >100 -    
IWK+GLT 12.5 50 4 x   
 Polymyxin 
B 




IWK 12.5 12.5 1 x   
GLT 50 50 1 x   
IWK+GLT 12.5 25 2 x   
 Polymyxin 
B 
     0.5 
Escherichia 
coli 
ATCC 25922  
IWK 12.5 12.5 1 x   
GLT 50 >100 -    
IWK+GLT  12.5 100 8  x  
 Polymyxin 
B 




IWK 25 50 2 x   
GLT 25 >100 >4  x  
IWK+ GLT 6.25 100 16  x  
 Polymyxin 
B 




IWK 100 - -    
GLT 100 - -    
IWK+GLT 50 - -    
 Polymyxin 
B 
     0.5 
Gram-positive        
Staphylococcu
s  aureus 
ATCC 6538P 
IWK 25 50 2 x   
GLT >100 - -    
IWK+GLT 25 50 2 x   
 Vancomyc
in 




IWK 12.5 >100 >4  x  
GLT 6.25 >100 >4  x  
IWK+GLT 3.12 >100 >4  x  
Vancomyc
in 





Table 3. Minimum inhibitory concentration (MIC) values of DAAO-derived 
antimicrobial peptides on Lactobacilli determined by the microdilution method. 
MIC (µM) 











IWK > 110  > 110  > 110  > 110  
GLT > 100  > 100  > 100  > 100  
Erythromycin 1.4 2.8 0.7 0.7 





Supplemental Data 1. In silico analysis of DAAO sequences 
 
Suppl. Table 1: Prediction of N-terminal signal sequence for secretion in DAAOs from 
different sources. 
 





Suppl. Fig. 1. Sliding window analysis of mouse DAAO sequence. AS values were 
calculated using parameters optimized for S. aureus strain C623 and the 
hydrophobicity scale “Parker-Arg0”. Plots were obtained using window lengths of 
22 (blue line) and 33 residues (red line). Dotted lines indicate AS values 
corresponding approximately to hypothetical MIC values of 100 (bottom), 10 and 1 











 SignalP 3.0 SignalP 4.1 SecretomeP 2.0 Signal-3L Signal-3L 
2.0 
Human 0.749 0.447 0.782 yes no 
Mouse 0.700 0.415 0.693 yes yes 
Rat 0.699 0.415 0.685 yes yes 
Porcine 0.756 0.455 0.667 yes no 
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Supplementary Data 2. Production of Δ1-16 DAAO 
 
Suppl. Table 2: Comparison of the best fermentation conditions used for the 





Suppl. Table 3: Purification trials for Δ1-16 hDAAO and for His-hDAAO wild-

















Cultivation broth TB LB TB  
IPTG (mM) 0.1 1 0.1 
Temperature after induction (°C) 25 37 37 
Time of cell collection after 
induction (h) 
6 3 4 
OD600nm at induction 0.8 0.6 8 









Type Ion-exchange chromatography Affinity chromatography  
Column/Resin Anionic and cationic (DEAE, SP 
FF, Q FF) 
HiTrap chelating (Ni2+), 
Strep-trap 
Buffer Tris, BisTris-propane, MES Na pyrosphosphate, PBS, 
Tris 
pH 6, 8, 8.7, 9.2 7.2, 7.4, 8.0 
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Supplementary Data 3. Western blot analyses of rat intestine samples 
 
As summarized in Suppl. Table 4, different bands were recognized by anti-N-
terminal and anti-C-terminal hDAAO antibodies in rat tissues. In details, two bands 
at a molecular mass higher than wild-type DAAO have been recognized by the anti-
N-terminal hDAAO antibody, namely at 100 and 55 kDa, which are apparent in both 
mucosal and luminal layers: these bands most likely should correspond to aspecific 
signals. Both the antibodies recognized a band at 40 kDa, but in different samples. 
Indeed, the anti-N-terminal antibody recognized bands at 35, 25 and ~ 10 kDa while 
the anti-C-terminal antibody recognized bands at 30 and 20 kDa that most likely 
derived from elimination of an N-terminal region. Notably, the fragments of > 25 
kDa mass should be recognized by both antibodies but this was not observed. 
Altogether, the employed antibodies seem to detect aspecific signals in rat intestinal 
samples. 
 
Suppl. Table 4: Schematic recognition pattern obtained using different antibodies in 
Western blot analyses on rat intestinal tissues. 
 
Relative amount: 
* < 0.1 ng DAAO/µg total proteins 
MW (kDa) -hDAAO-Nterm (DaBio)  -hDAAO-Cterm (DaBio) 








   




   
~ 40 mucosal (proximal,  
medial, distal) 
**/***  EP layer medial * 
~ 35 luminal distal **    
30    mucosal (proximal, 
medium, distal) 
luminal distal 









   
20    mucosal medial ** 
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** 0.1-0.5 ng DAAO/µg total proteins 
*** 0.5-1 ng DAAO/µg total proteins 
**** > 1 ng DAAO/µg total proteins  
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Supplementary Fig. 2. Western blot analysis of mouse intestine samples using anti-
C-terminal (panel A) or anti-N-terminal hDAAO antibodies (panel B). In each lane an 











Supplementary Fig. 3. Western blot analysis of proximal and distal mucosal samples 
from wild-type or DAAO-/- mice using an anti-C-terminal mDAAO antibody. In each 






























Supplementary Fig. 4. Western blot analysis of DAAO-/- mouse intestine samples 
using anti-C-terminal (panel A) or anti-N-terminal hDAAO antibodies (panel B). In 







Suppl. Fig. 5. Coomassie (A) and native-PAGE (B) of proximal mucosal sample (lane 
6). Different amount of recombinant hDAAO was used as reference (0.2, 1 and 2 µg, 
corresponding to lanes 1, 2 and 3, respectively). Human (lane 4) and mouse (lane 5) 
cerebellum was used as positive control. The specificity of the activity signal 
































D-amino acid oxidase (DAAO, EC 1.4.3.3) is a peroxisomal, hydrogen 
peroxide-generating flavoenzyme which catalyzes the degradation of 
uncharged D-AAs (Pollegioni et al., 2007; Saitoh et al., 2012). DAAO plays 
different roles in several organisms: in mammals, the flavoenzyme is mainly 
expressed in kidney, liver, and brain (Pollegioni et al., 2007). In the first two 
organs it plays a detoxifying role by catabolizing exogenous D-AAs, while in 
the latter one DAAO degrades D-Ser, which acts as co-agonist of glutamate 
by binding to the “strychnine-insensitive glycine modulatory site” of NMDAr: 
in the brain, D-Ser plays a key role in main physiological processes such as 
synaptic plasticity, learning and memory (Mothet et al., 2000). The glycine 
modulatory site is not saturated under normal conditions, thus, even small 
alterations in D-Ser concentration may affect NMDAr functionality.  
A model of D-Ser metabolism, the “serine shuttle model” (Wolosker, 2011) 
proposes that this neuromodulator is synthesized in neurons by the PLP-
dependent enzyme serine racemase (SR) that can also degrade the D-AA. D-
Ser is then released by neurons and taken up by astrocytes. Considering the 
low levels of SR in astrocytes, DAAO should play a key role in D-Ser catabolism 
in these cells. Indeed, the flavoenzyme activity, through the regulation of D-
Ser cellular levels (and release), may affect the NMDAr-dependent 
physiological functions. A relationship between D-Ser signaling deregulation, 
NMDAr dysfunction and CNS diseases is presumed (Billard, 2008). In 
particular, decreased concentration of synaptic D-Ser, which induces a 
hypoactivation of NMDAr, has been associated to psychiatric disorders, such 
as schizophrenia and bipolar disorder (Verrall et al., 2007; Madeira et al., 
2008; Collingridge et al., 2013). On the other hand, an increase in D-Ser levels 
is responsible of hyperactivation of NMDAr and induces excitotoxicity: it has 
been related to the onset of neurodegenerative diseases, such as 
amyotrophic lateral sclerosis, ALS (Wolosker et al., 2008). Actually, the 
substitution of R199 with a tryptophan in hDAAO has been correlated to 
familial ALS (Mitchell et al., 2010). 
In 2006, the recombinant human DAAO (hDAAO) was expressed in E. coli and 
purified as active holoenzyme and the crystallographic structure was solved 
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(Kawazoe et al., 2006; Molla et al., 2006). hDAAO exhibits the well-known 
properties of FAD-containing flavooxidases: it stabilizes the anionic 
semiquinone species, it is able to covalently bind sulfite, it is fully converted 
into the reduced form in anaerobic conditions and in the presence of the 
substrate, a form which is highly reactive with oxygen (Curti et al., 1992; 
Molla et al., 2006). 
However, the human enzyme shows some peculiar features that distinguish 
it from other DAAOs: i) hDAAO shows a head-to-head mode of monomer-
monomer interaction and it is a dimer in both apoprotein and holoenzyme 
forms. The stable mode of interaction between monomers is due to the 
composition of the region located at the interface of the two subunits, which, 
differently from all other DAAOs, is negatively charged (Kawazoe et al., 2007; 
Kawazoe et al., 2006; Molla et al., 2006); ii) the human enzyme binds FAD 
very weakly (the Kd value is the highest among known DAAOs): the sole 
difference between human and pig DAAOs is the conformation of the 47-
VAAGL-51 hydrophobic stretch, which, in the previous enzyme is shifted 
away from the FAD. Due to the low cofactor binding affinity, a significant 
fraction of hDAAO is present in solution as inactive apoprotein that shows a 
more “relaxed” and less stable conformation. The addition of exogenous FAD 
protects the enzyme from proteolytic cleavage, suggesting that binding or 
dissociation of the cofactor might represent a mechanism regulating hDAAO 
activity. Notably, the presence of a ligand in the active site induces an 
increase in the cofactor binding affinity (Kawazoe et al., 2006; Kawazoe, et 
al., 2007; Caldinelli et al., 2010); iii) the activity and the half-life of hDAAO are 
affected by pLG72 binding (Sacchi et al., 2008; Pollegioni et al., 2018). 
Despite the key role played by hDAAO in some important physiological 
processes, much remains to be unraveled concerning the modulation of its 
functional properties. This PhD project was aimed to deep into the 
characterization of hDAAO. 
 
At first, we focused on determination of the biochemical properties of 
hDAAO. At conditions resembling the physiological ones (37 °C, pH 7-8), 
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hDAAO is stable but not fully active: since the peroxisomal pH value is 
between 7.1 and 8.2 (Jankowski et al., 2001), the enzyme activity represents 
70% of its maximal value. Moreover, we studied the effect of various divalent 
ions and/or nucleotides (Ca2+, Mg2+, ATP and GTP) on the functional and 
structural properties of hDAAO. These molecules are present at significant 
levels in the brain and are involved in the regulation of D-Ser metabolism: 
indeed, it has been shown that the oligomeric state and the activity of serine 
racemase are influenced by divalent cations like calcium, magnesium and 
manganese, as well as by nucleotides like ATP, ADP or GTP. (Baumgart and 
Rodriguez-Crespo., 2008; Bruno et al., 2017). However, the DAAO activity is 
not affected by these molecules, which also alter to a slight extent its 
secondary structure.  
The substrate specificity profile of hDAAO was clarified: the human enzyme 
prefers hydrophobic amino acids. Interestingly, some DAAO substrates are 
molecules playing a role in neurotransmission. D-cysteine seems the best 
substrate. It could represent the physiological substrate of DAAO in specific 
tissues: in brain and kidney, it was recently proposed to be converted to H2S 
by DAAO and 3-mercaptopyruvate sulfurtransferase (Shibuya et al., 2013). 
Also, DOPA is a relevant molecule in neurotransmission: the oxidation of this 
substrate by hDAAO is confirmed. Some discrepancies with previous results 
are apparent: hDAAO shows on D-DOPA the highest apparent kcat value, but 
the apparent substrate affinity and inhibition are lower than those reported 
by (Kawazoe et al., 2007). L-DOPA does not compete with the D-form for the 
binding to the hDAAO active site, while other L-amino acids can bind the 
active site of the enzyme, although with a very low efficiency (L-Ser shows a 
Ki = 26.2 mM vs. a physiological concentration of 0.1 mM). 
The binding of substrate competitive inhibitors was determined following the 
quenching of protein fluorescence. The Kd value for CBIO is similar to the Kd, 
IC50 and Ki values reported in literature (Ferraris et al., 2008). Notably, for 
benzoate a biphasic binding process is apparent pointing to the presence of 
two different protein conformations in equilibrium (with different affinity for 
the ligand) or of two different binding pockets for benzoate (as reported in 
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Kohiki et al., 2017) (Fig. 9A), suggesting that a ligand bound in the second 
pocket located at protein interface could influence the structural and 
functional properties of the active site. 
Concerning flavin binding, it has been previously demonstrated that the 
interaction between the apoprotein and FAD is stabilized by an active site 
ligand (Caldinelli et al., 2010; Molla et al., 2006) boosting the holoenzyme 








Figure 17. Scheme of the different forms of hDAAO observed in vitro and effect of 
several molecules on hDAAO structure. 
 
Here, we demonstrated that in solution hDAAO apoprotein exists in two 
alternative conformations with different affinity for the cofactor: the 
equilibrium is shifted towards the one at higher affinity by the presence of an 
active site ligand. The presence of the competitive inhibitor benzoate favors 
the conformation at higher affinity for the flavin cofactor, reaching a Kd value 
like that of rat or pig DAAOs (Frattini et al., 2011). Altogether, these findings 
suggest that the binding of an active site ligand could represent a mechanism 
for the regulation of the enzyme activity: the free enzyme, largely present in 
solution as inactive apoprotein, is rapidly turned into the active holoenzyme 
in the presence of the substrate (Figure 18). Thus, at physiological level, the 
presence of the substrate itself should push the formation of the active 

















Figure 18. Scheme of the different conformations of hDAAO apoprotein observed 
in vitro. 
 
Subsequently, the investigations focused on the effect of single positions in 
the functionality of the enzyme. In previous studies the role of D31, R199, 
W209, R279 and G331 related to known SNPs were studied (Caldinelli et al., 
2013; Cappelletti et al., 2015). These hDAAO variants were classified into two 
classes, based on their biochemical properties and on their effect on hDAAO 
functionality: i) hypoactive and ii) hyperactive (Sacchi et al., 2018). Here, we 
focused on G183R hDAAO variant, the human counterpart of the natural 
single-base mutation (yielding the G181R substitution) that in ddY mice 
inactivates the enzyme, yielding an increased D-Ser concentration and 
consequent altered NMDAr functions (Labrie et al., 2010). This mouse model  
was used to perform behavioral tests, which concur to clarify the role of 
DAAO in the mechanisms related to NMDAr transmission. Despite this, no 
characterization of the protein variant and of the way by which G181R 
substitution impacts on the enzyme functionality was carried out. Thus, we 
introduced the corresponding substitution in human DAAO and investigated 
the main properties of the protein variant. The recombinant G183R hDAAO 
variant was expressed in E. coli and fully purified as inactive apoprotein. Also 
after an extensive dialysis to push the reconstitution of the holoenzyme, the 
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recombinant G183R variant resulted inactive. The substitution of G183 
resulted in a significantly alteration in the binding to the cofactor in presence 
of an active site ligand: the arginine in position 183, located close to the 
cofactor, might create new interactions with surrounding residues, 
negatively affecting the ability to bind FAD in the correct orientation for the 
catalysis.  
Notably, when expressed in the U87 cell line, G183R hDAAO is not fully 
targeted to peroxisomes and forms protein aggregates showing a strong 
colocalization with ubiquitin. According to its impaired activity, its 
overexpression significantly (7-fold) increases D-Ser cellular concentration, 
although did not result in enhanced apoptosis. These results warn about the 
use of mice lacking DAAO activity because of the G181R single point 
mutation. The consequence of this substitution in DAAO are complex and 
possibly misleading: the effects due to impairment of D-Ser degradation 
overlaps with the ones related to aggregates accumulation.   
Moreover, we focused on the role of R120, a residue located at protein 
interface and thus putatively affecting the oligomerization state. Indeed, 
R120 has been also proposed to play a role in ligand and FAD binding: the 
overlay of the structures of hDAAO (in complex with benzoate, imino-DOPA, 
imino-serine and the substrate-free) did not show any difference in the 
conformations of the residues of the putative second binding-site, pointing 
to the side chain of R120 in the structure of hDAAO in complex with benzoate 
as the only difference. Moreover, R120 belongs to a NTS that, after 
phosphorylation, might activate the translocation of the protein to the 
nucleus (TPx sequence; in rat DAAO this signal is 117-TPS-119 corresponding 
to the 118-TPR-120 sequence in the human enzyme) (Chuderland et al., 2008; 
Luks et al., 2017). Indeed, it has been recently suggested that rat DAAO is 
present in both cytosol and nucleus of proximal tubule epithelial cells 
following treatment with the drug propiverine (Luks et al., 2017). Thus, two 
variants at position 120 (R120E and R120L) were designed and characterized 
to mimic the activation of NTS and to verify the involvement of this residue 
in ligand binding process and enzyme functionality. 
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The R120 hDAAO variants, produced as soluble holoenzymes, possess an 
altered tertiary structure. In particular, the R120E variant show a significant 
alteration of the near-UV CD and fluorescence spectra, suggesting a change 
in the exposure of aromatic residues. Moreover, for both the R120E and 
R120L variants, a significant decrease in Tm was observed, pointing to an 
alteration in protein flexibility. Structural data indicated that the substitution 
of R120 alters the electrostatic interactions with the facing residues on the 
other monomer, without affecting the oligomerization state of the protein, 
always present in solution as a dimer. Concerning the kinetic properties, 
while both the variants show a 2-fold higher kinetic efficiency than the wild-
type enzyme for D-Ala (due to a higher kcat), the kinetic efficiency on D-Ser is 
similar to the value reported for the wild-type enzyme. Considering the level 
of D-Ser in the brain (0.3 mM) and in kidney (0.14 mM) (Hashimoto et al., 
1993; Huang et al., 1998), R120 hDAAO variants show a low ability to degrade 
D-Ser, as the wild-type enzyme is. This could be a way to finely tune D-Ser 
concentrations, avoiding an excessive degradation. Concerning D-Cys, the 
R120L variant shows an increased kcat value, resulting in a slightly higher 
kinetic efficiency for this substrate. Interestingly, at high D-Cys concentration 
an inhibition effect is apparent for both the variants, which is absent for the 
wild-type hDAAO (the in vivo concentration of this D-amino acid is 
approximatively 0.2 mM) (Stipanuk et al., 2006). The substitution of R120 
does not alter the ability to bind classical hDAAO inhibitors, thus excluding a 
connection between R120 and the binding process related to the second 
putative ligand binding site. 
The most relevant change following the R120 substitution is the tighter 
binding of FAD. R120 hDAAO variants exist in solution in two apoprotein 
forms, with the first one showing a Kd for the flavin cofactor 10-fold lower 
than the wild-type enzyme. Moreover, and differently from the wild-type 
counterpart, the presence of an active site ligand does not favour the 
apoprotein form at higher affinity: FAD binding to R120 hDAAO variants is 
biphasic both in the absence and in the presence of benzoate. The activity 
values at low FAD and D-Ser concentrations (resembling the physiological 
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conditions) for R120 hDAAO variants are similar to those of the wild-type 
enzyme, probably because of the higher Km for this substrate. 
Altogether, R120 hDAAO variants can be classified among the hyperactive 
hDAAO variants group, showing an improved catalytic efficiency and FAD 
affinity (Sacchi et al., 2018). The alterations related to R120 substitution seem 
to be due to the structure-function relationships of the specific region close 
to the interface between monomers. Actually, the properties of R120 hDAAO 
variants resemble those of W209R hDAAO (SNP rs11347906) (Cappelletti et 
al., 2015): W209 is also located at the monomer-monomer interface, is part 
of the second (putative) binding site (Kohiki et al., 2017), and its substitution 
results in an increased activity on D-Ala and a tighter FAD binding, with no 
change in ligand binding properties. 
 
Immunolocalization analysis on U87 glioblastoma cells transiently 
transfected for R120 variants revealed that R120 substitution alters the 
subcellular localization of the enzyme: the substitution of R120 favors the 
mistargeting to the nucleus, in particular in the presence of a glutamate at 
position 120. Moreover, R120 hDAAO variants also shows an increased 
propensity to form cytosolic aggregates. Interestingly, the expression of 
hDAAO variants at position R120 does not alter cell viability, suggesting that 
the mistargeted (nuclear) variants should be inactive, e.g. for the absence of 
the substrate. This is a relevant observation since the oxidative stress induced 
by H2O2 generated by hDAAO reaction would lead to cell death by inducing 
DNA fragmentation and telomeric damage by oxidizing nucleobases and 
cleaving sugar-phosphate backbone (Richter-Landsberg & Vollgraf, 1998; 
Veal et al., 2007; Coluzzi et al., 2014). 
Notably, also SR was previously demonstrated to be mistargeted to the 
nucleus and inactivated under stress conditions (Kolodney et al., 2015), 
suggesting that the nuclear translocation of the enzymes related to D-Ser 




Despite the fact that DAAO has always been considered a peroxisomal 
protein, recently its localization has held some surprises: in addition to its 
presence at the cytosolic, nuclear and extrasynaptic levels (Sacchi et al., 
2008; Popiolek et al., 2011; Luks et al., 2017), DAAO protein and activity were 
previously detected in the epithelium of proximal and middle small intestine 
of mice and humans (Sasabe et al., 2016). Indeed, it has been proposed that 
the flavoenzyme might play a role in controlling the homeostasis of gut 
microbiota through the production of H2O2 (Sasabe et al., 2016). A 37 kDa 
processed form of the protein appeared to be secreted in the lumen by 
goblet cells, due to the presence of a signal peptide and a predicted cleavage 
site near the N-terminus (Sasabe et al., 2016). However, despite 
bioinformatic analyses by several softwares confirm the presence of the 
putative signal peptide, the fact that it belongs to the Rossmann fold motif, 
which contains the Wierenga sequence (GxGxxG) required for cofactor 
binding, suggests that the processed enzyme might not be folded and active. 
Indeed, the molecular dynamics simulations indicate that the overall 
structure of the variant lacking the N-terminal sequence should be less stable 
than the full-length enzyme. 
The experiments on the recombinant hDAAO variant confirm the 
computational analysis, showing that the enzyme form lacking the residues 
from 1 to 16 is unstable and inactive; accordingly, the presence of an active 
enzyme in the lumen requires a hDAAO possessing the N-terminal sequence 
required for cofactor binding and essential for the activity. Notably, a recent 
assay of DAAO activity in mice tissues did not identify any enzymatic activity 
in small intestine (whole as well as proximal, middle and distal fractions) (Kim 
et al., 2019). These evidences do not exclude that an alternative secretion 
pattern should be active for hDAAO.  
The analysis of the primary sequence of the enzyme by a specific in silico tool 
suggests the presence of two potential cryptic antimicrobial peptides, 
pointing to an alternative mechanism of action of hDAAO in the gut, not 
based on hDAAO-produced H2O2. In order to clarify this issue (and the 
putative secretion pattern) Western blot analyses were performed on small 
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intestine samples from rat and mouse using different antibodies. By using 
three commercial anti-hDAAO antibodies, bands at different mass values 
were recognized, largely due to unspecific recognition. Actually, bands at 40, 
35 and 27 kDa were observed in the mucosal and luminal content of mouse 
small intestine using anti-N-terminal and anti-C-terminal hDAAO antibodies. 
MS analysis detected the presence of hDAAO-derived peptides in the 40 and 
27 kDa bands, suggesting the presence of a processed form of the enzyme in 
the latter band. The same analysis were performed on DAAO-/- mice tissues 
as a negative control: again bands at 40, 35 and at lower molecular mass were 
apparent, but MS analysis did not identify DAAO-generated peptides 
Notably, the two peptides corresponding to the putative antimicrobial 
sequences inside DAAO sequence (namely 
257IWKSCCKLEPTLKNARIVGELTGFRPVRPQVRL289 and 
313GLTIHWGCAMEAANLFGKILEEKKLSRLPPSHL345) were found to be able to 
assume a secondary structure in presence of membrane-mimic detergents 
and LPS from E. coli and showed antibacterial and bactericidal activity on 
both Gram-positive and Gram-negative pathogenic bacteria, but not on 
Lactobacilli species, which represent the commensal microbiota. These 
results point to the ability of hDAAO to select the gut microbiota mainly by 
generating antibacterial peptides following extracellular proteolytic 
digestion.  
 
In conclusion, these studies demonstrate that hDAAO activity is finely tuned 
through ligand/flavin binding. The subcellular targeting of hDAAO also seems 
a way to modulate hDAAO functionality. If the flavoenzyme is active in the 
nucleus and whether hDAAO mistargeting is related to specific pathological 
states or involved in physiological processes is still unknown and should be 
clarified. These modulations allow hDAAO to fulfil different physiological 
functions, such as the control of D-Ser levels in the brain and of other D-AAs 
in different tissues or the selection of microbiota in the gut.  
A main issue that remain to be clarified is the mechanism of antibacterial 




reproduce the intestinal conditions will be required to investigate the 
secretion of the flavoenzyme, the generation of AMPs and their efficacy.  
A full elucidation of the regulation mechanisms of this human flavoenzyme, 
especially related to its role in different tissues, will allow the understanding 
of important physiological processes as well as the development of novel 
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The stereoselective flavoenzyme D-amino acid oxidase (DAAO) catalyzes the oxidative
deamination of neutral and polar D-amino acids producing the corresponding α-keto
acids, ammonia, and hydrogen peroxide. Despite its peculiar and atypical substrates,
DAAO is widespread expressed in most eukaryotic organisms. In mammals (and humans
in particular), DAAO is involved in relevant physiological processes ranging from D-amino
acid detoxification in kidney to neurotransmission in the central nervous system, where
DAAO is responsible of the catabolism of D-serine, a key endogenous co-agonist of
N-methyl-D-aspartate receptors. Recently, structural and functional studies have brought
to the fore the distinctive biochemical properties of human DAAO (hDAAO). It appears
to have evolved to allow a strict regulation of its activity, so that the enzyme can finely
control the concentration of substrates (such as D-serine in the brain) without yielding
to an excessive production of hydrogen peroxide, a potentially toxic reactive oxygen
species (ROS). Indeed, dysregulation in D-serine metabolism, likely resulting from altered
levels of hDAAO expression and activity, has been implicated in several pathologies,
ranging from renal disease to neurological, neurodegenerative, and psychiatric disorders.
Only one mutation in DAO gene was unequivocally associated to a human disease.
However, several single nucleotide polymorphisms (SNPs) are reported in the database
and the biochemical characterization of the corresponding recombinant hDAAO variants
is of great interest for investigating the effect of mutations. Here we reviewed recently
published data focusing on the modifications of the structural and functional properties
induced by amino acid substitutions encoded by confirmed SNPs and on their effect
on D-serine cellular levels. The potential significance of the different hDAAO variants in
human pathologies will be also discussed.
Keywords: D-amino acid oxidase, D-amino acids, D-serine levels, protein variants, structural-functional
properties, protein conformation, human pathologies
Abbreviations: DAAO, D-amino acid oxidase; hDAAO, human DAAO; D-AAs, D-amino acids; NMDAR, N-methyl-D-
aspartate type glutamate receptor; SNP, single nucleotide polymorphism; CBIO, 5-chloro-benzo[d]isoxazol-3-ol; CNS, central
nervous system; ROS, reactive oxygen species.
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INTRODUCTION
The peroxisomal flavoprotein D-amino acid oxidase (EC 1.4.3.3,
DAAO) is characterized by a strict stereoselectivity and a
broad substrate specificity. Since the first identification of
the enzyme activity by Krebs in 1935 (Krebs, 1935) and the
following purification of the protein from pig kidney (Yagi et al.,
1967; Curti et al., 1973), it was subjected to extensive studies
becoming the prototype of the dehydrogenase-oxidase class of
FAD-dependent flavoenzymes (Fitzpatrick and Massey, 1982).
DAAO catalyzes the oxidative deamination of most neutral and
polar D-amino acids (D-AAs) to their imino acids counterparts
and concomitantly reduces the cofactor FAD. Once released,
imino acids non-enzymatically hydrolyze to α-keto acids and
ammonia, while the reduced flavin is concomitantly reoxidized
by molecular oxygen producing hydrogen peroxide (H2O2;
Figure 1). DAAO is therefore considered a marker enzyme
associated with the generation of ROS in peroxisomes.
Despite its atypical substrates, DAAO is widespread in nature:
the enzyme activity has been identified in most eukaryotic
organisms, the only exception being plants. The protein from
a variety of sources, ranging from microrganisms to mammals
including humans, have been purified and characterized
(Pollegioni et al., 2007; Khoronenkova and Tishkov, 2008).
In different organisms, DAAO fulfills distinct physiological
functions: it is involved in the catabolism of D-AAs in yeasts
(allowing the microorganisms to grow on these substrates as
carbon, nitrogen and energy sources); while it plays important
regulatory roles in higher organisms. Indeed, in mammals
DAAO is implicated in relevant processes ranging from D-
AA detoxification and the modulation of excretion in kidney,
to neurotransmission in the central nervous system (CNS).
Therefore, abnormal levels of the enzyme activity have been
shown/proposed to play a significant role in pathologies. Here
we provide for the first time a review of human DAAO (hDAAO)
variants containing single point amino acidic substitution
encoded by single nucleotide polymorphisms (SNPs) reported in
the database. Their structural and functional properties, as well as
their substantiated or presumed role in diseases, will be discussed.
DAAO INVOLVEMENT IN MAMMALIAN
KEY PHYSIOLOGICAL PROCESSES
In mammals DAAO is mainly expressed in kidney, liver, brain
and to a lesser extent in the small intestine and in neutrophilic
leukocytes (Pollegioni et al., 2007, see Table 1). Worthy of
note, until 1980s no systematic studies on DAAO from higher
organisms were performed for several reasons: the enzyme
content and stability were thought to be low, the levels of
its substrates D-AAs were barely detectable (their presence in
tissues was even questioned) and therefore, no relevant biological
functions for the enzyme had been figured out at that time.
However, starting from the mid-1990s interest aroused by this
enzyme has grown exponentially. Thanks to improved analytical
methods based on high performances liquid chromatography
(HPLC), significant levels of different D-AAs were detected in
brain and other tissues (Nagata et al., 1992; Hashimoto et al.,
1993; Hamase et al., 1997). Afterwards, specific physiological
roles for D-isomers were demonstrated (Wang et al., 2000;
Wolosker et al., 2002; Fuchs et al., 2005) and a key function of
DAAO in their metabolic control was proposed (Nagata et al.,
1989; Nagata, 1992).
Liver and kidney are among the most DAAO-rich organs,
with the only exception for mouse liver, in which the enzyme
has been shown to be absent (Konno et al., 1997). Interestingly,
DAAO activity was reported in hepatocytes from mouse fetuses
(Dabholkar, 1986), but it disappeared in the liver of adult
animals, where DAAO mRNA and protein were undetectable
(Konno et al., 1997; Wang and Zhu, 2003). The reason why
mouse is the only mammal showing no expression of DAAO in
the liver remains an intriguing issue. In kidney, the enzyme was
observed in proximal tubule cells by the detection of the encoding
transcript (Koibuchi et al., 1995) and enzyme histochemistry
in mice (Sasabe et al., 2014). The identification of the mutant
ddY/DAAO−/− mice strain, expressing a fully inactive protein
variant due to the naturally occurring substitution of a Gly by an
Arg at position 181 (Konno and Yasumura, 1983), proved to be
of primary importance in the elucidation of DAAO physiological
functions. The urine of these animals was reported to contain
abnormally high amounts of D-AAs (originating from the cell
walls of intestinal bacteria, endogenous racemization or the
assumption from the diet). Thus, it was inferred that in liver
and kidney (and, to a lesser extent, in the urinary apparatus and
in colon) DAAO was responsible for their elimination. More
recently, in kidney and brain the enzyme was shown to be
involved in the metabolism of the gaseous signaling molecule
hydrogen sulfide (H2S) through the DAAO/3-MST pathway, an
alternative generation pathway (Shibuya et al., 2013).
The flavoenzyme was shown to be also expressed in the
granule fraction of normal mature human granulocytes. In
these cells DAAO, appropriately linked to myeloperoxidase,
was proposed to be part of a cellular strategy to recognize
and counteract foreign phagocytized microorganisms (Cline and
Lehrer, 1969).
Analogously, the role of DAAO in controlling the homeostasis
of gut microbiota has been recently reported (Sasabe et al., 2016).
Both enzymatic activity and protein expression were detected in
the proximal and middle small intestine of mice and humans
(Table 1), associated to the villus epithelium. Unexpectedly, a
processed form of the mouse protein appeared to be secreted
in the lumen by goblet cells, likely due to the presence of a
signal peptide and a predicted cleavage site near the N-terminus
(Sasabe et al., 2016). DAAO-mediated oxidative deamination of
free D-AAs (present as microbial products) with the consequent
production of H2O2, was shown to represent an important factor
in host defense, and in themodulation ofmicrobiota composition
(Sasabe et al., 2016).
In the CNS, DAAO was proposed to exert an important
physiological function (undoubtedly, the most investigated one).
It appeared responsible for the catabolism of endogenous D-
Serine (D-Ser), a key neuromodulator for the development
of neural circuits, which acts as a co-agonist of N-methyl-
D-aspartate receptors (NMDAR). Thus, it was suggested
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FIGURE 1 | Scheme of the reaction catalyzed by DAAO on the substrate D-Ser.
that DAAO contributes to normal neuronal functioning.
Consistently, D-Ser levels distribution in the CNS was found
to precisely mirror DAAO expression one, both in rodents and
humans. The cellular mechanisms involved in the kinetics of
serine enantiomers have been the subject of a heated debate.
A widely accepted scenario was summarized in the so-called
“serine shuttle” model (Wolosker, 2011). According to this
hypothesis, D-Ser is predominantly produced in neurons by
the stereoconversion from L-serine (provided by astrocytes)
catalyzed by the PLP-dependent enzyme serine racemase (SR)
(Wolosker, 2011; Wolosker and Radzishevsky, 2013), and
shuttled to astrocytes where it is stored and released. Here
DAAO, mainly expressed in this cell type contrary to SR,
is believed to exert a key role in the regulation of D-Ser
cellular concentrations and release, thus indirectly modulating its
availability at the synapse and affecting NMDAR activation state
through the reduced occupancy of the co-agonist site.
Due to the different methodologies used to detect the
presence of DAAO, complexities, and controversies were
raised concerning its expression levels and distribution in
the mammalian CNS, in terms of both region and cell type
(Table 1 summarizes the available data on humans). In rodents,
histochemistry methods based on the detection of the enzyme
activity led to traditionally consider DAAO as a hindbrain
enzyme, highly expressed in the cerebellum (in particular in
Bergmann glia), spinal cord and brain stem (Horiike et al., 1994;
Kapoor and Kapoor, 1997; Sasabe et al., 2012). On the other
hand, immunohistochemistry allowed the detection of low levels
of DAAO also in frontal cortex and hippocampus (Moreno et al.,
1999).
Both DAAO activity and immunoreactivity was instead
consistently detected in the human forebrain, albeit at only
a small fraction of that seen in cerebellum (Verrall et al.,
2007; Madeira et al., 2008; Table 1). A recent elegant study,
performed in both human and mouse tissues, investigated the
flavoenzyme distribution using a novel activity staining method
based on FITC-conjugated tyramide (Sasabe et al., 2014). The
authors confirmed the presence of DAAO in human forebrain
regions, but differently from previous studies (Verrall et al.,
2007), detected the enzyme activity only in the white matter,
throughout the corticospinal tract and in the spinal gray matter,
within astrocytes mainly located in the motor pathway. The high
hDAAO levels found in spinal cord (Table 1) and brain stemwere
consistent with its role in preventing excitotoxic cell death in
these regions.
Significant levels of hDAAO activity were detected in the
nigrostriatal system (Table 1; Sasabe et al., 2014), suggesting
that the flavoenzyme might affect not only glutamatergic
but also dopaminergic neurons. Intriguingly, hDAAO was
shown to efficiently metabolize D-DOPA: it is converted to
dihydroxyphenylpyruvic acid, which is then transaminated to L-
DOPA via what is known as the alternative pathway for dopamine
biosynthesis (Kawazoe et al., 2007a,b; and reference therein).
These findings suggested that D-DOPA might be the preferential
substrate of hDAAO in the nigrostriatal system instead of D-Ser,
and that the enzyme could be implicated in the metabolism of
dopamine, norepinephrine, and epinephrine.
Other roles of DAAO, exerted through the degradation of D-
Ser or other D-AAs, might be envisaged. Indeed, D-Ser may also
modulate glycinergic transmission by antagonizing NR1/NR3A
or NR1/NR3B receptors, which are insensitive to glutamate and
activated by glycine (Chatterton et al., 2002; Takarada et al.,
2009). On the other hand, the alternative DAAO substrate D-
proline can activate glycine receptors (Hamasu et al., 2010),
whereas D-leucine is a potent regulator of the blood–brain
barrier encephalin transport system (Banks and Kastin, 1991).
It is still not known, whether these various additional actions
of D-AAs may effectively be regulated by DAAO and have any
significance with regard to its involvement in pathologies.
DAAO AND PATHOLOGIES: PROPOSED
ROLES AND IMPLICATIONS
Kidney Diseases
Experimental evidence pointed out a role of DAAO in some
chronic renal pathologic damages, such as D-Ser and D-
propargylglycine induced nephrotoxicity (Konno et al., 2000;
Maekawa et al., 2005), due to the intracellular DAAO-mediated
generation of H2O2, which in turn can produce even more
aggressive ROS (Krug et al., 2007). Accordingly, renal ROS
levels exhibits strong dependence on DAAO activity. On the
other hand, a more recent study performed in rats reported that
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TABLE 1 | DAO gene and protein expression in humans.
Tissue Region Gene expression*
(Log10 TPM)
Protein expression** Cell type Main indicated function(s)
Liver + + + Hepatocytes Detoxification of DAAs








+ Enterocytes Host defense, controls microbiota composition
Brain Cerebellum + + + Astrocytes D-Ser catabolism
Spinal cord
(c-1)
++ Motor neurons D-Ser catabolism
Substantia
nigra
++ D-Ser catabolism, D-DOPA metabolism
Hypothalamus nd
Hippocampus nd





*Box plot of DAO gene transcripts levels in different human tissues. Values are shown in TPM (transcripts per kilobase million). Box represent the median and 25 and 75th percentiles.
The data presented in this column were obtained from the Genotype-Tissue Expression (GTex) Project Portal, dbGaP accession number phs000424, v7.p2 on 15/02/2018 (https://
www.gtexportal.org/home/gene/DAO).
**Expression data as reported on the human protein atlas site (https://www.proteinatlas.org/ENSG00000110887-DAO/tissue) and in the literature cited in this review. + low expression;
++ medium expression, + + + high expression; nd, not detected.
renal ischemia-reperfusion injury, a major cause of acute kidney
injury, substantially reduced renal DAAO activity (Zhang et al.,
2012). The proposed underlying pathophysiological mechanism
appeared very complex, involving among others ATP depletion,
calcium overload, ROS generation, apoptotic and inflammatory
responses (Eltzschig and Eckle, 2011). The observed change in
the local level of DAAO activity was attributed to the markedly
reduced pH value in kidney upon ischemia (Garcia et al., 2007;
Prathapasinghe et al., 2008).
Emerging evidence suggested that H2S also actively regulates
renal function and is implicated in numerous acute and chronic
kidney diseases. The broad renal protective effect of exogenous
H2S has been recently reviewed (Cao and Bian, 2016), but the
systemically administration of H2S raised matter of concern due
to its well-known toxicity (Guidotti, 2010). Considering the role
of DAAO in the DAAO/3-MST H2S generation pathway, its
targeting by D-cysteine administration has been proposed as a
way to safely deliver H2S to the kidney (Shibuya et al., 2013).
Chronic Pain and Related Diseases
Neuropathic pain that arises after nerve injury is characterized
by ongoing neurotransmission of pain signals through spinal
circuits via the dorsal root ganglion and dorsal horn neurons
(Basbaum et al., 2009). NMDARs are expressed in spinal cord
neurons and play a key role in the development of ongoing pain
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states via central sensitization (Latremoliere andWoolf, 2009). A
pioneering study reported that tonic pain-related behavior was
exaggerated in the ddY/DAAO−/− mice lacking DAAO activity
(Wake et al., 2001), indicating that the resulting increased D-
Ser levels potentiated NMDARs activation leading to a buildup
in the second phase of the formalin response. More recent
investigations (Zhao et al., 2010; Gong et al., 2011), further
confirmed that DAAO in the spinal cord acts as a pronociceptive
factor and demonstrated the efficacy of DAAO inhibitors in
models of tonic and chronic pain, generally believed to be
mediated by central sensitization. In this context, the systemic
administration of the DAAO inhibitor 4H-furo[3,2-b]pyrrole-5-
carboxylic acid was shown to reverse pain-related behaviors in rat
models of neuropathic and inflammatory pain, with a reduction
in the electrophysiological activity in spinal cord dorsal horn
neurons and peripheral afferent inputs (Hopkins et al., 2013).
It cannot be excluded that the role of DAAO in chronic
pain involves other mechanisms, independent from NMDAR
modulation. Indeed, conditions of nerve injury may include
changes in local concentrations of ROS, as it has been reported for
formalin-induced pain (Lu et al., 2012). The inhibition of DAAO
activity was observed to reduce the spinal H2O2 level (Lu et al.,
2012; Gong et al., 2014) and to increase D-Ser levels in the brain
and plasma (Adage et al., 2008; Duplantier et al., 2009; Hopkins
et al., 2013).
Interestingly, spinal DAAO has been reported to contribute
to pain hypersensitivity induced by perturbation of the
sleep-regulating circuitries in the CNS (i.e., a “physiological”
process) through the deprivation of sleep, that produces pain
hypersensitivity without an accompanying nerve or tissue injury
(Wei et al., 2013). Also in this case, the role of DAAO has been
suggested to be related to the production of ROS species. H2O2
produced by the enzyme could act on the pronociceptive TRPA1
channel expressed by central terminals of primary afferent nerve
fibers in the spinal dorsal horn.
Neurodegenerative and Neuropsychiatric
Disorders
Multiple lines of evidence suggested that dysfunctions in D-Ser
metabolism leading to an excessive or a defective production
or release, might be associated with chronic neurodegeneration.
D-Ser levels were shown to be greatly increased in the spinal
cord of patients with familial and sporadic forms of amyotrophic
lateral sclerosis (ALS), altered in Alzheimer’s disease affected
individuals, and downregulated in schizophrenia (Billard, 2008;
Wolosker et al., 2008). Whether the observed abnormal levels
depend on the altered expression and/or activity of serine
racemase or DAAO is still under investigation.
ALS is the most common adult-onset neuromuscular disorder
characterized by the selective degeneration of motor neurons in
the spinal cord, brain stem and motor cortex, leading to fatal
paralysis. Substantial advances in understanding ALS disease
mechanisms has come from the identification of pathogenic
mutations in dominantly inherited familial ALS (fALS). Notably,
a coding mutation in the DAO gene transmitted with the
disorder was identified in a three generational fALS kindred
(Mitchell et al., 2010). This mutation yielded to a substitution
of Arg by Trp at codon 199, and impaired the enzyme activity.
The overexpression of R199W hDAAO in primary motor
neuron cultures or motor neuron cell lines was reported to
promote the formation of ubiquitinated protein aggregates, to
activate autophagy and to increase apoptosis, whereas the wild-
type protein was without effect on cell survival (Paul and de
Belleroche, 2012; Paul et al., 2014). Although these pathogenic
effects could be mediated primarily by the accumulation of the
mutant protein, other factors might be relevant, such as the
impaired activity of DAAO and the consequential dysfunctional
effects on D-Ser metabolism. Accordingly, co-culturing motor
neurons with glial cells expressing R199W hDAAO variant
was sufficient to induce apoptosis in motor neurons, an effect
reversed by the treatment with an NMDAR antagonist selective
for the D-serine/glycine site. These observations indicated that
the way by which the observed neurotoxic effect was transmitted
crucially depended on D-Ser (Paul et al., 2014).
Interestingly, studies performed in ddY/DAAO−/− mice
showed that these animals developed an abnormal limb reflex
and a significant loss of motor neurons in lumbar spinal cord
at 8 months (Sasabe et al., 2012). Both in this transgenic line
and in the SODG93A mouse model of ALS, D-Ser was shown
to accumulate in the spinal cord during the progression of
ALS-related abnormal processes. This was accompanied by a
marked suppression of DAAO activity in the reticulospinal tract,
a pathway known to play an important role in regulating motor
neuron excitability (Sasabe et al., 2012). Consistently to these
studies, a recently generated transgenic mouse line expressing
R199W DAAO (DAOR199W) exhibited the characteristic features
of several ALS models including SOD1G93A mice (decreased
body weight, marked kyphosis and loss of motor neurons
in spinal cord), albeit the overall survival of these animal
appeared to be unaffected by the transgene expression (Kondori
et al., 2017). Despite no overt ALS phenotype was observed
in DAOR199W mice, marked abnormal structural , and motor
features associated with a significant loss of lumbar motor
neurons, were evident. It was proposed that, as seen in other
cases, while a mutation can cause a lethal disease in humans,
it may not be possible to generate the same phenotype in a
transgenic mouse model carrying the same mutation (Kondori
et al., 2017). In fact, hDAAO showed fairly different biochemical
properties compared to the rodent’s enzyme (Frattini et al.,
2011). Notably, enhanced ubiquitination was detected in the cell
bodies of large motor neurons of DAOR199W mice, confirming
that a prominent feature of the cells expressing the mutant
DAAO R199W allele was the presence of ubiquitinated protein
aggregates.
Two recent studies have further supported the relevance
of DAAO dysfunction to ALS pathogenesis. A comprehensive
exome sequencing study revealed that, among the known ALS
predisposition gene, DAO is the only one where the presence of
DNA variants is significantly associated with clinical outcome,
decreasing rates of survival (Cirulli et al., 2015). In a work
investigating the function of an RNA binding protein encoded
by the HnRNPA2B1 gene, and the effect of the ALS-associated
mutation D290V (promoting the protein aggregation in the
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nucleus and abnormal splicing events), it was found that the most
significant and robust splicing change after depletion of hnRNP
A2/B1 in the mouse spinal cord was the skipping of exon 9 within
DAO gene, yielding to a shorter transcript isoform (Martinez
et al., 2016). This alteration resulted in a reading frameshift and
early termination of the protein. The resulting DAAO isoform
was predicted to lack 2 α-helices and 3 β-sheets: it was highly
unstable and its enzymatic activity was largely impaired.
Beside motor disorders, Alzheimer’s disease (AD) is
characterized by cognitive impairments such as dementia
and neurodegeneration. Although different mechanisms, such
as neuronal apoptosis and inflammatory responses, are thought
to be involved in the pathogenesis, increasing evidence has
suggested that alterations in various receptors might account
for the progression of cognitive decline. Excitotoxicity (i.e.,
the cell death mediated by calcium overload) induced by the
overstimulation of NMDAR has been indicated as a potent
mechanism in AD pathophysiology (Tannenberg et al., 2004).
In this regard, elevated D-Ser levels were reported in patients
(Madeira et al., 2008) and could be considered as a pro-death
signal in AD that promotes, in conjunction with glutamate, the
neurotoxicity exhibited by inflammatory processes. However, the
role of NMDAR activity in AD appeared to be more complex.
Different studies showed impaired NMDAR signaling pathway
in the cerebral cortex and hippocampus of aging brains (Billard,
2008): a defective activation of NMDAR due to reduced D-
serine level was shown to occur in aged tissues (Junjaud et al.,
2006; Mothet et al., 2006). Being synaptic NMDAR-mediated
transmission crucial to neuronal survival, the impaired activation
of the receptor (inducing apoptosis and neuronal cell death)
might result in loss of neuronal plasticity and cognitive deficits
in the aging brain (Ikonomidou et al., 1999; Lei et al., 2008).
This NMDAR hypoactivity-induced neurodegeneration was
postulated to contribute to AD pathogenesis (Olney et al., 1997;
Wozniak et al., 1998) and it could be involved in the progression
of aging brain from mild cognitive impairment to AD. In this
regard, it has been proposed that NMDAR-enhancing agents
might be beneficial for the early declining process of AD.
Supporting this idea, D-Ser was shown to exert a neuroprotective
effect against apoptosis, promoting neuronal survival (Esposito
et al., 2012) and the DAAO competitive inhibitor sodium
benzoate was found to ameliorate cognitive and overall function
in patients with early phase AD (Lin et al., 2014). Furthermore,
recently increased levels of DAAO have been reported in the
serum of mild cognitive impairment patients, as well as mild and
severe AD patients, compared to healthy individual (Lin et al.,
2017). Worthy of note, the flavoenzyme levels increased with the
severity of cognitive deficit and were significantly associated with
D-Ser serum content.
Recent studies highlighted the role of synaptic transmitters
and their receptors in the etiology of psychiatric disorders.
Converging pharmacological, genetic, and neuropathological
studies have led to the widely accepted NMDAR hypofunction
model of schizophrenia (Coyle et al., 2003; Coyle, 2006; Stone and
Pilowsky, 2007). In particular, a deficiency of D-Ser signaling was
proposed to be responsible for the altered activation state of the
receptor. Several lines of evidence supported this hypothesis: (i)
decreased D-Ser levels were reported in serum and cerebrospinal
fluid of schizophrenia affected individuals (Hashimoto et al.,
2003, 2005); (ii) clinical trials demonstrated the beneficial effects
of D-Ser as an add-on therapy to antipsychotic treatment
(Heresco-Levy et al., 2005); (iii) D-Ser produced behavioral and
neurochemical alterations consistent with clinical effects when
administered to animalmodels (Verrall et al., 2010 and references
therein). These findings suggested that DAAO, through its role
in D-Ser metabolism might contribute to the proposed NMDAR
dysfunction in schizophrenia. This hypothesis was strengthened
by the discovery of its interaction with the product of the primate
specific geneG72, linked to schizophrenia and encoding the small
protein pLG72. Indeed, it was shown tomodulate DAAO activity,
even though along the years the effect of the DAAO-pLG72
protein complex formation has been contrasting: at first, pLG72
was proposed to act by increasing the enzyme activity (and
accordingly it was defined DAAO activator, DAOA; Chumakov
et al., 2002); while subsequent in vitro and cellular studies
repeatedly and consistently indicated that pLG72 negatively
affected DAAO functional properties, and acted by reducing its
activity and destabilizing the protein structure (Sacchi et al.,
2008, 2016; Pollegioni et al., 2018). Although some aspects of
DAAO-pLG72 interaction need further investigations, several
meta-analyses have provided a moderate degree of support for a
genetic association between G72, DAO, and schizophrenia, thus
sketching them in the category of schizophrenia susceptibility
genes.
DAAO involvement in the pathophysiology of the
neuropsychiatric disease was proposed also based on altered
levels of enzyme expression and activity detected in post-mortem
brain tissues from affected individuals, rather than merely on
genetic analysis, which can be inconclusive in the case of a
complex multifactorial disorder. Increased enzymatic activity
and gene or protein expression were reported in cerebral cortex
(Madeira et al., 2008), cerebellum (Kapoor et al., 2006; Verrall
et al., 2007; Burnet et al., 2008), medulla oblongata and choroid
plexus (Ono et al., 2009) of schizophrenic patients, suggesting
that the onset of the disease is associated with abnormal DAAO
levels in different brain areas.
hDAAO Biochemical Properties
hDAAO structural and biochemical properties have been
extensively investigated using the recombinant enzyme produced
in E. coli (Molla et al., 2006; Sacchi et al., 2008; Caldinelli et al.,
2010). Meanwhile, the crystallographic structure was resolved
(Kawazoe et al., 2006). The human enzyme was reported to be
a stable homodimer, characterized by a head-to-head mode of
monomer interaction (Figure 2A). Each monomer (347 amino
acids, 40.3 kDa) was shown to contain a non-covalently bound
FAD molecule and to be composed by 11 α-helices and 14 β-
strands, that fold into two interconnected regions: a substrate
binding domain, with a large twisted antiparallel β-sheet forming
the active-site roof and part of the oligomerization interface; and
a FAD binding domain containing the dinucleotide bindingmotif
(Rossmann fold). The cofactor was found to be buried in the
protein core in an elongated conformation, with the isoallxazine
ring located at the interface of the two domains and the re-face
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FIGURE 2 | Three-dimensional structure of hDAAO holoenzyme (PDB code 2DU8; Kawazoe et al., 2006). (A) Schematic view of the head-to-head mode of
monomers interaction. α-helices, β-strands and coils are drawn in cartoon representation. The FAD cofactor and the inhibitor sodium benzoate are shown as sticks,
colored in yellow and red, respectively. The protein surface is drawn in dark and light gray, and the second putative ligand binding pocket located at protein monomer
interface, is highlighted. (B, C) Details of the active site of the enzyme in complex with (B) imino-serine (PDB 2E49; Kawazoe et al., 2007a), and (C) benzoate (PDB
2DU8; Kawazoe et al., 2006). FAD (yellow), iminoserine and benzoate (blue) as well as side chains of important residue in the active are shown as sticks. Figures were
prepared using PyMol.
in the inner part of the active site (Kawazoe et al., 2006; Molla,
2017).
Based on the enzyme three-dimensional structure, several
considerations can be made. The substrate binds to the active
site where it is positioned above the re-side of the cofactor,
in the correct orientation with respect to the reactive N(5) of
the isoalloxazine moiety: the dehydrogenation of the substrate
occurs by the direct hydride transfer of the α-hydrogen from
the α-carbon of the D-amino acid to the flavin N(5) (Figure 1).
Several H-bond interactions concur in fixing and stabilizing the
substrate in the active site (Figure 2B). Namely, α-COOH group
of the substrate interacts with the active site residues Arg283 and
Tyr228, whereas the α-NH2 group is connected with Gly313 and
the C(4)=O of the cofactor. The substrate side chain is located
in an active site pocket made up by bulky and hydrophobic
residues (i.e., Leu51, Gln53, Leu215, and Ile230; Kawazoe et al.,
2006). Further, the “roof” of the active site is formed by the
side chain of Tyr224 that is part of a mobile loop (216-228),
which switches from a close to an open conformation to allow
the product/substrate exchange during the catalysis.
hDAAO showed peculiar biochemical properties. Differently
to others DAAOs (Mattevi et al., 1996; Pollegioni et al., 2007;
Frattini et al., 2011), the enzyme appeared to be a homodimer,
in both the holo- and the apoprotein form (Molla et al.,
2006). This was proposed to depend on a distinctive charge
distribution at the dimer interface, where a significantly higher
amino acidic substitution frequency compared to the overall
protein was observed (33% vs. 15%, respectively; Kawazoe et al.,
2006). The binding of the FAD cofactor to the human enzyme
was determined as the weakest among known DAAOs (Kd =
8.0µM for hDAAO vs. 0.2 and 0.02µM for pig kidney and
yeast DAAOs, respectively), although the presence of a ligand
in the active site stabilized the flavin interaction (Kd = 0.3µM)
(Molla et al., 2006; Caldinelli et al., 2010). Due to the low
affinity of FAD interaction, hDAAO was reported to be present
in solution as an equilibrium of holo- and apoprotein forms
(Caldinelli et al., 2010). Benzoate binding has been recently
shown to promote a conformational switch yielding a form with
a higher avidity for FAD (Murtas et al., 2017a). DAAO-catalyzed
oxidative deamination was demonstrated to follow a ternary-
complex mechanism (Pollegioni et al., 1993; Umhau et al., 2000).
For hDAAO the reductive half-reaction was very fast (117± 6 s−1
on D-Ser) but the turnover was much slower (6.3 ± 1.4 s−1), the
product release representing the rate-limiting step (Molla et al.,
2006; Molla, 2017). Because of the plasticity of the active site
lid, hDAAO showed a wide substrate specificity. Best substrates
were shown to be hydrophobic D-AAs (D-DOPA > D-Tyr >
D-Phe > D-Trp); among them D-DOPA yielded to the highest
kcat value, although different kinetic parameters were reported
(Kawazoe et al., 2007a; Murtas et al., 2017a). The human enzyme
was also reported to catabolize small uncharged D-AAs (D-Cys
> D-Ala > D-Pro > D-Ser) (Molla et al., 2006; Kawazoe et al.,
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2007a; Frattini et al., 2011; Murtas et al., 2017a). Notably, some
of them play a relevant role in neurotransmission. In particular,
hDAAO showed the highest catalytic efficiency for D-cysteine, an
intermediate of H2S metabolic pathway (see above; Murtas et al.,
2017a). Glycine and acidic D-AAs were only poorly degraded by
the human enzyme (Molla et al., 2006; Murtas et al., 2017a).
It has been demonstrated that hDAAO functionality is
modulated by the interaction with other proteins. In particular,
the enzyme was shown to specifically bind to the small
and primate-specific protein pLG72: two hDAAO homodimers
interacted with two pLG72 molecules in a 200 kDa protein
complex (for a recent review on pLG72-hDAAO interaction see
Pollegioni et al., 2018). In vitro, the complex formation modified
hDAAO tertiary structure, causing a time-dependent loss of
activity (Sacchi et al., 2008). Accordingly, at the cellular level
hDAAO-pLG72 interaction positively affected D-Ser cellular
levels and decreaseed hDAAO half-life (Sacchi et al., 2008, 2011;
Cappelletti et al., 2014). The structural details of the interaction
remain to be fully elucidated: a prominent role of the C-terminal
region in the modulation of hDAAO activity was initially
proposed (Chang et al., 2013); but further analyses performed
by using different recombinant pLG72 deletion variants, while
confirming that C-terminal terminal region is likely required
to induce the alterations in hDAAO conformation associated
with the loss of catalytic functions, indicated that the N-terminal
region of the protein was crucial for the strength of the protein
complex formation (Birolo et al., 2016). The enzyme activity
was reported to be also negatively modulated by bassoon, a
protein of the cytoskeletal matrix, enriched in the presynaptic
active zone. hDAAO-bassoon interaction was proposed to play
a homeostatic role in preventing D-Ser depletion by an active
and extraperoxisomal hDAAO form detected in at presynaptic
terminals (Popiolek et al., 2011). Worthy of note, bassoon
inhibitory effect might in part explain why hDAAO enzymatic
activity was barely detectable in the forebrain (Verrall et al.,
2007), where hDAAO was thought to be mainly expressed in
neurons, albeit at fairly low levels.
Since abnormal changes in hDAAO activity leading to
locally decreased D-Ser levels have been correlated with severe
neurological disorders (such as schizophrenia), the design, and
selection of hDAAO inhibitors to be used as drugs has gained
a growing interest (Ferraris et al., 2008). The mode of binding
of the substrate-competitive inhibitor benzoate to the hDAAO
active site is shown in Figure 2C. An exhaustive dissertation
about the structural details relevant for hDAAO inhibitors
binding has been recently published (Molla, 2017).
Despite the tremendous work that has been done so far, there
are still some aspects concerning hDAAO structural/functional
relationships that must be clarified: recent computational and
labeling analyses has suggested the presence of an unexpected,
additional ligand binding site located at the interface between
the two monomers of the holoenzyme (Figure 2A; Kohiki
et al., 2017). This hypothesis was supported by experimental
evidences showing two different phases in benzoate binding to
the holoenzyme, and indicating the existence of two different
conformations with different ligand affinities or two different
ligand binding sites (Murtas et al., 2017a).
Noteworthy, altogether these investigations suggest that
evolution has adopted sophisticated strategies to finely modulate
the activity of hDAAO in order to use this enzyme in different




Based on cellular and biochemical studies, the R199W, R199Q,
G183R, andG331V hDAAO variants could be related to the onset
of neurodegenerative diseases. For all these protein variants,
the substitution significantly reduced (when not fully abolished)
the enzyme activity. This in turn, might result in increased D-
Ser levels at the synapses and a consequent hyperactivation of
NMDAR, a condition known to induce cytotoxicity and neuronal
cell death (Mitchell et al., 2010). The G183R hDAAO variant
corresponds to the coding SNP that naturally occurs in the
ddY/DAAO−/− mice strain expressing the homologous G181R
DAAO characterized by the complete loss of the enzymatic
activity (Konno and Yasumura, 1983). On the other hand, the
R199W hDAAO variant has been associated with the onset of
fALS (Mitchell et al., 2010) and, to date, it is the unique hDAAO
variant linked to a human disease. The R199W substitution was
shown, not only to strongly affect the enzyme activity (Cappelletti
et al., 2015), but also to promote protein aggregation and to
be responsible of primary motor neuron degeneration (Mitchell
et al., 2010; Paul and de Belleroche, 2012). The R199Q hDAAO
variant corresponds to a confirmed substitution reported in
the SNPs database (rs200850756). As expected, this protein
variant showed biochemical features resembling those reported
for the R199W one (Cappelletti et al., 2015). Finally, the G331V
substitution is encoded by the reported hDAAO SNP rs4262766.
Its overexpression in U87 human glioblastoma cell line resulted
in low viability of the transfected cells, since it was shown to
promote the formation of toxic protein aggregates and to induce
apoptosis (Caldinelli et al., 2013). Among the aforementioned
substituted residues, G183 and R199 are highly conserved in
DAAOs from different sources (Figure 3).
As we can deduce from hDAAO three-dimensional structure,
G183 belongs to the α9 α-helix, which is close to pyrophosphate
and ribityl groups of the cofactor (Figures 4A,B). Here, the
substitution of the wild-type residue with an arginine likely
leads to additional electrostatic and H-bond interactions with
the surrounding residues side chain, as well as with the –CO
and –NH backbone groups that are in close contact with the
adenine nucleotide moiety of FAD (Figure 4B). It has been
proposed that this results in local alterations of the protein
variant conformation that negatively affect the cofactor binding
and its correct orientation required for hydride transfer during
catalysis (Murtas et al., 2017b).
R199 is on the β-strand β8, which lies close to the FAD
and substrate binding site. Intriguingly, this residue is placed
at the protein surface (∼11 Å from the isoalloxazine ring, thus
pretty close to the active site), at the center of a tight H-bond
network with residues of α-helix α10 and β-strands β8 and
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FIGURE 3 | Frequency of sequence conservation among DAAOs from different sources. WebLogo representation of conserved residues identified by the alignment of
DAAOs from mammals (Homo sapiens, Mus musculus, Rattus norvegicus, Sus scrofa) and yeast (Rhodotorula gracilis and Trigonopsis variabilis). The x-axis
represents amino acid position (the annotated numbering refers to the human enzyme). The y-axis indicates the sequence conservation at that position (measured in
bits), whereas the height of symbols is proportional to degree of conservations of single residues. Panels represent sequence stretches of 31 amino acids containing
the residues that are substituted in the hDAAO variants discussed in this review (shown in red). Residues belonging only to the yeast sequences are shown in blue.
Figure prepared using WebLogo 3.0 (Crooks et al., 2004).
β12, secondary structure elements belonging to the interface
domain (Figures 4A,C). Moreover, since R199 interacts with
R283, its substitution might affect the conformation of this key
active site residue, possibly impairing the ability of hDAAO
variants to stabilize the binding of substrate/inhibitors. Indeed,
not only the carbonyl group on the main chain of R199 directly
interacts with R283 side chain, but the side chain is H-bonded to
T280 belonging to the same β-strand of R283 (β12) (Figure 4C;
Cappelletti et al., 2015). In this context, the substitution of R199
with a Trp has been proposed to be responsible of a significant
alteration in the conformation of the loop between β11 and
α10 due to the different steric hindrance. On the other hand,
the substitution with a Gln likely causes the loss of a positive
charge and consequently of the existing electrostatic interaction.
Altogether, the R199W and R199Q have been suggested to
promote the disruption of relevant interactions, thus affecting
the overall protein conformation and the enzymatic activity
(Cappelletti et al., 2015).
On the other hand, G331 appears to be highly conserved
in higher organisms only (Figure 3). It is located on the C-
terminal α-helix, near the protein surface, apparently exposed
to the solvent (Figures 4A,D). G331 is far from both the active
site and the interface between monomers, in a region probably
involved in the protein folding process and exposed in the
folding intermediate(s) (Caldinelli et al., 2004). In this case,
the substitution of the wild-type Gly with a Val has been
proposed to affect the helix structure and produce a hydrophobic
surface, which makes the hDAAO variant prone to aggregation
(Caldinelli et al., 2013).
Expression in E. coli and Biochemical
Properties
The different hDAAO variants have been overexpressed in E. coli
as recombinant proteins fused with an N-terminal 6XHis-Tag,
and subjected to further characterization. Growth conditions
were modified and adapted for each hDAAO variant (Caldinelli
et al., 2013; Cappelletti et al., 2015; Murtas et al., 2017b), since
using the expression conditions set up for the wild-type enzyme
all the protein variants were largely produced as inclusion bodies,
in the insoluble fraction of the cell extract. Despite the optimized
fermentation protocols led to increased levels of soluble protein
expression, the purification yield was always lower than for the
wild-type protein (see Table 2). The G183R hDAAOwas purified
as fully inactive apoprotein (Murtas et al., 2017b). Analogously,
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FIGURE 4 | Structural models of hDAAO inactive variants. (A) The position of the point mutations on the protein dimeric structure (PDB code: 2DU8; Kawazoe et al.,
2006) is shown. Substituted residues encoded by SNPs are depicted as thick sticks in red, while FAD cofactor is reported in yellow. (B–D) Details of the protein
microenvironment surrounding at the mutated residues in the different hDAAO variants. The substituted residues are shown as sticks in magenta. The surrounding
residues within a distance of 4 Å are shown as sticks in gray. Loops, α-helices and β-sheets indicated in the text are shown as cartoon in red, blue and green,
respectively. The substrate-competitive inhibitor benzoate and the FAD cofactor are shown as sticks in orange and yellow, respectively. H-bond interactions are
reported as black dashed line. Negatively charged (blue), positively charged (red) and neutral (gray) surfaces of the C-terminal α-helix are shown in (D). Figure were
prepared with PyMol. Adapted from Caldinelli et al. (2013); Cappelletti et al. (2015); Murtas et al. (2017b).
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the purified R199W and R199Q variants were largely purified
in apoprotein form, and showed a significantly reduced specific
activity compared to the wild-type hDAAO (Table 2; Cappelletti
et al., 2015). On the other hand, the expression and purification
yields for the G331V hDAAO were consistently too low to allow
a detailed biochemical characterization. However, its estimated
specific activity closely resembled the value determined for the
recombinant wild-type hDAAO (Table 2; Caldinelli et al., 2013).
Several attempts were performed to reconstitute G183R
hDAAO variant (Murtas et al., 2017b); however, the resulting
preparation, despite showing the absorbance spectrum of the
oxidized holoenzyme, was still inactive. R199W and R199Q
hDAAO variants showed a dramatically reduced catalytic
efficiency with respect to the wild-type enzyme, mostly due
to a consistent increase in the Km values (Table 3). Notably,
when measurements were performed using 1mM D-Ser
(a concentration similar to that detected in normal brain;
Hashimoto et al., 1995) the activity of R199W and R199Q
hDAAO variants was undetectable (Cappelletti et al., 2015).
Furthermore, a significantly decreased cofactor binding
affinity was observed for the two hDAAO variants, both in
the free and benzoate complexed forms (Table 4; Cappelletti
et al., 2015). On the other hand, the G183R hDAAO variant
retained the FAD binding affinity, albeit the strength of the
interaction drastically decreased in presence of an excess of
benzoate (Table 4; Murtas et al., 2017b). The binding properties
of all the variants in general appeared altered: an overall decrease
in binding affinity for known competitive inhibitors compared
to the wild-type enzyme has been observed (Table 4). Notably,
the most pronounced changes were detected for the R199W
and R199Q variants; in particular, the estimated Kd values for
benzoate were 300-fold and 600-fold higher compared to the
wild-type one, respectively. The ability of R199Q and G183R
hDAAO to interact with the regulatory protein pLG72 was
unaffected by the substitution (Cappelletti et al., 2015; Murtas
et al., 2017b; Table 4). In the case of the R199W hDAAO instead,
its oligomeric state (see below) made unfeasible the identification
of the hDAAO-pLG72 protein complex formation.
Alterations in Protein Conformation
As determined by circular dichroism (CD) analyses, the
G183R, R199W, and R199Q hDAAO holenzymes conformation
appeared to be modified with respect to the wild-type
holoenzyme (Figure 5): while minor changes in secondary
structure elements content were observed for G183R and R199W
protein variants (Figure 5A), their tertiary structure appeared to
be specially affected (Figure 5B). In particular, the near-UV CD
spectrum of the G183R hDAAO holoenzyme strictly resembled
the apoprotein one. Only minor alterations compared to the
wild-type enzyme were instead detected in the near-UV CD
spectra of the apoprotein forms of the different hDAAO variants
(Figures 5C,D; Cappelletti et al., 2015; Murtas et al., 2017b).
Furthermore, protein stability studies performed by analyzing the
temperature sensitivity of parameters that allowed to monitor
changes in secondary and tertiary structures (the CD signal at
220 nm and tryptophan fluorescence, respectively), revealed that
the melting temperature estimated for the R199W and R199Q
variants was up to 13◦C higher compared to the wild type one
(Cappelletti et al., 2015), pointing to a decrease in the protein
flexibility.
Size exclusion chromatography studies indicated that hDAAO
oligomeric state was unaffected by the G183R substitution
(Murtas et al., 2017b). On the other hand, the holoenzyme form
of R199W hDAAO was found to be tetrameric, at concentration
≥ 1 mg/mL. Moreover, at lower concentrations, both the
holo- and the apoprotein forms of the R199W and R199Q
variants showed a chromatographic profile in-between a dimeric
and a tetrameric state, suggesting that they assumed a less
tightly packed conformation compared to the wild-type hDAAO
(Figure 6, Cappelletti et al., 2015).
Cellular Studies
In Cos-7 cells expressing R199W hDAAO (following transient
transfection), the inactive variant, similarly to the wild-type
enzyme, was shown to be correctly targeted to peroxisomes,
where it forms heterodimers with the endogenously expressed
wild-type protein. This results in a significant reduction
of the enzyme activity, suggesting a potential dominant
negative effect of the fALS associated mutation (Mitchell
et al., 2010). Accordingly, U87 human glioblastoma cells
clones stably expressing G183R, R199W and R199Q hDAAO
variants as chimeric protein with the N-terminal region
fused with the enhanced yellow fluorescent protein (EYFP),
showed significantly increased D-Ser cellular concentrations. In
particular, a 7-fold increase in D-Ser levels was observed in cells
expressing the G183R variant compared to cells expressing the
wild-type protein (Table 5), suggesting that the availability of the
neuromodulator at the synapses may be also affected (Cappelletti
et al., 2015; Murtas et al., 2017b). Worthy of note, the expression
of R199W and R199Q hDAAO (as well as the wild-type enzyme)
did not alter U87 cells viability (Cappelletti et al., 2015), as was
instead apparent in motor neurons (Mitchell et al., 2010). Similar
results were obtained in cell clones expressing the G183R variant
(Murtas et al., 2017b). On the other hand, U87 cells transiently
expressing G331V hDAAO showed significantly reduced cells
viability. Accordingly, isolating stable cell clones overexpressing
this hDAAO variant was not feasibile (the transfected cells did
not survive to the selection procedure) and cellular studies
were performed in transiently transfected cells (Caldinelli et al.,
2013). The observed effect was accompained by the formation of
consistent amount of the overexpressed protein aggregates and
a significant increase in apoptosis, as assessed by caspase activity
detection (Caldinelli et al., 2013). Intriguingly, both the G183R
and G331V hDAAO variants appeared to be partially mistargeted
within the U87 transfected cells: the two variants formed
extraperoxisomal protein aggregates, which largely colocalized
with ubiquitin (Caldinelli et al., 2013; Murtas et al., 2017b).
Both the low solubility and the cytosolic localization of G331V
hDAAO, which was supposed to be active (thus to oxidize
cytosolic D-Ser producing cytotoxic H2O2), might explain the
observed low cell viability (Caldinelli et al., 2013). Notably, the
overexpression of the inactive G183R hDAAO did not enhance
apoptosis (Murtas et al., 2017b).
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TABLE 2 | Expression conditions of recombinant hDAAO variants in E. coli.
hDAAO variant Wild-typea G183Rb R199Qc R199Wc G331Vd D31Hd W209Rc R279Ad
E. coli strain BL21 BL21 BL21 BL21 Origami BL21 BL21 BL21
(DE3) (DE3) (DE3) (DE3) (DE3) (DE3) (DE3) (DE3)
STAR STAR STAR STAR STAR STAR STAR
FERMENTATION CONDITIONS
Cultivation broth TB TB TB TB TB TB TB TB
Riboflavin addition (µM) / / / 10 / / / /
IPTG (mM) 0.1 0.6 0.6 0.6 0.1 0.1 0.6 0.1
Temperature after induction (◦C) 37 37 30 23 37 37 37 37
Time of collection after induction (h) 4 20 20 2 4 4 20 4
Purified protein (mg/L) 7.0 5.4 2.0 3.0 0.1 20.0 10.0 10.0
Specific activity (U/mg) 12.0 / 1.2 4.1 2.9 (11.6)* 14.0 12.0 10.5
Purity (%) ≥90 ≥90 ≥90 ≥90 25 ≥90 ≥90 ≥90
The specific activity was determined using the oxygen consumption assay (0.25mM oxygen, 25◦C) at 28mM D-alanine in presence of an excess of FAD (200µM).
*Value estimated based on the ∼ 25% purity (see text for details).
aMolla et al., 2006; bMurtas et al., 2017b; cCappelletti et al., 2015; dCaldinelli et al., 2013.
TABLE 3 | Apparent kinetic parameters of hDAAO variants.
hDAAO variant D-Serine D-Alanine
kcat (s
−1) Km (mM) kcat/Km (s
−1m M−1) kcat (s
−1) Km (mM) kcat/Km (s
−1mM−1)
Wild-typea 3.0 ± 0.1 7.5 ± 3.1 0.4 5.2 ± 0.2 1.1 ± 0.2 4.7
R199Qb ≥8 ≥2000 0.004 ≥10 ≥2000 0.005
R199Wb ≥15 ≥2000 0.0075 ∼15 ∼ 400 0.04
D31Hc 3.0 ± 0.2 3.9 ± 0.9 0.77 6.0 ± 0.2 0.95 ± 0.1 6.3
W209Rb 7.2 ± 0.2 17.3 ± 3.5 0.42 11.8 ± 0.2 1.2 ± 0.2 8.6
R279Ac 2.5 ± 0.1 3.4 ± 0.5 0.74 8.6 ± 0.1 1.0 ± 0.1 8.6
The activity was assayed at air saturation (0.25mM oxygen), 25◦C, and pH 8.5.
aMolla et al., 2006; bCappelletti et al., 2015; cCaldinelli et al., 2013.
TABLE 4 | Binding properties of hDAAO variants.
hDAAO variant FAD (Kd, µM)
a Benzoate (Kd, µM) CBIO (Kd, µM) CPZ
a (Kd, µM) pLG72
c interaction
Free form Benzoate complex
Wild-typed 7.9 ± 0.2 0.3 ± 0.1 7.0 ± 2.0b 101 ± 24.0b 5.0 ± 0.1 Yes
G183Re 8.4 ± 1.9 235 ± 26.0 6500 ± 400a 628 ± 25.0a 9.3 ± 0.2 Yes
R199Qf 33.5 ± 1.6 28.4 ± 3.9 4160 ± 230b 342 ± 11.0b 16.2 ± 5.3 Yes
R199Wf 40.3 ± 2.6 14.6 ± 1.4 2140 ± 130b 157 ± 30.0b 11.1 ± 1.6 n.d.
D31Hg 1.8 ± 0.1 0.13 ± 0.02 4.6 ± 0.4b n.d. 4.8 ± 0.3 Yes
W209Rf 1.9 ± 0.1 0.15 ± 0.001 3.9 ± 1.2b 96.0 ± 36.0b 2.0 ± 0.8 Yes
R279Ag 0.9 ± 0.1 0.03 ± 0.002 8.0 ± 0.5b n.d. 6.4 ± 0.3 Yes
aKd values determined by monitoring the quenching of protein fluorescence.
bKd values determined by monitoring the perturbation of flavin absorbance spectra.
cAnalysis of pLG72 binding performed by gel-permeation chromatography. The hDAAO R199W elution volume is close to that of the hDAAO-pLG72 complex, making unfeasible the
identification of the complex.
n.d. = not determined.
dMolla et al., 2006; eMurtas et al., 2017b; fCappelletti et al., 2015; gCaldinelli et al., 2013.
Hyperactive hDAAO Variants Potentially
Involved in Psychiatric Disorders
Beside the reported inactivating mutations, other amino acidic
substitutions were identified in hDAAO. The analysis of the
hDAAO protein sequences deposited in the databank revealed
a discrepancy at positions 31 and 279, which were indicated
as “sequence conflicts.” Namely, Asp31 was substituted with an
His residue in a sequence reported in the Uniprot database
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FIGURE 5 | Comparison of the CD spectra of wild-type (black), G183R (blue), R199W (green) and R199Q (red) hDAAO variants. (A,C) Far-UV CD spectra of (A) the
holoenzyme and (C) the apoprotein forms of the hDAAO variants (0.1 mg/mL protein concentration). (B,D) Near-UV CD spectra of (B) the holoenzyme and (D) the
apoprotein forms of the hDAAO variants (0.4 mg/mL protein concentration). From (Caldinelli et al., 2013; Cappelletti et al., 2015; Murtas et al., 2017b).
(http://www.uniprot.org/uniprot/P14920), and Ala279, present
in the original sequence of the human DAO gene cloned from
kidney lysates (Momoi et al., 1988), was substituted by an Arg
in the subsequently deposited sequences. To date, it is still
unclear whether these differences are due to polymorphisms or
sequencing/cloning artifacts. On the other hand, the W209R
is a substitution encoded by a confirmed SNP (rs111347906)
reported in the database, but currently not associated with a
human disease (Cappelletti et al., 2015).
Worthy of note, all the resulting hDAAO substitutions (D31H,
R279A, and W209R) were found to exert an opposite effect
on the enzyme functionality compared to the ones discussed
above: they yielded to hyperactive protein variants (Caldinelli
et al., 2013; Cappelletti et al., 2015). The characterization of
these protein variants prompted our group to propose their
potential involvement in the onset of psychiatric disorders such
as schizophrenia: an excessive degradation of D-Ser caused by
an abnormal increase of hDAAO enzymatic activity might result
into a significant reduced availability of the neuromodulator
at the synapses and the consequent hypofunction of NMDAR.
This represents a molecular mechanism that could explain many
symptomatic features of schizophrenia (Coyle et al., 2003; Coyle,
2006; Stone and Pilowsky, 2007; Pollegioni and Sacchi, 2010).
D31 is a non-conserved residue (Figure 3) located at the β-
strand β2 on the protein surface, far from both the substrate and
the flavin binding sites, as well as from the dimerization interface
(Figure 7A). For this reason, the effect of the D31H substitution
was explained in terms of a long-range interaction affecting the
overall protein conformation and propagating from the site of the
substitutions to other regions in the structure (Caldinelli et al.,
2013). Nonetheless, it is possible to speculate that conformational
alterations in this position might involve the loop between the β6
and the α8, which central region is close to the nucleotide moiety
of the FAD cofactor (Figure 7B).
Conversely, W209 is a well-conserved residue in higher
organisms (Figure 3). It is positioned in the loop between β-
strands β8-β9 (close to α-helix α4), at the monomers interface
(Figure 7A). However, this residue is not involved in relevant
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hydrophobic interactions with other residues on the surface of
the facing subunit: the loss of the indole portion of the tryptophan
side chain likely induces minimal modifications of the interaction
energy of the hDAAO monomers. Moreover, the positive charge
provided by theW209R substitutionmight result in an additional
electrostatic interaction with the negatively charged side chain
of E85 of the facing subunit (Figure 7C), de facto stabilizing the
dimeric structure (Cappelletti et al., 2015).
R279 is a further non-conserved residue (Figure 3), located
on the β-strand β12, which is involved in a double interaction:
(i) it contacts the FAD binding site (it is H-bonded with the
carbonyl oxygen of P41, close to the α-helix α2 in the region
containing the VAAGL motif, which has been proposed to play
an important role in determining the affinity of hDAAO for the
cofactor; Kawazoe et al., 2006), (ii) contributes to the definition
of the interface between the two dimers (Figure 7D). The R279A
mutation could affect the flavoenzyme binding affinity for the
cofactor by altering the conformation of the VAAGL peptide,
directly through the loss of the interaction with P41, or indirectly
by a general rearrangement of the β12-α2 interface region
(Caldinelli et al., 2013).
FIGURE 6 | Size-exclusion chromatography elution profiles of wild-type
(black), R199Q (red) and R199W (green) hDAAO holoenzymes (5mg /mL
protein concentration). From (Cappelletti et al., 2015).
Expression E. coli and Biochemical
Properties
Differently to the inactivating hDAAO substitutions, D31H and
R279A variants were successfully overexpressed in E. coli and
purified to homogeneity by using the same conditions set up for
the wild-type protein (Table 2; Caldinelli et al., 2013). On the
other hand, the fermentation conditions of the W209R variant
required further optimization to obtain a final amount of protein
similar to the wild-type one (Table 2; Cappelletti et al., 2015).
All these hDAAO variants retained the specific activity of the
wild-type flavoenzyme (Table 2; Caldinelli et al., 2013; Cappelletti
et al., 2015). They showed a significantly higher affinity for the
flavin cofactor (up to 9-fold for R279A hDAAO; see Table 4),
thus inducing an increase of the amount of the active holoenzyme
species in solution (Caldinelli et al., 2013; Cappelletti et al., 2015).
For the D31H and R279A hDAAO variants an improved catalytic
efficiency was apparent, due to a decrease in the Km value for
D-Ser and a significant increase in the kcat values for D-Ala
(Table 3). TheW209R hDAAO variant showed an increase in the
apparent kcat on both the substrates (Table 3). Notably, this latter
variant wasmore active than the wild-type hDAAOwhen 0.3mM
D-Ser and 5µM FAD were present in the reaction mixture, i.e.,
under conditions reproducing physiological ones (Cappelletti
et al., 2015).
For all hyperactive variants, no substantial alteration in
inhibitors binding affinity was observed (Table 4; Caldinelli et al.,
2013; Cappelletti et al., 2015). Furthermore, all variants retained
the ability to interact with the hDAAO binding partner pLG72
(Caldinelli et al., 2013; Cappelletti et al., 2015).
Alterations in Protein Conformation
The CD spectra of the holoenzyme and apoprotein forms of
the D31H and R279A variants appeared unaltered compared to
wild-type-DAAO (Figures 8A–D), indicating that the introduced
substitutions did not significantly affect the protein conformation
(Caldinelli et al., 2013). On the other hand, differences in far-UV
and near-UV CD spectra for the W209R variant were reported
(Cappelletti et al., 2015), pointing a decreased α-helix content
in the holoenzyme form (∼31% of vs. 37% of wild-type protein;
Figures 8A,C; Cappelletti et al., 2015). No alterations of the
oligomerization state were instead observed (Caldinelli et al.,
2013; Cappelletti et al., 2015).
TABLE 5 | Effect of the expression of EYFP-hDAAO on the cellular concentrations of serine enantiomers.
Stably transfected cells Transiently transfected cells
Time upon transfection
24 h 48 h
hDAAO variants Wild-typea G183Rb R199Qa R199Wa D31Hc R279Ac Wild-typea W209Ra Wild-typea W209Ra
D-Serine (pmol) 1.5 ± 0.3 13.3 ± 1.4 5.9 ± 0.7 2.9 ± 0.9 0.59 ± 0.2 0.38 ± 0.3 12.4 ± 0.6 9.0 ± 1.0 7.1 ± 0.5 5.7 ± 0.01
L-Serine (pmol) 72.8 ± 27.2 45.0 ± 1.6 153 ± 18.4 84.1 ± 18.3 53.7 ± 10.1 28.8 ± 10.8 203 ± 7.0 207 ± 0.8 111 ± 1.7 119 ± 10.3
D-/(D+L)-Serine (%) 2.2 ± 0.5 28.2 ± 8.3 3.7 ± 0.01 3.3 ± 0.3 1.2 ± 0.6 1.2 ± 0.6 5.8 ± 0.4 4.2 ± 0.06 6.0 ± 0.3 4.6 ± 0.04
HPLC analyses were performed on U87 human glioblastoma cells stably or transiently expressing the different hDAAO variants.
aCappelletti et al., 2015; bMurtas et al., 2017b; cCaldinelli et al., 2013.
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FIGURE 7 | Structural models of hDAAO hyperactive variants. (A) Location of the point mutations on the protein dimeric structure (PDB code: 2DU8; Kawazoe et al.,
2006). Substituted residues encoded by SNPs are depicted as thick sticks in green, while FAD cofactor is reported in yellow. (B–D) Details of the protein
microenvironment surrounding at the mutated residues in the different hDAAO variants. The substituted residues are shown as sticks in magenta. The surrounding
residues within a distance of 4 Å are shown as sticks in gray. Loops, α-helices, and β-sheets indicated in the text are shown as cartoon in red, blue, and green,
respectively. The substrate-competitive inhibitor benzoate and the FAD cofactor are shown as sticks in orange and yellow, respectively. The VAAGL sequence is
shown as a cartoon in light blue in (D). H-bond interactions are reported as black dashed line. Figure were prepared with PyMol. Adapted from Caldinelli et al. (2013);
Cappelletti et al. (2015).
Cellular Studies
In transiently transfected U87 cells the D31H and R279A
hDAAO variants fused with EYFP were correctly targeted:
the time course of subcellular compartimentalization closely
resembled that observed for the wild-type enzyme, and 72 h
after transfection they were largely localized to peroxisomes.
According to the biochemical characterization, HPLC analysis
performed on U87 cell clones stably expressing similar levels of
D31H, R279A, or wild-type hDAAO showed that the decrease in
D-Ser cellular level was significantly higher in cells expressing the
hyperactive variants compared to hDAAO wild-type expressing
one (Table 5). This evidence was used to further substantiate
the proposed role of hDAAO on D-serine levels related to
schizophrenia onset (Caldinelli et al., 2013).
On the other hand, isolating U87 cell clones stably expressing
the highly active W209R hDAAO proved to be unfeasible, since
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FIGURE 8 | Comparison of CD spectra of wild-type (black), D31H (blue), R279A (green) and W209R (red) hDAAO variants. (A,C) Far-UV CD spectra of (A) the
holoenzyme and (C) the apoprotein forms of hDAAO variants (0.1 mg/mL). (B,D) Near-UV CD spectra of (B) the holoenzyme and (D) the apoprotein forms of hDAAO
variants (0.4 mg/mL). From (Caldinelli et al., 2013; Cappelletti et al., 2015).
its expression was shown to significantly affect cells viability:
a massive cell death was reported during the clone selection
procedure (Cappelletti et al., 2015). Analyses of D-Ser cellular
content were therefore performed on transiently transfected
cells. As observed for the other hyperactive variants, W209R
hDAAO expression resulted in strongly reduced D-Ser cellular
levels compared to control cells expressing the wild-type enzyme
(Table 5; Cappelletti et al., 2015). In this case however, an
excessive accumulation of H2O2 produced by the hDAAO
catalyzed reaction was suggested to represent the factor affecting
cell viability after transfection (see above).
CONCLUSIONS
Structural and functional studies have highlighted the peculiar
biochemical properties of hDAAO (Molla et al., 2006; Sacchi
et al., 2008, 2012; Caldinelli et al., 2010; Pollegioni and Sacchi,
2010; Cappelletti et al., 2014; Murtas et al., 2017a). It only weakly
binds the FAD cofactor, shows a stable homodimeric state, and
a relatively low activity on its physiological substrates (D-Ser,
D-Ala, D-Cys, and D-DOPA). Moreover, hDAAO activity and
half-life appears to be specifically modulated by the interaction
with the regulatory protein pLG72 (Sacchi et al., 2008, 2011;
Cappelletti et al., 2014; Pollegioni et al., 2018) and bassoon
(Popiolek et al., 2011). The flavoenzyme activity must be finely
tuned to fulfill what is thought to be its main relevant function:
controlling D-Ser concentration in the brain. Altered levels of
the neuromodulator may affect NMDAR functions and receptor-
related processes involved in cognitive ability such learning and
memory (Collingridge et al., 2013; Morris, 2013).
Dysregulation in D-Ser signaling, potentially due to altered
DAAO activity, has been implicated in the NMDAR dysfunctions
observed in various diseases, such as familial and sporadic
ALS (Mitchell et al., 2010; Paul and de Belleroche, 2012), AD
(Tannenberg et al., 2004; Billard, 2008; Madeira et al., 2015)
schizophrenia (Verrall et al., 2007; Madeira et al., 2008; Habl
et al., 2009) and chronic pain (Zhao et al., 2010; Gong et al.,
2011). Accordingly, it is of great relevance to biochemically
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characterize the hDAAO variants reported in protein or SNP
databases, especially in the case that the introduced amino
acidic substitutions significantly affect the enzyme functional
properties. In this regard, hDAAO variants can be basically
grouped into two classes: inactive and hyperactive.
G183R, R199W, and R199Q variants are characterized by
significantly reduced or fully abolished (in the case of G183R
hDAAO) enzymatic activity. They show impaired ligand binding
properties due to local or general perturbation in the protein
conformation (Cappelletti et al., 2015). In G183R hDAAOvariant
changes in secondary structure elements likely induce variations
in the conformation of the FAD binding domain negatively
affecting the correct binding of the cofactor (Murtas et al., 2017b).
On the other hand, large modifications affecting the tertiary
structure of R199W and R199Q hDAAO variants deeply impact
on their catalytic efficiency (Cappelletti et al., 2015). Differently,
G331V substitution affects the enzyme activity and stability
because the induced changes in the C-terminal α-helix promote
protein aggregation, strongly reducing the variant solubility
(Caldinelli et al., 2013). On the other hand, in D31H, W209R
and R279A hDAAOvariants the substitutions (and eventually the
induced conformational perturbations) have an opposite effect.
These protein variants show slightly to significantly improved
ligand binding affinities and catalytic efficiency. In particular,
W209R hDAAO shows a 2-fold higher turnover number since
the substitution appears to facilitate the product release from the
reoxidized enzyme after the catalysis (Cappelletti et al., 2015).
Most importantly, all the reviewed hDAAO variants have
been shown to directly and significantly impact on D-Ser
cellular levels when they are overexpressed in a U87 cell line
(Caldinelli et al., 2013; Cappelletti et al., 2015; Murtas et al.,
2017b): this finding confirms their potential significance in
pathological conditions where the accumulation or the excessive
degradation of their physiological substrates is an important
feature. It has been also highlighted that hDAAO variants
aggregation and mislocation, and/or the induced overproduction
of H2O2 (in or outside the peroxisomes), might represent
important factors significantly affecting cell viability and making
the effect of the expression of the different variants even more
complex.
Thus, the expression of hDAAO inactive variants in
cohorts of individual, as proved for R199W one, might
confer susceptibility to neurodegenerative disorders such as
ALS and AD, due to an abnormal accumulation of D-Ser
which, when associated to elevated glutamate levels, could lead
to excitotoxicity related to the hyper-activation of NMDAR.
Differently, hyperactive variants might induce a deficit in
NMDAR-mediated transmission due to a decreased availability
of D-Ser at the synapses and the hypofunction of the receptor,
a condition that in turn has been postulated to be involved
in schizophrenia (and eventually AD) onset. Their expression
would also be significant in individuals affected by, or sensitive
to, chronic pain. The overproduction of H2O2 by hDAAO
hyperactive variants (together with the exaggerated depletion
of D-Ser) may contribute to the elucidation of the molecular
mechanism of the central sensitization typical of this neurological
condition.
We are aware that, despite the key role played by hDAAO
in some important physiological processes, much remains to be
unravel concerning the modulation of its functional properties.
The ongoing characterization of variants corresponding to
confirmed SNPs in the database will deepen our understanding
of the structure/function relationships of this enzyme, and of
the effect of their alteration in pathological conditions, providing
effective tools to propose and design novel and more effective
therapeutic treatments.
Moreover, the potential of the novel genome editing tool
based on the clustered regularly interspaced short palindromic
repeats (CRISPR)/CRISPR-associated protein-9 nuclease
(CRISPR/Cas9) has been recently explored for modeling
neurodegenerative diseases which pathomechanisms that have
not yet been fully uncovered, including ALS (Kruminis-Kaszkiel
et al., 2018). Indeed, both a zebrafish (Armstrong et al., 2016)
and a mouse (Liu et al., 2017) ALS models have been developed
by using this genome engineering technology to introduce
patients-specific mutations in genes associated to the disease.
Therefore, the possibility to develop animal models carrying
DAAO selected activating or inactivating mutations might
represent an invaluable system to investigate further the
molecular mechanisms involved in pathological conditions,
ranging from neuropsychiatric to neurodegenerative disorders,
in which dysregulation of D-Ser metabolism likely play a key
role.
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D-Amino acid oxidase (DAAO) is an FAD-containing flavoenzyme that catalyzes with
absolute stereoselectivity the oxidative deamination of all natural D-amino acids, the only
exception being the acidic ones. This flavoenzyme plays different roles during evolution
and in different tissues in humans. Its three-dimensional structure is well conserved
during evolution: minute changes are responsible for the functional differences between
enzymes from microorganism sources and those from humans. In recent years several
investigations focused on human DAAO, mainly because of its role in degrading the
neuromodulator D-serine in the central nervous system. D-Serine is the main coagonist of
N-methyl D-aspartate receptors, i.e., excitatory amino acid receptors critically involved
in main brain functions and pathologic conditions. Human DAAO possesses a weak
interaction with the FAD cofactor; thus, in vivo it should be largely present in the inactive,
apoprotein form. Binding of active-site ligands and the substrate stabilizes flavin binding,
thus pushing the acquisition of catalytic competence. Interestingly, the kinetic efficiency of
the enzyme on D-serine is very low. Human DAAO interacts with various proteins, in this
way modulating its activity, targeting, and cell stability. The known properties of human
DAAO suggest that its activity must be finely tuned to fulfill a main physiological function
such as the control of D-serine levels in the brain. At present, studies are focusing on
the epigenetic modulation of human DAAO expression and the role of post-translational
modifications on its main biochemical properties at the cellular level.
Keywords: D-amino acid oxidase, D-serine, substrate specificity, structure-function relationships, NMDA receptor
INTRODUCTION
Using FAD as cofactor, D-amino acid oxidase (DAAO, EC 1.4.3.3) catalyzes with strict
stereoselectivity the oxidative deamination of neutral D-amino acids. DAAO has been discovered
in pig kidney in 1935 (Krebs, 1935) and during the years it has been investigated as a prototype
of FAD-dependent oxidases and has been the object of a plethora of studies: 96,325 publications
concerning DAAO have appeared over the years (Scopus, 1 October 2018) with a significant
increase from 2000 onward. D-Amino acids are dehydrogenated by DAAO into imino acids that
spontaneously hydrolyzed to the corresponding α-keto acids and ammonia; the reoxidation of
FADH2 on molecular oxygen generated hydrogen peroxide (Figure 1).
The reaction catalyzed by DAAO is of biotechnological relevance since it can be used in
biocatalysis (to produce α-keto acids from D-amino acids or 7-aminocephalosporanic acid from
Abbreviations: ALS, amyotrophic lateral sclerosis; CBIO, 5-chloro-benzo[d]isoxazol-3-ol; fALS, familial amyotrophic lateral
sclerosis; DAAO, D-amino acid oxidase; hDAAO, human DAAO; NMDAR, N-methyl-D-aspartate type glutamate receptor;
SR, serine racemase.
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FIGURE 1 | Reaction catalyzed by DAAO.
cephalosporin C, to resolve racemic mixtures of natural and
synthetic amino acids, etc.), in biosensors, and in cancer therapy,
to mention only the main applications (Pilone and Pollegioni,
2002; Caligiuri et al., 2006a,b; Pollegioni and Molla, 2011). For
such a use, DAAO was isolated from microorganisms: those
from Trigonopsis variabilis and Rhodotorula gracilis have been
investigated in depth (Pollegioni et al., 2002, 2008; Arroyo et al.,
2007).
The investigations on DAAO from higher organisms started
in the 1980s. The enzyme’s physiological role was long debated
largely because the levels of D-amino acids were barely detectable
and their presence in many tissues was questioned. Later on,
appreciable levels of various D-amino acids were determined in
brain and other tissues based on improved analytical methods
(mainly high-performance liquid chromatography) (Nagata,
1992; Nagata et al., 1992; Hashimoto et al., 1993; Hamase et al.,
1997). This cleared the path to identifying specific physiological
roles for D-amino acids (Wang et al., 2000; Wolosker et al., 2002;
Fuchs et al., 2005) and to propose for DAAO a key role in their
metabolic control. Here, the ability of D-serine to act in the
central nervous system as a coagonist of N-methyl D-aspartate
receptors (NMDAR), excitatory amino acid receptors critically
involved in learning and memory, stimulated the field.
D-Serine is mainly synthesized in neurons by racemization
of the L-enantiomer catalyzed by the pyridoxal phosphate-
dependent enzyme serine racemase (SR, EC 5.1.1.18) (Wolosker
et al., 1999). L-Serine is provided by astrocytes possessing a
specific metabolic pathway, referred to as the “phosphorylated
pathway,” the primary route for the net synthesis of L-serine in
the brain, considering the low permeability of the amino acid
at the blood-brain barrier (Furuya et al., 2000). SR can also
catabolize D- and L-serine through an α,β-elimination reaction
to give pyruvate (Foltyn et al., 2005). From a cellular point of
view, SR is a “complex” enzyme since its activity is modulated by
energy level (ATP), metal ions, post-translational modifications,
and protein interactors; for details, see (Pollegioni and Sacchi,
2010; Conti et al., 2011; Dellafiora et al., 2015; Beato et al.,
2016). Once released by neurons, D-serine is rapidly taken
up and stored in astrocytes (Wolosker, 2011; Wolosker and
Radzishevsky, 2013). SR is poorly expressed in astrocytes, which
instead produce DAAO; in these cells the flavoenzyme indirectly
controls its availability at the synapse by regulating D-serine
cellular concentrations and affects the activation level of NMDAR
by modulating the occupancy of the co-agonist site.
ROLE OF DAAO IN PHYSIOLOGICAL AND
PATHOLOGICAL CONDITIONS
DAO gene is present in a single copy in human chromosome
12 (12q23-24 region) (Konno, 2001, AA): its structure has been
detailed in Figure 3 of Pollegioni et al. (2007). A definite report
of the DAO gene and protein expression in human tissues, with
a particular focus on the brain regions, was recently reported, see
Table 1 in Sacchi et al. (2018) and Figure 2 of Molla (2017). The
highest amount of DAAO protein is observed in liver and kidney:
in the latter organ, the enzyme is expressed in proximal tubule
cells (Koibuchi et al., 1995; Sasabe et al., 2014a). DAAO was
associated with chronic, pathologic renal damage, e.g., D-serine
and D-propargylglycine induced nephrotoxicity due to DAAO-
mediated generation of H2O2 (Konno et al., 2000; Maekawa et al.,
2005; Krug et al., 2007).
The elucidation of the physiological functions of DAAO was
accelerated by investigating the mutant ddY/DAAO−/− mice
strain expressing the inactive G181R enzyme variant (Konno
and Yasumura, 1983): large amounts of D-amino acids were
excreted in the urine of these animals. Accordingly, in liver
and kidney (as well as in the urinary tract and in colon)
DAAO eliminates D-amino acids originating in the cell walls of
intestinal bacteria, from endogenous racemization, or from the
diet. Indeed, increased D-serine levels were apparent in brain
regions normally characterized by high DAAO expression in
wild-type animals (Morikawa et al., 2001; Miyoshi et al., 2009).
In kidney and brain, the flavoenzyme is a component
of the DAAO/3-MST pathway related to hydrogen sulfide
(H2S) generation (Shibuya et al., 2013). Within peroxisomes,
DAAO metabolizes D-cysteine (mostly provided by food) to
3-mercaptopyruvate, which is then imported into mitochondria
where it is converted to H2S by 3-mercaptopyruvate
sulfurtransferase (3MST). H2S regulates kidney excretory
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FIGURE 2 | Substrate preference of hDAAO. The apparent kinetic properties
have been determined at 21% oxygen saturation, pH 8.5, and 25◦C. All values
were from Molla et al. (2006) with the exception of (a) Murtas et al. (2017b),
Frattini et al. (2011); (b) Kawazoe et al. (2007b).
function and modulates blood pressure by affecting the release of
renin.
The expression of DAAO was also reported in the granule
fraction of mature human granulocytes (specifically on the cell
surface), where it was proposed to participate in recognizing
and counteracting foreign, phagocytosed microorganisms
(Cline and Lehrer, 1969; Robinson et al., 1978). Within the
phagosome, DAAO metabolizes D-alanine (derived from the
peptidoglycan of the bacterial cell wall) producing H2O2,
which in turn is the oxidant substrate for myeloperoxidase
that converts chloride to hypochlorous acid, a strongly
microbicidal compound. Compared to the wild-type strain,
the aforementioned ddY/DAAO−/− mice show a higher
susceptibility to S. aureus infection (Nakamura et al., 2012).
It was recently reported that DAAO plays a role in controlling
the homeostasis of gut microbiota (Sasabe et al., 2016): DAAO
(protein and activity) was identified in the proximal and middle
small intestine of mice and humans, associated to the villus
epithelium. A proteolyzed form of mouse DAAOwas reported to
be secreted in the lumen by goblet cells: this extracellular form
is likely secreted by an N-terminal signal peptide and cleaved
at the level of a putative cleavage site also located at the N-
terminus (Sasabe et al., 2016). The H2O2 generated by DAAO
during the catabolism of free D-amino acids of microbial origin
represents an important factor in host defense (it protects the
mucosal surface from the cholera pathogen) and in modifying
microbiota composition (Sasabe et al., 2016).
In the central nervous system, DAAO is the enzyme mainly
responsible for catabolism of D-serine: notably, in rodents
and humans DAAO expression mirrors D-serine distribution.
DAAO (activity and immunoreactivity) was mainly detected
in cerebellum and, at lower levels, in the forebrain (Verrall
et al., 2007; Madeira et al., 2008). A quite recent investigation
confirmed DAAO expression in human forebrain regions and, at
the same time, also highlighted that its activity is present in the
white matter, throughout the corticospinal tract, and in the spinal
gray matter, where it is localized in astrocytes mainly situated in
the motor pathway (Sasabe et al., 2014b). The significant hDAAO
activity assayed in spinal cord and brain stem is coherent with the
proposed function in preventing excitotoxic cell death.
Morover, hDAAO activity was identified in dopaminergic
neurons of the nigrostriatal system (Sasabe et al., 2014b):
hDAAO is known to efficiently metabolize D-DOPA (see below);
thus, the enzyme could affect the metabolism of dopamine,
norepinephrine, and epinephrine.
In spinal cord neurons, NMDARs are expressed and are
involved in the development of ongoing pain states via central
sensitization (Latremoliere and Woolf, 2009). The tonic, pain-
related behavior was amplified in the ddY/DAAO−/− mice strain
(Wake et al., 2001): the boost in the second phase of the formalin
response is due to the potentiated NMDAR activation by the
ensuing increased D-serine concentration. Later on, the role
of DAAO as a pronociceptive factor in the spinal cord was
confirmed (Zhao et al., 2010; Gong et al., 2011). Notably, the
administration of DAAO inhibitors in rat models of tonic and
chronic pain reversed pain-related behaviors and decreased the
electrophysiological activity in spinal cord dorsal horn neurons
and peripheral afferent inputs (Hopkins et al., 2013a). Among
the putative ways in which DAAO is involved in chronic pain,
a change in local levels of reactive oxygen species has been
reported for formalin-induced pain (Lu et al., 2012). In this
case, by inhibiting DAAO activity, a decrease in the production
of spinal H2O2 levels is apparent (Lu et al., 2012; Gong et al.,
2014). Interestingly, spinal DAAO has been also involved in
pain hypersensitivity induced by perturbing sleep-regulating
circuitries in the central nervous system through the deprivation
of sleep, a process that generates pain hypersensitivity with no
nerve or tissue injury (Wei et al., 2013). The H2O2 generated by
DAAO could target the pronociceptive TRPA1 channel expressed
by central terminals of primary afferent nerve fibers in the spinal
dorsal horn.
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FIGURE 3 | hDAAO three-dimensional structure (pdb codes 2e49). (A) The hDAAO protomer is constituted by two domains: the substrate and the FAD-binding
domain (in blue and red, respectively). The entrance to the active site is indicated by a large arrow. The thin arrow indicates the putative additional ligand-binding site
(Kohiki et al., 2017). (B) The substrate is located above the re-side of the isoalloxazine ring of FAD, in a cavity of ∼220 Å3. (C) hDAAO is a stable homodimer,
characterized by a head-to-head mode of monomer interaction (Kawazoe et al., 2006). (D) The substrate dehydrogenation ensues by the direct hydride transfer of the
α-H from the α-C of the D-amino acid to the flavin N(5), see dotted line (Umhau et al., 2000). Following hydride transfer, a negative charge is generated on the reduced
flavin, which is stabilized by the positive charge generated on the imino group of the product. This figure has been generated by modeling a D-Tyr molecule instead of
the original ligand imino serine. Figure prepared with 3dproteinimaging.com.
Amyotrophic lateral sclerosis (ALS) is a rapidly progressing,
adult-onset, neuromuscular disease distinguished by the selective
loss of motor neurons. A recent, comprehensive, exome-
sequencing study revealed that the only DNA variants associated
with clinical outcome of ALS and with lower rates of survival
are located on the DAO gene (Cirulli et al., 2015). Actually,
the R199W DAAO substitution was identified in a three-
generational familial ALS (fALS) kindred (Mitchell et al.,
2010). This substitution impaired DAAO activity, boosted
the formation of ubiquitinated protein aggregates, promoted
autophagy activation, and increased apoptosis when the protein
was overexpressed in motor neuron cell lines or primary motor
neuron cultures (Paul and de Belleroche, 2012; Paul et al.,
2014). The transgenic mouse lines expressing R199W DAAO
(DAOR199W) were unaffected in survival although they exhibited
the features common to several ALS mice models, i.e., decreased
body weight, marked kyphosis, and loss of motor neurons in
spinal cord (Kondori et al., 2017). Recently, it was reported that
the most significant and robust splicing change after depletion
of hnRNP A2/B1 in the mouse spinal cord was the skipping of
exon nine within DAO gene, yielding a reading frameshift and
early termination of the protein, predicted to lack 2 α-helices and
3 β-sheets and to generate a highly unstable and inactive variant
(Martinez et al., 2016).
Impaired NMDAR signaling pathways are known to occur in
the hippocampus and cerebral cortex of aging brains (Billard,
2008); in aged tissues a hypoactivation of NMDAR is related
to decreased D-serine levels (Junjaud et al., 2006; Mothet et al.,
2006). Neurodegeneration induced by NMDAR hypoactivity was
also proposed to contribute to AD and to be related to the
progression of aging brain from mild cognitive impairment to
AD (Olney et al., 1997; Wozniak et al., 1998). Compared to
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healthy individuals, the serum levels of DAAO are increased in
patients affected by mild cognitive impairment and mild and
severe AD (Lin et al., 2017), and DAAO levels correlate with the
severity of cognitive deficit and with the D-serine level.
Alterations in D-serine levels have been observed in
Alzheimer’s disease (AD) and have been suggested to represent
a pro-death signal (Billard, 2008; Madeira et al., 2015).
An NMDAR hypofunction was also related to schizophrenia
(Coyle et al., 2003; Coyle, 2006; Stone and Pilowsky, 2007):
the altered activation state of the receptor was proposed to
depend on a deficiency in D-serine signaling (Hashimoto et al.,
2003, 2005; Verrall et al., 2010). The protein and activity levels
of hDAAO were altered in post-mortem brain tissues from
schizophrenic patients in cerebral cortex (Madeira et al., 2008),
cerebellum (Kapoor et al., 2006; Verrall et al., 2007; Burnet et al.,
2008), medulla oblongata, and choroid plexus (Ono et al., 2009).
Further support comes from the discovery that the G72 gene,
encoding the small protein pLG72, the main hDAAO-specific
binding protein (see below), has been linked to schizophrenia
(Chumakov et al., 2002; Sacchi et al., 2008, 2016; Pollegioni
et al., 2018). Additional meta-analyses supported a genetic
association between DAO, G72, and schizophrenia: they have
been classified as schizophrenia susceptibility genes (Sacchi et al.,
2016).
CELLULAR PROPERTIES OF hDAAO
DAAO is considered a marker of peroxisomes since it contains
a classical PTS1 signal at the C-terminus (Horiike et al., 1994;
Moreno et al., 1999). Notably, an active DAAO form has
been reported in the cytosol, both in glial cells and neurons
(Sacchi et al., 2008, 2011; Popiolek et al., 2011). In astrocytes
overexpressing hDAAO, the cytosolic form seems to transiently
accumulate in this compartment before targeting peroxisomes
(Sacchi et al., 2011). Recent reports on rats demonstrated
that DAAO is present both in the cytosol and nuclei of
proximal tubule epithelial cells following treatment with the drug
propiverine (Luks et al., 2017a,b) and that intestinal epithelial
cells in mice secrete the flavoenzyme into the lumen (Sasabe et al.,
2016).
The degradation pathway of hDAAO was investigated in
U87 glioblastoma cells stably expressing the flavoenzyme fused
to the C-terminus of the enhanced yellow fluorescent protein
(EYFP, thus generating a peroxisomal chimeric protein) or at
the N-terminus (thus producing a cytosolic chimeric protein
since the PTS1 signal is masked). hDAAO is a long-lived
protein showing a half-life > 60 h. The peroxisomal EYFP-
hDAAO is degraded via the lysosomal/endosomal pathway,
whereas the cytosolic hDAAO-EYFP protein is ubiquitinated
and targets the proteasome. Overexpression of the interacting
protein pLG72 (showing a rapid turnover, half-life in the
25–40min range) increases the turnover of DAAO (half-life
∼6 h) (Sacchi et al., 2011): hDAAO-pLG72 complex formation
seems to represent a means to play a protective role against




A comparison of the main biochemical properties of mammalian
DAAOs is reported in Sacchi et al. (2012). Recombinant hDAAO
is produced in fairly large amounts in E. coli cells (Kawazoe et al.,
2006; Molla et al., 2006; Romano et al., 2009). It is purified as
active holoenzyme by adding exogenous FAD to the purification
buffers: hDAAO shows the classical properties of flavoprotein
oxidases, such as a quick reaction with O2 in the reduced form
and stabilization of the anionic red flavin semiquinone.
In the 6–10 pH range, hDAAO shows a good activity and
stability (Murtas et al., 2017b). From the fitting of the activity
values determined at different pH values, two dissociations were
apparent: a pKa of 2.5 and 11.1, respectively. Notably, the enzyme
is fully stable after 60min of incubation at 4◦C at pH values≥3.0
and ≤10.0. The flavoenzyme is stable up to 45◦C, a temperature
corresponding to the optimum for the enzymatic activity. The
melting temperature determined following the loss of activity was
∼55◦C (Murtas et al., 2017b), higher than the values determined
using the changes in protein fluorescence intensity (Caldinelli
et al., 2010): this result suggests that the alteration in protein
conformation brings forward the loss of enzymatic activity.
hDAAO activity is not affected by the presence of divalent ions
(Ca2+ and Mg2+) and/or nucleotides. Similarly, the reducing
agent N-acetyl-cysteine, a derivative of L-cysteine, acting as
antioxidant and anti-inflammatory agent and that is able to
modulate NMDAR activity (Kumar, 2015), does not affect the
activity of hDAAO (Murtas et al., 2017b).
Substrate Specificity
hDAAO shows a wide substrate acceptance: the best substrates
are hydrophobic and bulky D-amino acids (D-DOPA > D-
Tyr > D-Phe > D-Trp, Figure 2). The highest kcat value
was determined for D-3,4-dihydroxy-phenylalanine (D-DOPA)
(Kawazoe et al., 2007a,b; Murtas et al., 2017a,b), also showing a
high affinity due to two additional H-bonds between the OH-
groups of the substrate and His217 and Gln53 (Kawazoe et al.,
2007a). However, the oxidation of D-DOPA is hindered by the
substrate inhibition effect, Ki of 0.5 (Murtas et al., 2017b) or
41mM (Kawazoe et al., 2007b).
hDAAO is also active on small, uncharged D-amino acids
(D-Cys > D-Ala > D-Pro > D-Ser) (Molla et al., 2006;
Kawazoe et al., 2007b; Frattini et al., 2011; Murtas et al.,
2017b). Purified recombinant hDAAO shows a low catalytic
efficiency on what is known as the main physiological substrate,
D-serine. Whether in vivo (and especially in glial cells) an
increase in kinetic efficiency is achieved by the binding with
a cellular compound (i.e., a protein or a small size ligand) or
by a post-translational modification is still unknown: this issue
deserves further investigations. The highest catalytic efficiency
was determined for D-cysteine, a compound involved in H2S
generation (see above) (Shibuya et al., 2013).
hDAAO is not active on glycine and acidic D-amino acids
(NMDA and D-Glu) while the activity on D-Asp is hampered
by the high apparent Km (in the molar range) (Molla et al.,
2006; Murtas et al., 2017b). hDAAO also oxidizes D-kynurenine
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with an apparent Km value (0.7mM) resembling that determined
for D-cysteine. Kynurenic acid, the product of D-kynurenine
oxidation, binds to the modulatory glycine site of the NMDAR
resulting in an inhibitory effect. Furthermore, hDAAO is also
active on D-cycloserine, an NMDAR modulator (Kumar, 2015).
The substrate promiscuity of hDAAO supports the hypothesis
that this flavoenzyme might play a role in different tissues and
cells.
The activity of hDAAO on D-serine is partially inhibited
by the L-enantiomer (Murtas et al., 2017b). L-Serine acts
as competitive inhibitor (Ki of 26.2mM). Under anaerobic
conditions L-serine, as well as L-alanine or L-valine, are able
to reduce FAD. However, a physiological concentration of L-
serine (corresponding to ≤2mM in brain tissues and in blood)
(Weatherly et al., 2017) should not modify the oxidation of
D-serine by hDAAO.
Kinetic Mechanism
For all known DAAOs, the oxidative deamination of D-amino
acids follows a ternary-complex mechanism (Pollegioni et al.,
1993; Umhau et al., 2000; Molla et al., 2006). The substrate
dehydrogenation ensues by the direct hydride transfer of the α-H
from the α-C of the D-amino acid to the flavin N(5): please see
below and Figure 3D. The distance between these atoms is 3.6 Å
in the hDAAO-imino serine complex: owing to the tetrahedral
geometry of the substrate α-C, the mentioned atoms should be
closer in the Michaelis complex (∼3.2 Å). Following hydride
transfer, the reduced flavin is negatively charged: the positive
charge of the product imino group electrostatically stabilizes the
reduced cofactor.
For mammalian DAAOs, and especially for hDAAO, the
first half of the reaction (the reductive half-reaction), namely,
the conversion of the tetrahedral D-amino acid into the planar
imino acid coupled to the flavin reduction is fast (117 ± 6
s−1 on D-serine), significantly faster than turnover (6.3 ± 1.4
s−1). The rate-limiting step in hDAAO catalysis is the product
release (Molla et al., 2006; Molla, 2017). The rate of imino acid
release from the reduced enzyme is < 1 s−1, too slow to allow
the reoxidation step to start from the free, reduced enzyme.
Accordingly, reoxidation must start from the corresponding
reduced enzyme-imino acid complex: the second-order reaction




Each hDAAO protomer contains 347 amino acids (40.3 kDa),
harbors one molecule of FAD, and is composed of 11 α-helices
and 14 β-strands. hDAAO is constituted by two interconnected
regions: an FAD-binding domain containing the dinucleotide
binding motif (Rossman fold) and a substrate-binding domain
in which a large, twisted, antiparallel β-sheet forms the active-
site roof and part of the oligomerization interface (Figures 3A,B).
hDAAO is a stable homodimer: the two monomers interact via a
head-to-head geometry (Figure 3C; Kawazoe et al., 2006).
In the active site, the substrate is located above the re-
side of the isoalloxazine ring of FAD, in a cavity of ∼220 Å3
(Figure 3B). The substrate is bound via several hydrogen bonds
in the correct orientation with respect to the flavin N(5) position
for catalysis to proceed: the α-carboxylic group of the substrate
electrostatically interacts with Arg283 and Tyr228, whereas
the α-amino group interacts with Gly313 and the C(4)=O of
FAD. The side chain of the substrate is placed in a pocket
made up of hydrophobic residues (Leu51, Gln53, Leu215, and
Ile230), named the substrate-specificity pocket (Kawazoe et al.,
2006). The active-site “roof” is shaped by the side chain of
Tyr224, a residue belonging to a mobile loop (216–228): the
product/substrate exchange during catalysis is facilitated by the
switch of this residue from a closed to an open conformation.
This conformational change significantly influences the enzyme
properties: limiting the turnover, increasing the hydrophobicity
of the active site, and allowing hDAAO to bind large substrates
(Molla et al., 2006; Kawazoe et al., 2007b).
The strict stereoselectivity of DAAO for the D-enantiomer
of the amino acids is rationalized by the four-location model
for enantioselectivity (Mesecar et al., 2000; Umhau et al., 2000;
Mörtl et al., 2004). According to this model, the substrate
establishes three interactions—using the α-carboxylic group, the
α-amino group and the side chain—with the active site residues
indicated above: the exact binding produces a “functional
direction” exemplified by the alignment of the α-H of the
substrate and the N(5) of FAD, which allows hydride transfer
(Figure 3D).
Oligomeric Structure
Different from other DAAOs (Mattevi et al., 1996; Pollegioni
et al., 2007; Frattini et al., 2011), an 80 kDa homodimer is
generated by both the holo- and the apoprotein form of hDAAO
(Molla et al., 2006). This results from a distinguishing charge
distribution at the dimer interface (a region corresponding
to ∼1,500 Å2, i.e., the 9.8% of the overall solvent accessible
surface, Figure 3C), where a significantly higher amino acidic
substitution frequency was observed than for the overall protein
(33 vs. 15%, respectively) (Kawazoe et al., 2006). Notably,
the urea-induced dissociation of dimeric hDAAO generates
protein conformers prone to aggregation (Caldinelli et al.,
2009).
FAD Binding
In hDAAO the FAD cofactor shows an elongated conformation
and it is buried in the protein core: the isoalloxazine ring is
located at the interface between the two subdomains with the re-
side facing the interior of the active site (Kawazoe et al., 2006;
Molla, 2017). At this side of the flavin ring, the conformation of
the surrounding residues is highly conserved among mammalian
DAAOs. Conversely, at the si-face, the conformation of the
hydrophobic stretch (47-VAAGL-51, a structurally ambivalent
peptide) differs between the human and porcine enzymes,
causing loss of the H-bond between Ala49 and N(5) of the
cofactor and likely decreasing the strength of the interaction of
the flavin cofactor and the rate of flavin reduction (Kawazoe et al.,
2006).
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hDAAO possesses the weakest binding of the FAD cofactor
(Kd = 8.0µM) among known DAAOs (Kd = 0.2 and 0.02µM
for pig and yeast DAAOs, respectively). Accordingly, hDAAO
exists in solution as an equilibrium of holo- and apoprotein forms
(Caldinelli et al., 2010). The presence of an active-site ligand
increases the affinity of the flavin to the protein moiety, Kd =
0.3µM (Molla et al., 2006; Caldinelli et al., 2010). Quenching of
protein fluorescence intensity during titration of the apoprotein
with the cofactor, in the presence or absence of sodium
benzoate, is a biphasic process (Murtas et al., 2017b), suggesting
that the apoprotein form exists in two conformations with
differing cofactor binding affinity: the higher intensity amplitude
associated with the first phase observed in the presence of
benzoate indicates that binding of an active-site ligand favors the
protein conformation with the higher avidity for FAD (Murtas
et al., 2017b). A second possibility is the presence of two binding
sites. Here, a recent investigation based on computational and
labeling analyses suggests that an additional ligand-binding site is
located at the monomer-monomer interface (Figure 3A; Kohiki
et al., 2017).
The holoenzyme reconstitution is a sequential process:
in the first step, FAD binds the apoprotein moiety and
recovers the catalytic activity; in the second step, a slow,
secondary conformational change generates the final holoenzyme
conformation (Caldinelli et al., 2009). Notably, the first step is
20-fold faster when benzoate is present (Caldinelli et al., 2010).
The melting temperature for the unfolding of the holoenzyme
is 6–9◦C higher than for the corresponding apoprotein
(Caldinelli et al., 2009).
The observed increase in cofactor binding affinity in the
presence of benzoate suggested that, in addition to the different
conformation of the hydrophobic VAAGL sequence observed
in the hDAAO-benzoate complex (Kawazoe et al., 2006), an
alternative conformation of the substrate-free enzyme should
exist that binds the cofactor less efficiently (Murtas et al., 2017b).
In any case, the structure of the free enzyme form (PDB 2e48)
overlaps that of the hDAAO-benzoate complex (PDB 2du8).
Based on the in vivo concentration of FAD (∼5µM), it is
conceivable that in the cell an equilibrium between the hDAAO
holoenzyme (active) and the apoprotein (inactive) form exists,
with the latter one being predominant in the absence of an
active-site ligand.
Ligand Binding
hDAAO inhibitors can essentially be grouped into substrate-
competitive and cofactor-competitive inhibitors (Molla et al.,
2006; Sacchi et al., 2012; Terry-Lorenzo et al., 2014; Molla,
2017). Among the active-site ligands, small aromatic (aryl)
carboxylic acids or acid isosteres are powerful hDAAO
inhibitors used as scaffolds for developing novel drugs (see
below). These compounds, such as benzoate, o-aminobenzoate,
substituted quinilinones, or 4H-furo[3,2-b]pyrrole-5-carboxylic
acid (Figure 4), bind the flavoenzyme similarly to the substrate:
the inhibitor COOH group (or the corresponding C=O or OH
substituents) interacts with Arg283 and Tyr228, an H-bond
donor binds Gly313, and the remaining part interacts with the
hydrophobic region of the active site (that can accommodate
molecules containing 12–13 atoms) (Duplantier et al., 2009).
In the hDAAO-inhibitor complex, the side chain of Tyr224 is
shifted toward the inner part of the active site and forms a
strong π-π stacking interaction, “sandwich,” between its aryl
chain and the re-side of the isoalloxazine ring of the cofactor.
The strongest interaction is observed when the aromatic rings
are slightly displaced [i.e., with 3-hydroxyquinolin-2(1H)-one]
(Figure 4) and not perfectly stacked (i.e., with benzoate). When
saturated analogs of these compounds are used, a drop in the
binding affinity is apparent, indicating the relevance of the π-π
stacking interaction.
The binding of aromatic carboxylic acids to the hDAAO
holoenzyme inhibits the flavoenzyme and perturbs its absorbance
spectrum in the visible region. For example, benzoate yields a
shoulder at ∼497 nm (Kd = 7µM and Ki = 9 7µM) (Kawazoe
et al., 2006; Molla et al., 2006); anthranilate binding generates a
spread classical charge transfer band at ∼580 nm (Kd = 40µM)
(Molla et al., 2006). The ligand-binding site is present in the
apoprotein form, too, as made apparent by the alteration in
protein fluorescence and in thermostability of the latter hDAAO
form when the substrate D-serine or the substrate analog tri-
fluoro-D-alanine is added (Caldinelli et al., 2009, 2010).
Conversely to benzoate, for the binding of the inhibitor
6-chloro-benzo[d]isoxazol-3-ol (CBIO) (Figure 4) to hDAAO
a single-step binding process is evident and the Kd value
estimated following the quenching of protein fluorescence
intensity corresponds well to the Kd, IC50, and Ki values
determined using different methods.
ADP and CPZ (Figure 4) (IC50 of 580 and 5µM, respectively)
behave as FAD-competitive inhibitors for binding to hDAAO
(Iwana et al., 2008; Sacchi et al., 2008; Terry-Lorenzo et al., 2014).
In particular, CPZ binding generates a protein conformation
more sensitive to proteolysis and thermal unfolding than the
native holoenzyme (Caldinelli et al., 2010). The near-UV CD
spectra show that the tertiary structure of hDAAO-CPZ complex
differs from that of the hDAAO-FAD: the former more closely
resembles that of the apoprotein (Caldinelli et al., 2010).
Notably, the ligands D-serine, FAD, benzoate, and CPZ did
not affect the formation of the hDAAO-pLG72 complex (see
below).
MODULATION OF hDAAO ACTIVITY
By Protein Interaction
Human flavoenzyme function is modulated by interacting with
various proteins. hDAAO, through the PTS1-type peroxisomal-
targeting signal, interacts with the Pex5p receptor, a protein
involved in protein import and in the assembly of peroxisomes
(Ghosh and Berg, 2010).
Genome-wide association studies and meta-studies in
different populations have linked polymorphisms in the
gene encoding pLG72 protein with schizophrenia and other
psychiatric diseases (Drews et al., 2013; Sacchi et al., 2016;
Pollegioni et al., 2018). In particular, hDAAO specifically
binds to the primate-specific protein pLG72: two hDAAO
homodimers interact with two pLG72 molecules, yielding
a 200-kDa protein complex (Kd = 0.08–0.53 µM); for a recent
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FIGURE 4 | Structural formula of selected hDAAO inhibitors classified based on their mechanism of enzyme inhibition.
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review (see Pollegioni et al., 2018). In vitro, the formation of the
200-kDa complex does not alter the kinetic parameters or the
binding with the FAD cofactor of hDAAO, but rather induces a
change in its overall tertiary structure, causing a time-dependent
inactivation (Sacchi et al., 2008). By using low-resolution
techniques (i.e., limited proteolysis coupled to mass spectroscopy
and cross-linking experiments) structural elements involved in
forming the interface surface in the hDAAO-pLG72 complex
have been identified, highlighting the role of the N-terminal
region of pLG72 in forming the oligomerization interface (Birolo
et al., 2016; Sacchi et al., 2017). hDAAO in transiently transfected
glial cells (i.e., the U87 human glioblastoma cell line) is largely
localized in peroxisomes but also present in cytosol (Sacchi
et al., 2011) while pLG72 shows a mitochondrial localization.
We proposed that, in this model cell system, newly synthesized
hDAAO interacts with pLG72 on the cytosolic side of the
outer mitochondrial membrane (Sacchi et al., 2011). Such an
interaction increases the D-serine/total serine ratio and decreases
hDAAO activity and half-life, see above (Sacchi et al., 2008, 2011;
Cappelletti et al., 2014). We recently proposed that pLG72 (itself
or recruiting further proteins) might target the cytosolic form
of hDAAO to the ubiquitin-proteasome system, thus starting
its degradation (Cappelletti et al., 2014). This mechanism could
represent a further process to regulate the D-serine levels in the
hindbrain where the flavoenzyme is expressed in glial cells.
Analogously, the activity of hDAAO is negatively regulated by
bassoon, a component of the cytoskeletal matrix, mainly located
at the presynaptic active zone. The hDAAO-bassoon complex
formation has been proposed to prevent D-serine depletion
acting on the active, extraperoxisomal enzyme form located at
presynaptic terminals (Popiolek et al., 2011). The inhibitory effect
of bassoon may account for the difficulties in detecting hDAAO
activity in the forebrain (Verrall et al., 2007), a region where the
enzyme is mostly expressed in neurons.
By hDAAO Inhibitors
Abnormal changes in hDAAO activity yielding locally decreased
D-serine levels have been correlated with neurological disorders
(e.g., schizophrenia); therefore, the identification of hDAAO
inhibitors (to slowing down the neuromodulator degradation
process) to be used as drugs has garnered growing interest.
This treatment has beneficial effects on cognition and learning
functions (Hopkins et al., 2013b).
More than 500 substrate-competitive inhibitors have been
identified so far (Gilson et al., 2016). Analogously to the
substrate, their chemical structure contains a planar moiety
which interacts with the active-site residues close to the FAD
cofactor isoalloxazine ring and a second portion which is
positioned in the substrate side-chain binding pocket. The “core”
of the planar moiety is usually formed by one or two fused
rings (one of which might be aromatic) and contains at least
a carboxylic group to establish the H-bond interaction with
Arg283. The second part of the inhibitor molecule corresponds to
the side chain of the substrate: this portion, depending on the size
and chemical features, forms further interactions with residues
belonging to the substrate specificity pocket and/or to the active
site entrance.
A comprehensive review about the details of inhibitor binding
to hDAAO has been published recently (Molla, 2017). It ranks
classical and novel compounds in four classes:
(i) classical inhibitors: typically single-ring ligands, i.e., benzoate,
anthranilate, and improved variations (Sacchi et al., 2012;
Katane et al., 2013). The compound 5-methylpyrazole-3-
carboxylic (Figure 4) acid is a prototype of this class of
compounds in which two C atoms of the ring are substituted
byN: the optimizedH-bonds network allows a high affinity for
hDAAO (Ki = 0.39µM). This compound crosses the blood-
brain barrier in rats, thus raising the D-serine level in certain
brain regions (Adage et al., 2008);
(ii) second-generation inhibitors: larger compounds than classical
inhibitors since they are characterized by two substituted,
heterocyclically fused rings, which form additional H-bonds
and van der Waals interactions with residues forming the
active site, i.e., compounds derived from 3-hydroxyquinolin-
2(1H)-one and CBIO (Ferraris et al., 2008; Katane et al., 2013).
The main drawback of the last compound is the low passage
through the blood-brain barrier: such a compound does not
increase D-serine levels in the brain (Ferraris et al., 2008);
(iii) third-generation inhibitors: bulky and flexible compounds
whose side chain binds to an additional “subpocket” at the
entrance of the active site generated by a conformational
change in Tyr224 induced by ligand binding (Raje et al., 2013;
Terry-Lorenzo et al., 2014);
(iv) novel-generation inhibitors: molecules that can interact
with the hDAAO-pLG72 complex since they contain the
“ebsulfur” (2-phenyl-2,3-dihydro-1,2-benzothiazol-3-one)
substructure that forms S-S thiol bonds with the cysteines
of hDAAO, when the protein is partially unfolded due to
pLG72 binding (Terry-Lorenzo et al., 2015). Compound
[2-(2,5-dimethylphenyl)-6-fluorobenzo[d]isothiazol-3(2H)-
on (Figure 4) inhibits hDAAO, acting as both FAD- and
D-serine-competitive inhibitor. The so-called “compound
22,” classified as a class C compound by Terry-Lorenzo
et al. (2015), only acts as hDAAO inhibitor under oxidizing
conditions. This compound does not dissociate from the
flavoenzyme in jump-dilution experiments and stably
inactivate the enzyme: recovery of the DAAO activity is
obtained only by adding a reducing agent.
By Single Point Substitutions
Based on biochemical properties, hDAAO variants
corresponding to known single nucleotide polymorphisms
or sequence conflicts have been grouped into two classes:
hypoactive and hyperactive; for a recent review (see Sacchi et al.,
2018). The conditions and levels of recombinant expression of
seven variants of hDAAO are reported in Table 2 of Sacchi et al.
(2018).
The G183R, R199W, and R199Q hDAAOs show significantly
decreased enzymatic activity (or fully abolished for the latter
variant, see Figure 5), and a perturbation of the conformation:
(a) in G183R hDAAO, corresponding to the coding mutation
occurring in the ddY/DAAO−/− mice strain expressing the
inactive G181R DAAO (Konno and Yasumura, 1983), alterations
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FIGURE 5 | Apparent kinetic parameters of wild-type and hDAAO variants,
determined at air saturation (0.25mM oxygen), 25◦C, and pH 8.5 (Molla et al.,
2006; Caldinelli et al., 2013; Cappelletti et al., 2015).
in secondary structure elements likely alter the conformation of
the flavin binding domain and thus negatively affect the cofactor
binding (Murtas et al., 2017a); (b) the tertiary structure of R199W
(the variant associated with the onset of fALS) and R199Q
variants is significantly altered: this favors aggregation propensity
but does not modify the interaction with pLG72 (Cappelletti
et al., 2015; Murtas et al., 2017a); (c) in G331V hDAAO the
change in the C-terminal α-helix promotes protein aggregation,
strongly affecting the variant solubility (Caldinelli et al., 2013).
At the cellular level, both G183R and G331V variants were partly
mistargeted: they formed cytosolic protein aggregates, which
largely colocalized with ubiquitin, and resulted in increased
apoptosis (Caldinelli et al., 2013; Murtas et al., 2017a).
On the other hand, the D31H, W209R, and R279A
substitutions have the opposite effect on hDAAO activity,
resulting in slightly or significantly improved catalytic efficiency
(Figure 5) and FAD affinity. For example, a 2-fold increased
turnover number was apparent for the W209R hDAAO,
which was more active than the wild-type hDAAO using
0.3mM D-serine and 5µM FAD, i.e., concentrations resembling
physiological conditions (Cappelletti et al., 2015).
FIGURE 6 | Effect on the cellular D/(D+L) serine ratio in U87 human
glioblastoma cells stably expressing EYFP-hDAAO variants (Caldinelli et al.,
2013; Cappelletti et al., 2015; Murtas et al., 2017b). The effect of W209R
substitution was established on transiently transfected cells (not shown): a
figure of 4.2 ± 0.1 vs. 5.8 ± 0.4 was determined at 24 h for the variant and
wild-type hDAAO, respectively.
Following overexpression in U87 cells, all the investigated
hDAAO variants significantly altered the cellular levels of
D-serine (Figure 6; Caldinelli et al., 2013; Cappelletti et al.,
2015; Murtas et al., 2017a). The expression of inactive variants
of hDAAO could produce susceptibility to neurodegenerative
disorders due to augmented D-serine levels which, when
paralleled by elevated glutamate levels, could lead to
hyperactivation of NMDAR and thus to excitotoxicity. In
contrast, a deficit in NMDAR-mediated transmission might
be related to the expression of hyperactive variants due to an
abnormal decrease in D-serine at the synapses, as proposed
in schizophrenia onset. Furthermore, hDAAO hyperactive
variants produce nonphysiological levels of H2O2: this process
could contribute to the molecular mechanism of the central
sensitization typical of chronic pain.
To delve into the structure-function relationships in
mammalian DAAOs, alanine-scanning analysis of first and
second shell residues of the enzyme from pig prompted the focus
on active-site lid residues (region 221–225) and on the positions
55 and 56 in hDAAO (Subramanian et al., 2018). Molecular
dynamics simulations identified a narrow tunnel that could
provide access to the active site of hDAAO, named tunnel T1.
The Y55 residue was suggested to be involved in anchoring the
lid loop in the closed conformation (its dynamics are hampered
by Y314), modulating the solvent access and substrate/product
exchange at the active site and separating T1 from an additional,
putative tunnel. The Y55A substitution facilitated accessibility of
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the active site: a 2-fold increase in specific activity on D-Trp was
observed.
BY POST-TRANSLATION MODIFICATIONS
The molecular mechanisms by which hDAAO expression and
acquisition of catalytic activity are achieved inside the cell are
still largely unknown: a fine and careful regulation through post-
translational modification(s) is expected. Actually, hDAAO was
proposed to be regulated by nitrosylation (Shoji et al., 2006). In
detail, the activity of DAAO, in a membrane fraction of U87
glioblastoma cells, was enhanced by NO in a dose-dependent
manner. The authors proposed that, in astrocytes, NO may
inhibit SR and enhance hDAAO activities thus accelerating D-
serine degradation. Following D-serine supply from astrocytes to
neurons, synthesis of nitric oxide in neurons may temporarily be
increased, yielding a feedback regulation of the neuromodulator.
CONCLUSIONS
With the final aim to use hDAAO in different tissues responding
to several needs, evolution adopted complicated regulatory
strategies to modulate the activity of the flavoenzyme. In
human brain tissues, hDAAO should be mainly present in
the apoprotein, inactive form considering the physiological
concentration of FAD and its weak interaction with the
apoprotein moiety. Conversion of the inactive hDAAO
apoprotein into the active holoenzyme is facilitated
by the presence of an active-site ligand, such as the
substrate: this represents an efficient way to maintain
the level of selected D-amino acids in the physiological
range.
We are conscious that, despite the important role played by
hDAAO in main physiological processes, the modulation of its
functional properties is still largely unknown. A main issue is the
modulation of the activity by post-translational modifications (as
known for serine racemase) and by further interacting proteins.
A second matter is the role of hDAAO activity in important
human diseases. Here, a way to elucidate links with cell functions
is represented by the investigation of the role of epigenetic
modifications on DAO gene expression in different cells and
tissues during development and pathological conditions. In this
regard, a CpG methylation analysis of the DAO promoter was
performed recently and brain region-specific epiallelic profiles
were detected in schizophrenic patients and healthy controls
(Keller et al., 2018). These different methylation signatures have
been proposed to be indicative of cell populations containing the
DAO gene in different functional states.
The known properties of hDAAO strengthen our belief that
the flavoenzyme activity must be finely tuned to fulfill a main
physiological function such as the control of D-serine levels in
the brain.
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